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Abstract 
The bacterium Clostridium difficile is responsible for recent epidemics of gastroenteritis and 
currently causes over twice as many deaths per year as the other major hospital ‘superbug’, 
MRSA. Since the bacterium is resistant to conventional antibiotics there is an urgent need to 
develop novel therapies. C. difficile secretes a family of proteins that are held in place on the 
cell wall by non-covalent forces, producing a proteinaceous coat (the surface layer or S-
layer) that surrounds the entire cell. These S-layer proteins (SLPs) are immunogenic in 
humans and play a role in binding to host cells. Synthesis of the C. difficile S-layer involves 
site-specific proteolytic cleavage of the SlpA precursor by an as yet unidentified C. difficile 
protease. Identification of the protease that processes SlpA has proven challenging, due in 
part to a lack of established genetic tools in C. difficle.  
Here the development of novel chemical probes that can disrupt S-layer formation by 
inhibiting the protease are described, and found to be powerful chemical proteomic tools 
for both protease identification and exploring the process of S-layer formation. Screening 
and inhibition experiments were first performed to identify novel synthetic irreversible 
protease inhibitors combining an electrophilic warhead with a specific sequence element 
matching the SlpA cleavage. These compound series were shown to possess structure-
dependent activity, and inhibited cultures were also more sensitive to lysozyme-induced cell 
lysis, suggesting that correct processing and assembly of the S-layer is important for cell 
envelope integrity. Optimised inhibitors were further developed into ‘activity-based probes’ 
(ABPs) carrying an affinity tag, and were successfully used to isolate and identify de novo the 
key protease involved in cleavage of SlpA, Cwp84, using a combination of different labelling 
and proteomics approaches. These probes also permitted identification of Cwp84 activity 
across a wide range of clinical strains. In later work, the scope of the warhead element was 
explored in more detail, and the potential antibacterial effects of the inhibitors were 
investigated in both wild type and genetically engineered strains. Finally, the contributions 
of this work in terms of both chemical technology and C. difficile biology are critically 
assessed.  
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Chapter 1 Introduction 
 
Identification, characterisation and assignment of function to members of a proteome 
associated with specific biological processes in the cell is a central theme in post-genomic 
biology. Although conventional genomic [1-2] and proteomic [3-6] methods have 
provided many useful insights into quantification of transcripts and proteins, they are 
only  indirect indicators of biological function, and suffer from a limited capacity to 
measure the catalytic activity of proteins involved in post-translational mechanisms [7]. 
Consequently, new and more efficient methods that can provide a deeper understanding 
of protein activity in a particular complex biological system would enable access to 
system-level functional information about biochemical networks that are important, for 
example, in the complex search for viable drug targets. In this study, the application of 
one of such method, termed activity-based protein (or proteome) profiling (ABPP) [8-10] 
is discussed, in particular its implementation in the discovery and functional 
characterisation of proteases involved in the formation of the surface layer of 
Clostridium difficile [11]. This study provides compelling evidence that, when coupled 
with chemical proteomic methods, ABPP is a powerful tool for studying S-layer 
biogenesis in this challenging pathogen that lacks robust technologies for genetic 
engineering, and may reveal potential therapeutic targets involved in colonisation of the 
host. 
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1.1 Chemical proteomics 
Advances in genomic sequencing have brought biological research into a new era, in which 
scientists are facing new challenges in cataloguing and assigning functions to gene products. 
Although conventional genomic data analysis and proteomic study grant access to useful 
information on protein expression level and hypothesis regarding protein function, this 
method cannot be used for evaluation of protein function on a global scale. This is especially 
the case for proteins that are regulated by posttranslational processes or complex arrays 
such as substrate co-localisation regulation, allosteric control and co-regulation of 
endogenous inhibitors. To move away from inherent limitations of these methods, the field 
of chemical proteomics has introduced several strategies to permit the identification, 
quantification and manipulation of the full repertoire of enzyme activity in systems. 
Chemical proteomics [12-13] is a broad area that employs numerous different experimental 
techniques. The three main approaches are: the global proteomics approach, the 
compound-centric approach, and activity- or affinity-based protein profiling (ABPP). A 
comparison of these approaches is illustrated in Figure 1. 1. These methods have distinct 
advantages and disadvantages, and the choice of approach depends on the specific 
application[14]. 
The global proteomics approach is applied to determine changes in protein abundance and 
activity in response to drug treatment [15-18]. Cellular responses are evaluated in a global 
and unprejudiced manner after the biological system (which may be cells or a whole 
organism) is treated with a drug. However, this strategy is restricted to the most abundant 
proteins (affected either by inhibited signalling pathways or by a stress response and/or 
housekeeping) because observed changes are limited by the depth of the analysis. Several 
studies [19-21] have made use of the advantages of this strategy to study proteins of 
interest.  
The compound-centric approach is typically applied to characterise the mechanism of action 
of a known bioactive compound with its interacting proteins [13-14]. Usually this compound 
is immobilised onto an inert and biocompatible solid support prior to incubation with the 
biological extract to identify interacting proteins. Unfortunately, this method is still limited; 
it fails to provide data on protein function and is difficult to apply in living systems. 
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Moreover there are significant synthetic challenges, for example the difficulty of introducing 
the functional groups required for the immobilisation process. Publications using this 
approach have focused on kinase inhibitors [22-24], signalling molecules [25], cyclic 
nucleotides [26] or specific peptide sequences [27-28].  
 
Figure 1. 1: Comparison of three different chemical proteomics approaches: A) global proteomics approaches 
for determining changes in protein abundance and activity in response to drug treatment, B) ABPP involves 
specific targeting and subsequent purification of drug target protein classes with ABPs, and C) in the 
compound-centric approaches, bioactive compounds (drugs) are modified and immobilised on a solid support 
(drug matrix). Proteins that interact with this matrix are then analysed.  
ABPP analyses the enzymatic activity of a particular protein family under certain conditions 
(for example in a disease). As this approach is the main topic of this thesis, a detailed review 
follow in section 1.2. 
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1.1.1 Strengths and limitations of chemical proteomics 
Chemical proteomics enables the study of proteins in a highly dynamic system affected by 
small changes (e.g. the variation of bacterial culture conditions, cell treatments with drugs 
or inhibitors, stress, changing metabolic and regulatory processes, etc.) [29]. The different 
states of these changes can be monitored and investigated quantitatively in a unique and 
highly sensitive manner [30]. In addition, the identification of proteins by chemical 
proteomics usually comes with functional annotation. Such approaches also provide further 
information about uncharacterised proteins discovered by other means (e.g.: putative 
proteins from genomic analysis).  
Furthermore, chemical proteomics approaches are flexible and allow for the application of 
probes to entire proteomes or sub-proteomes of any cell type (e.g.: mammalian cells, 
plants, bacteria and viruses) without the restriction of having to engineer individual 
recombinant proteins [13]. Therefore, these proteins are studied in their natural, un-
engineered state and environment, including post translation modification and endogenous 
abundance levels, providing a genuine broad and in depth understanding of the system 
under investigation. This can include, at the molecular level, aspects of an enzyme’s 
mechanism or a protein’s interactions.  
Despite numerous advantages, this technique still has some limitations where 
improvements are needed. One prominent limitation is the relatively high amount of 
cellular material required and therefore the high consumption of probes, which can be 
expensive to synthesise, follows. However, this demand is reduced with the most recent 
developments depending on the working system and the abundance of the active enzymes. 
A second limitation is the dependence on the type of lysis operation, as only proteins that 
are present in the lysates can be captured, identified and investigated; proteins such as 
membrane proteins prove challenging. Nevertheless, the latest solubilisation technologies 
aid significantly in circumventing this problem and have allowed the successful identification 
of type I membrane proteins (e.g.: receptor tyrosine kinases [22, 31-32]).  
A third limitation is the high level of background that derives from abundant proteins 
interacting via nonspecific, hydrophobic or charged surface interactions with the proteins of 
interest. This problem can be reduced to a certain level by the careful choice of affinity 
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parameters in the pull down step and adding negative controls. Another challenge of this 
technique, which comes quite early in the study, is the synthetic hurdle in accessing the 
probes, which are crucial to the whole process.  
1.2 Activity-based protein (or proteome/proteomic) profiling (ABPP) 
ABPP [8-10], one of the emerging chemical proteomic strategies that utilises the ability of 
forming covalent bond of a chemical probe directly with the active site of proteins, is 
applied to profile the functional state of proteins in a complex proteome. The principle of 
ABPP is to design those specific chemical probes in such a way that they modify the target 
enzyme(s) covalently at the active site with the objective of detecting the activity and 
identity of the target enzymes directly in a living system [33]. Importantly, activity-based 
probes (ABPs) permit the detection of enzyme activity independently from the enzyme 
abundance and therefore provide access to low-abundance proteins which are usually 
difficult to characterise by other means. While ABPs have been designed to target the 
catalytic residues on enzymes, another form of chemical probe – called affinity-based 
probes (AfBPs) – have been designed to target non-catalytic residues on proteins relying on 
highly selective tight binding to the target proteins [34] (Figure 1. 2). Several groups have 
developed AfBPs on the basis of well-documented photo-affinity reagents [35], these 
probes were designed from tight-binding reversible inhibitors of target proteins coupled to 
a photoreactive molecule. Carefully designed AfBPs can tune the labelling of target enzymes 
in an activity-dependent fashion and therefore can be potent alternative tools to ABPs.  
 
Figure 1. 2: ABPs versus AfBPs [36]. ABPs label enzymes via their catalytic mechanism, whilst AfBPs make use 
of protein affinity, stabilised by non-specific cross-linking.  
 
PAGE
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The requirement of a catalytically active enzyme is the decisive property for the distinction 
of ABPs and AfBPs, as AfBPs can bind to a specific site which is not necessary the active site 
on the target enzyme, whilst ABPs only target the active site of the enzyme. In many cases, 
AfBPs have been applied to profile targets usually inaccessible to ABPs [37]. Because AfBPs 
lie outside the scope of this study, no further discussion is made of this type of probe. 
1.3 Activity-Based Probes (ABPs) 
ABPs are small molecules that typically possess structural components enabling the 
appropriate exploitation of the catalytic site chemistry of the target enzyme, including 
alkylation or acylation of a specific nucleophile group at the catalytic site. Because ABPs 
form a covalent bond with the enzyme at the active site, the catalytic activity is inactivated 
in the same manner as a “suicide substrate” or irreversible inhibitor. The detection of the 
bound proteins can be facilitated using a suitable tag or label. To date, ABPs have been 
applied for myriad enzyme classes including kinases [38-41], phosphatases [42-43], 
hydrolases [44], lipases [45], glycosidases [46-47], oxidoreductases [48-49] and proteases 
including cysteine proteases [50-53], serine proteases [54] and threonine proteases [55-56].  
1.3.1 Designing ABPs 
Designing an effective ABP requires certain fundamental knowledge of the catalytic site 
chemistry of the target enzymes. Therefore, the early stage developments of ABPs were 
mostly linked directly with the discovery and development of reversible and irreversible 
inhibitors. Conversion of inhibitors, which are usually derived from natural products [57] or 
a substrate mimetic [33], into ABPs are usually achieved by careful molecular engineering. 
Typically, ABPs consist of three parts: (1) a reactive group (the “warhead” or WH) for 
covalently binding and labelling the active site of the targeted enzymes; (2) a specificity 
element, which acts as recognition site and improves the selective labelling of a particular 
class or sub-class of enzymes, and (3) a reporter unit, which can be a tag or a label, for 
manipulation, measurement and identification of the labelled enzymes (Figure 1. 3). In 
addition to these components, ABPs may also contain a linker separating the specificity 
element from the reporter unit to minimise steric hindrance of the tag/label to the active 
part of the probe. Each part of an ABP is discussed in detail in the following sections. 
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Figure 1. 3: ABP anatomy with three key features and their representative examples. 
Design of ABPs follows two basic strategies: directed and non-directed [29, 33]. 
Development of the former is intended to target specific enzymes within a mechanistically 
related family, e.g. to target only serine proteases, not lipases, or a particular enzyme (or 
few enzymes) within a class. Usually, directed ABPs are based upon known inhibitors, which 
are either mechanism-based inhibitors containing reactive groups conferring a chemical 
preference for a particular enzyme class, or broad-spectrum inhibitors containing high 
affinity specificity element directing the probes to enzymes that share common catalytic site 
chemistry. Consequently, the target enzymes have to be characterised to a certain degree 
to provide necessary information about mechanism and structure. In contrast, non-directed 
ABPs are deliberately designed to be broad-spectrum, e.g. to target all serine hydrolases 
(including serine proteases, lipases, etc.), so as not to limit the discovery of potential new 
enzymes. This method usually applies one or more non-specific site-directed electrophiles 
and an array of specificity elements to screen a wide range of mechanistically distinct 
enzymes in a complex proteomes. Both strategies are widely used and their application will 
be described in later sections in targeting class-selective ABPs.  
 
 
Specificity elementWarhead
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1.3.1.1 Warheads 
Selectivity of a reactive group (warhead) is perhaps the greatest challenge in designing this 
part of the probe, because it has to be active and provide the required covalent 
modification to the specific residue on the target enzyme (e.g.: a nucleophilic amino acid 
residue in the active site) and simultaneously, it has to be inert towards other potential 
reactive species (e.g.: thiols, amines, alcohols) within the complex proteome. Because the 
results of ABPP experiments depend on the ABPs used, the tailoring of the warhead in 
respect of integrating the enzyme chemistry can define the specificity to certain catalytic 
class of enzyme of interest. Therefore, distinction is possible between enzymes e.g.: 
proteases, phosphatases and glycosidases. Typically, warheads are electrophilic traps such 
as sulfonates [48, 58], epoxides [51, 59-60] or Michael acceptors [61-62], that react 
irreversibly forming new covalent bonds with the nucleophilic residues at the active site of 
the enzyme. Affinity and inherited chemical reactivity are the decisive factors to define the 
reactivity of the warhead towards the enzyme active site. Adjusting these factors properly 
allows the selectivity between enzymes to be manipulated. For example, although the 
inactivation of serine and cysteine proteases relies on a catalytic amino acid nucleophile in 
the active site, they possess a different nucleophilic residue and distinct catalytic 
mechanisms. Therefore design of a warhead that reacts with one class and not the other is 
possible.  
1.3.1.2 Specificity elements 
Highly reactive warheads are often promiscuous and therefore they address a relative broad 
set of targets. In order to increase the selectivity of ABPs and narrow down the target panel, 
a specificity element is often incorporated into the probe to direct the probe to a desired 
well-defined enzyme or enzyme family. Normally, these specificity elements are a short 
peptide (ca. two to four amino acids), or peptide-like structures, that can be chemically 
linked with the warhead, or are a subunit within the structure of the parent inhibitor [63-
64]. In some cases, very large peptides or proteins have been used to gain a higher degree 
of target specificity [33]. A prominent example is the modification of recombinant ubiquitin 
with an electrophile warhead to probe proteases that process ubiquitin in vitro [46, 65-66]. 
This kind of probe is very useful when target specificity requires protein-binding domains.  
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1.3.1.3 Reporter units 
The purpose of a reporter unit on an ABP is to provide a “handle” for manipulating, 
visualising, identifying and quantifying the probe-modified enzymes. This reporter unit can 
be either directly appended to the probe via a linker or introduced at a later stage using 
bioorthogonal ligation [67-69] or click chemistry [36]. For the sake of distinguishing both 
cases, in this thesis a “tag” is a “clickable” group (e.g. an alkyne or azide) used for indirect 
(“two step”) labelling, whilst a “label” refers to a label (e.g. fluorophore, affinity label 
directly attached to the ABP.  
A “label” 
Labels for ABPs fall into three categories: affinity, fluorescent and radioactive. Biotin, an 
affinity label, is the most commonly used, because it is compatible with SDS-PAGE (Sodium 
Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis) and can be detected simply by 
Western blotting [63]. This label is also preferred over the others (fluorescent and 
radioactive labels), because it is cost effective and environmentally friendly, and facilitates 
the subsequent purification of the labelled enzymes on beads. However, detection by 
Western blot might be not the best approach for quantitative analysis due to some inherent 
limitations of the Western blot method.  
Fluorescent [45, 51, 70-71] and radioactive [60, 72] labels facilitate detection by direct 
scanning of gels after SDS-PAGE analysis with a fluorescent scanner or a phosphor imager 
[63]. Despite the higher cost compared to biotin, they benefit from several advantages such 
as time saving due fewer handling steps, greater sensitivity and greater dynamic range. 
Moreover, fluorescent labels can have other advantages, if different, non-overlapping 
excitation/emission fluorescent dyes are incorporated, allowing multiplexing of samples 
labelled with different coloured ABPs but visualised on the same gel for comparative 
evaluation [71, 73-74].  
A “tag” 
The physical properties of the appended label such as polarity, size, charge, structure and 
chemical reactivity may have a large impact on the behaviour of the probe as a whole, 
including inhibitory effect and cellular uptake [63]. Especially large labels may suffer from 
detrimental effect on enzyme recognition/labelling and PAGE analysis [37, 75]. To avoid 
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these potential limitations these labels may be replaced by a “clickable” tag allowing 
subsequent introduction of a capture reagent after the ABPs have been administered, using 
bioorthogonal ligation [67-68] or click chemistry [36]. The tags are small, predominantly 
alkyne or azide functional groups, and are typically linked directly into the specificity 
element, and therefore expected to have minimal effect on the probes [76]. In addition, tags 
are largely inert towards endogenous biological functionalities, allowing specific and 
effective bioorthogonal ligation with a capture reagent that contains a corresponding 
cyclisation partner, e.g. alkyne or azide, and a reporting group such as biotin, a fluorophore 
or a radioactive group, or a combination of such groups. 
Linker 
The linker connects the warhead/specificity element to the labels or tagged capture 
reagent. Its primary purpose is to create enough space between the connected components 
to prevent steric hindrance that might impede the accessibility of the warhead/specificity 
element to the active site, or the accessibility of the affinity label for purification purposes. 
Linkers can be either non-cleavable or cleavable. 
Non-cleavable spacers can be simple long-chain alkyl or poly-ethylene glycol (PEG). The alkyl 
linkers can be tailored to confer enhanced hydrophobicity and ease the permeability of 
probes into live cells or tissues. In contrast, PEG linkers provide better solubility to 
hydrophobic ABPs in aqueous environments. The choice of a suitable linker depends on the 
requirement of the ABPP application.  
Cleavable linkers facilitate the selective release of the labelled enzymes after purification on 
beads. The cleavage event can be either chemical (e.g.: cleavage of disulfide or diazo linker 
[77-80]) or enzymatic, utilising the relationship of proteases (e.g.: TEV protease [81-82]) and 
their corresponding peptide substrates. Application of cleavable linkers circumvents harsh 
elution conditions and minimises non-specific pull down of proteins, enhancing signal and 
reducing noise. 
1.3.2 Click chemistry 
Defined by K. Barry Sharpless and his co-workers in 2001 [83], “Click” chemistry (CC) has 
boomed in many applications [84-86]. In the last few years, CC has been adopted 
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extensively in ABPP ranging from clicking a tag with the capture reagent [87-89] to 
introducing linker unit [90-91] or rapid modular synthesis of ABPs and AfBPs [89, 92-93]. 
Originally, the term CC referred to a set of reactions that are modular, easy to perform, 
selective, stereospecific, giving very high yields and producing no (or only non-toxic) 
byproducts. Among them, azide-alkyne cycloadditions occupy a special place as their 
chemistries facilitate various biological applications [76, 94] (Figure 1. 4).  
 
Figure 1. 4: Click reaction: A) General uncatalysed Huisgen reaction. B) Proposed mechanism of the copper-
catalysed Huisgen cycloaddtion of alkynes and azides [95] 
Pioneering work by the groups of Cravatt, Overkleeft, Bogyo and Yao have utilised CC to 
synthesise probes by linking the reporter unit with the reactive moiety (Figure 1. 5A). For 
example, Cravatt et al. generated probes for selective labelling of carboxyesterase-1 (CE-1) 
from mouse heart proteomes by simply linking rhodamine or biotin and rhodamine together 
with the natural product FR182877 using CC [90]. In a similar approach, Yao and colleagues 
utilised CC to build up a whole combinatorial library of hydroxamate-containing small 
molecule probes against matrix metalloproteases [93]. Fuwa et al. generated a library of 
photo activatible probes by clicking biotinylated photo reactive molecules to alkyne-
incorporated benzodiazepine for the study of the enzyme γ-secretase [92]. Another elegant 
strategy is the synthesis of inhibitor scaffolds on a microarray using solid phase peptide 
A) 
 
B) 
 
28 
 
synthesis (SPPS) and then introducing the desired reporter unit into the probes using CC 
[34].  
Another application of CC in ABPP is two-step labelling (Figure 1. 5B), which was first 
reported independently by Cravatt and Overkleeft [96-97]. Using an azide-derivatised 
phenyl sulphonate probe, Cravatt and co-workers targeted GSTO1-1 enoyl CoA hydrolase 
(ECH-1) and aldehyde dehydrogenase (ALDH-1) in treated cell lysates from COS7 cells [96]. 
After this initial success, his group applied this principle of bioorthogonal ligation to other 
systems, e.g.: the profiling of fatty acid amide hydrolases by selectively labelling in animal 
brain, liver and kidney [98]; probing a glycolytic enzyme in cancer cells with a probe 
containing natural product scaffold MJE3 [99]; or inhibition and activation of cytochrome 
P450 enzymes [100]. The Overkleeft laboratory, on the other hand, employed functionalised 
vinyl sulfone probes to investigate proteasomes in cell lysates as well as in live cells [97]. 
Most of this work utilised copper (I) catalysed alkyne-azide cycloaddition (CuAAC), which 
can be suitable for detecting labelled protein samples, but not usually on live cells because 
of the cytotoxicity of copper. To override these problems, the Bertozzi lab worked on a 
copper-free variation, a strain-promoted alkyne-azide cycloaddition (SPAAC) reaction [76]. 
In this work, the researchers showed that the incorporation of azido-sugar onto the cell 
surface as glycoprotein through metabolic labelling could be visualised in living cells. Other 
groups have followed the approach and used similar click reagents to study cell-surface 
glycans via non-natural sugars [101], or other mammalian cell- surface proteins using lipoic 
acid ligase [102].  
 
Figure 1. 5: Application of CC in ABPP. A) Synthesis of inhibitors. B) Two-step labelling.  
A) Synthesis of inhibitors 
 
B) Two-step labelling 
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1.3.3 Affinity enrichment of labelled proteins 
Affinity pull down facilitates the enrichment of labelled proteins and separates them from 
non-labelled proteins, significantly reducing the complexity of the investigated proteome 
before mass spectrometric analysis (see Figure 1. 1) [103-105]. Here in this work, affinity 
enrichment is used for identifying the most catalytically active proteins. Although pull down 
assays are widely applied in chemical biology, their use still has some limitations, as 
discussed below.  
1.3.3.1 Solubility of target proteins  
Depending on the purpose of the study, preservation of the nature of labelled proteins, such 
as folding and assembly, may be desirable. In that case, it is necessary to avoid intensive 
agitation and degradation and therefore experiments should be implemented under non-
denaturing conditions. Soluble proteins such as cytosolic proteins do not tend to be 
problematic; however, insoluble proteins such as intact membrane proteins and insoluble 
cell components require more aggressive conditions such as sonication and strong 
detergents to solubilise the proteins [106-107]. It is possible that during the sample 
preparation some proteins are not solubilised and therefore are not pulled down. 
1.3.3.2 Abundance of the target protein 
One crucial requirement for any successful chemical proteomics experiments is sufficient 
expression of the target protein and the presence of potential off-target proteins in the cell; 
proteins with very low abundance in the cell may be missed. Another factor contributing to 
success is the strong binding of the ABPs to the target proteins. Besides the specific covalent 
bond between ABPs and target proteins, there is also non-specific binding (probably via non 
covalent, hydrophobic or charged surface interactions) of ABPs with abundant proteins and 
non-specific binding of abundant proteins to the affinity beads [13-14]. Consequently, the 
amount of enriched proteins does not give clear insight into the type of the binding (specific 
or non-specific) or the function of the protein (target or off-target). 
1.3.3.3 Background binding of proteins 
A number of background proteins can co-purify with the target proteins and cause a high 
background signal. These “contaminant” proteins could be those that bind non-specifically 
to the beads or to the target protein through second- or third-shell protein-protein 
interactions (“piggybacking”) [13]. Using increasingly stringent washing methods could 
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reduce the level of background proteins; however, it could also remove lower-abundance 
target proteins. Therefore, it is important to choose a suitable wash method for the pull 
down experiment.  
Usually, appropriate negative controls are introduced to enable the identification of 
background proteins by comparing proteins captured with non-treated samples and treated 
samples (either with active or inactive ABPs). This strategy could be problematic in the case 
of more complex proteomes due to the potentially high level of background, requiring other 
strategies, e.g.: the competition binding approach [32, 108], a stable isotope labelling 
strategy [12, 109] or serial affinity chromatography [110-111].  
1.3.3.4 Biotin binding proteins 
Biotin, known as Vitamin H, is an essential enzyme cofactor. It is acquired from various 
sources, for example, it is biosynthesised by human intestinal microflora. Many bacteria 
transport biotin into the cell via an active uptake mechanism, as it is an essential 
micronutrient for normal cellular function, growth and development [112-113]. Therefore 
biotin appended ABPs might be delivered more easily into the cell [114-115] and may target 
further potential proteins inside the cell. However, the key feature of biotin, responsible for 
its wide use in molecular biology, is its very high affinity for the protein avidin [116]. 
Attaching biotin to a protein of interest directly or via inhibitors/ABPs enables identification 
and/or characterisation of these proteins using protein tools such as avidin, or related 
analogues streptavidin and neutravidin [117], [118].  
Avidin is a tetrameric glycoprotein isolated from egg white and other tissues (birds, reptiles 
and amphibia) [117]. It exhibits very strong binding to biotin in one of the strongest non-
covalent bonds known. The carbohydrate moieties of avidin, a source of binding to lectin 
and sugars, account for about 10% of its total mass. 
Streptavidin isolated from Streptomyces avidinii possesses a high affinity for biotin, similar 
to that of avidin [118]. Unlike avidin, streptavidin has no glycosylation moiety and therefore 
it exhibits less non-specific binding. In addition, streptavidin is much less soluble in water 
than avidin [119].  
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NeutrAvidin is a deglycosylated form of avidin [120], commercialised by Thermo Scientific 
and Invitrogen. Because it lacks the glycosylation site, NeutrAvidin shows very low non-
specific binding. In addition, NeutrAvidin lacks the Arg-Tyr-Asp sequence, the motif that 
binds to cell surface proteins, possessed by streptavidin, and therefore it exhibits even less 
non-specific binding [120]. NeutrAvidin agarose resin is prepared by covalently coupling 
NeutrAvidin protein onto beaded agarose (polysaccharide based), which is stable at pH 2-11 
and leach-resistant.  
A comparison of these three biotin binding proteins is given in Table 1. 1. Affinity for biotin 
is similar in all cases; however, NeutrAvidin has the highest specificity and the lowest non-
specific binding.  
Comparison of biotin-binding proteins. 
  Biotin-Binding Protein 
Avidin Streptavidin NeutrAvidin 
Molecular Weight (of tetramer) 67K 53K 60K 
Biotin-binding Sites 4 4 4 
Isoelectric Point (pI) 10 6.8-7.5 6.3 
Affinity for Biotin (Kd) 10
-15 M 10-15 M 10-15 M 
Nonspecific Binding High Low Lowest 
Table 1. 1: A comparison of biotin-binding proteins [121]. 
1.4 Application of ABPs to different protease families 
1.4.1 Proteases 
Proteases are proteolytic enzymes that catalyse the selective hydrolysis of peptide bonds 
(Figure 1. 6). Proteases form one of the largest and most important groups of enzymes. 
They are involved in various important physiological processes such as protein turnover, 
digestion, cell differentiation and growth, cell signalling and migration, fertilization, blood 
coagulation and wound healing, immunological defence, and apoptosis [122]. Due to their 
ubiquity and roles in many biological processes, inhibitors of such proteases allow the 
regulation of undesired protease activity and can be used for therapeutic applications or as 
tools for biological studies [123].  
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Proteases have been classified into evolutionary families and clans by Rawlings and Barrett 
(1993, 1994) [124-125] based on similarities in tertiary structure, the order of catalytic 
residues in the primary sequence or common sequence motifs around the catalytic residues. 
This classification led to the development of the MEROPS database of proteases 
(http://merops.sanger.ac.uk) [126]. This database contains the listing of all known protease 
sequences of different families and clans.  
 
Figure 1. 6: A) Equation of peptide hydrolysis. B) Standard nomenclature for substrate residues (Pn) and their 
corresponding binding sites (Sn) [127]. 
Generally, proteases are divided in four major classes: aspartic, serine/threonine, cysteine, 
and metallo proteases [124-125]; they possess similar mechanisms of action, which involve 
an initial attack of a nucleophile onto a substrate carbonyl function. This nucleophile is a 
water molecule in the case of aspartic and metalloproteases, or a serine, cysteine or 
threonine in the remain classes [122].  
Most proteases are substrate sequence-specific, so that their chemical and physical 
properties define the possible binding of amino acid side chains of the substrates. Figure 1. 
6 shows the standard nomenclature introduced by Schlechter and Berger [127] to designate 
substrate or inhibitor residues (e.g. P3, P2, P1, P1’ ) that bind to the corresponding protease 
subsites (S3, S2, S1, S1’).  
Although proteases have long been known to be important in human pathological process 
and approximately 10% of drugs currently on the market target proteases, their activity and 
A) 
 
B) 
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regulation in disease are still not fully understood. Furthermore, the function of a vast 
number of encoded proteases predicted by genomic analysis still remains unknown. 
Application of ABPP could aid further understanding of proteases activities as well as 
implication and regulation in disease pathologies, or even identification of novel proteases 
as potential therapeutic targets. The application of ABPP for each protease class is discussed 
in the following sections.  
1.4.2 Serine and Threonine proteases 
Comprising approximately 1% of the predicted protein products of mammalian genomes, 
the serine hydrolases known as serine proteases are an extreme large family of enzymes 
[128-129]. Sharing a common catalytic mechanism involving a nucleophilic a serine residue, 
this enzyme family catalyses the hydrolysis of ester and amide bonds and play a significant 
role in a huge number of physiological and pathological processes including diabetes [130], 
cancer [131-132], inflammation [133-134] and angiogenesis [135].  
Fluorophosphonates (FP) - broad spectrum irreversible inhibitors that target over 100 
distinct serine hydrolases including proteases, peptidases, lipases, esterases and amidases - 
have been used as a powerful tool to characterise this class of enzyme in complex 
proteomes [10, 132]. These inhibitors benefit from several advantages such as selectivity 
towards serine hydrolases [136] and no cross-reactivity with other classes including 
cysteine, aspartic and metalloproteases [137]. Utilising these advantages, Cravatt and 
colleagues applied a panel of FP-biotin or fluorescein probes to characterise catalytically 
active serine hydrolases in human and mouse proteomes [10, 74, 132, 138]. Labelling was 
observed only with active hydrolases and not with inactive forms (serine nucleophile 
mutant, zymogen or inhibitor-bound hydrolase) [10, 132]. Despite these successes FP-based 
ABPs suffer from a drawback: broad reactivity prevents the application of these probes to 
lower-abundance enzymes. Recognising this limitation, a new generation of probes was 
developed named diphenylphosphonates possessing similar reactivity and mechanism 
towards serine hydrolases as FP-based probes but with narrower selectivity to trypsin-like 
serine proteases such as plasmin, β-tryptase and trypsin itself [133, 139-140]. Notably, 
adding a P2 proline residue into the probe design led to a significant increase of the 
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reactivity and selectivity of these probes towards tryptase compared to trypsin, confirming 
the important role of the probe design [133].  
 
Figure 1. 7: Structure of ABPs for serine proteases. FP-ABPs possess a relative broad-spectrum reactivity [138], 
whilst DPP-ABPs displays more selectivity to trypsin-like proteases [133, 139-140]. AdaK(Biotin)Ahx3L3VS probe 
was applied to label proteasomes in live cells [75].  
Another target of serine hydrolase family is the proteasome, a primary cytosolic protein 
degradation machinery present in almost all living cells [141]. Three types of active sites 
were found in all eukaryotic proteomes: β1 as caspase-like, β2 as trypsin-like and β5 as 
chymotrypsin-like [75, 142]. In addition, a threonine protease-like activity at the N-terminus 
was found from mutational and structural studies of the proteasome [75]. Several groups 
have been working on inhibition of proteasome both in live cells and in vitro using vinyl 
sulfone-based probes [56, 97, 142]. For example, Ploegh and co-workers targeted β-subunits 
and the Overkleeft lab has developed site-specific probes towards β1 and β5 units [142], 
while Kessler and colleagues concentrated on substrate specificity using peptide-based vinyl 
sulfone probes [75]. 
1.4.3 Cysteine proteases 
Cysteine proteases represent the second largest class of proteases involved in various 
human pathologies such as arthritis [143], apotosis [144], asthma [145], osteoporosis [146] 
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and cancer [145, 147]. Many electrophilic inhibitors that specifically target the nucleophilic 
cysteine thiol in the catalytic triad have been developed for cysteine proteases including 
diazo- and fluoromethylketones (FMKs) [148], vinylsulfones [149], epoxides [51, 59, 150-
151] and acyloxymethyl ketones (AOMKs) [152-154]. 
ABPs based on the epoxysuccinyl inhibitor E-64 [155], a natural product with many valuable 
properties such as a peptide-like structure and potent inhibitory activity towards several 
papain-like cysteine proteases, were studied extensively by several groups [51, 53, 72, 156-
157]. Bogyo and co-workers have developed bifunctional probes DCG-03 and -04 for 
profiling the activities of enzymes from crude extracts of cell and tissues, identifying 
multiple cathepsins [157]. Extending this study, this group has generated several second-
generation libraries of diversified, “double-headed” epoxysuccinyl probes for investigating 
the selectivity among cysteine proteases, or containing a cell-permeable unit for in situ 
monitoring of enzyme function [72]. Furthermore, development of isotope-code ABPs 
enables quantitative analysis of cysteine protease activity [158]. Significantly, these studies 
highlight the ability of appropriately applied ABP design to tune the selectivity for individual 
cathepsins. Recently, Bogyo and colleagues have optimised aza-peptidyl epoxide ABPs that 
specifically label legumain, a lysosomal cysteine protease, for whole body non invasive 
imaging [51].  
Ploegh and co-workers have also recognised the potential value of E-64 and developed an 
azido-tagged E-64 based probe to target cathepsin B in primary macrophages [156]. 
Cathepsin B is an abundant papain-like cysteine protease that has been shown to contribute 
to microbial infections, apotosis and cancer [147, 159]. In this study, the investigators 
applied two-step non-radioactive labelling using the Staudinger ligation to evaluate 
cathepsin activity in living cells [156]. In addition, affinity enrichment of labelled proteins 
enabled subsequent mass-spectrometry analysis and fluorescent imaging allowed 
visualisation of the subcellular activity of cathepsin B during infection of macrophages by 
Salmonella typhimurium within sub-cellular compartments of individual cells. 
AOMK probes display an exceptional class-wide reactivity with cysteine proteases and were 
studied by several groups. Bogyo and co-workers have reported AOMK probes that targeted 
two major sub-classes of cysteine proteases: the CD clans containing caspase-3, legumain 
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and arginine- and lysine-gingipains and the CS clans containing cathepsin B and L [53, 160]. 
The specificity of these probes towards certain enzymes was achieved by diversification of 
the single amino acid or an extended peptide attached to the AOMK warhead in the library 
of ABPs. These chemical tools were also applied to label multiple cysteine proteases of the 
above mentioned clans in crude cell extracts. Recently, this group has reported elegant 
experiments showing dynamic labelling of specific cysteine proteases using fluorescent cell-
permeable quenched AOMK probes [161].  
Vinyl sulfone based probes, if specifically designed, could also target cysteine proteases in 
addition to their use for serine protease profiling discussed above. For example, Bogyo and 
co-workers have developed a vinyl sulfone based probe, FY01, containing free α-amino 
dipeptides to target cathepsin C in rat liver extract [162]. Cathepsin C, expressed in most 
mammalian cells, is a lysosomal cysteine protease also known as dipeptidyl aminopeptidase 
I. This protease has a unique characteristic within the CA clan of the papain family: the 
ability to remove sequentially dipeptides from the amino-terminus of larger peptides. This 
property was integrated in the design of FY01. In the latest study, FY01 was found in 
another application for high throughput screening to identify novel enzyme inhibitors [52]. 
 
Figure 1. 8: Structure of ABPs for cysteine proteases. FY01 is a vinyl sulfone based probe targets capthepsin C 
[162]. AOMK probes with variation at P2 position (indicated as R in the structure) can label specifically CD and 
CS clans of cysteine proteases [53]. DCG-04 has led to identification of multiple cathepsins in crude cell 
extracts [157].  
 
 
37 
 
1.4.4 Metalloproteases and aspartic proteases 
Metalloproteases (MPs) and aspartic proteases differ from the protease classes discussed in 
previous sections in that they do not covalently bond to their substrates but utilise an 
activated water molecule for catalysis [163-164]. Therefore, ABP design for these proteases 
is more challenging, as mechanism-based inactivation by electrophilic reagents cannot be 
used. Alternatively, ABPs can exploit tight-binding, broad spectrum reversible inhibitors by 
incorporation of a photoreactive group into the inhibitor structures so that these ABPs bind 
to the target enzyme in a reversible manner. 
MPs, a relatively large and diverse family of enzyme that uses a metal-activated water 
molecule, often a zinc ion (Zn2+), for catalysis [163] regulate a number of physiological and 
pathophysiological processes including tissue remodelling [165], cancer [166-167], arthritis 
and heart disease [167]. The precise biological roles of MPs are still unclear and broad 
spectrum inhibitors of this enzyme class that entered clinical trials suffered from dose-
limiting toxicity. Therefore, profiling and characterisation of MPs is a pressing need in the 
chemical biology and medicinal chemistry fields. Working towards this purpose, Cravatt and 
colleagues have generated probes that selectively bind and modify the matrix MP active site 
[168]. The core features of these probes include a hydroxamic acid moiety to chelate the 
conserved zinc atom in MP active site, a peptide-like scaffold containing a benzophenone 
group for photoinduced chemical cross-linking of the active sites, and a reporter unit (biotin 
or fluorophore) for manipulating the labelled target.  
Similarly, Yao and colleagues reported a library of complementary peptidyl hydroxamate 
AfBPs with a diazirine moiety insteady of the benzophenone group [169], to target 
thermolysin from yeast extracts in an activity-dependent manner. Interestingly, the probes 
generated by both laboratories targeted only the active form of MPs and not the inactive 
form such as inhibitor bound or zymogen. As a result, these probes can be used in 
competitive ABPP experiments to evaluate selectivity of AfBPs in whole proteomes.  
However, single fluorescent probes reported by Saghatelian et al. for identifying MPs in 
lysates suffered from the narrow spectrum of MPs identified and suboptimal detection of 
the low level of MP activities due to inherent limitations of the method [168]. The Yao group 
has improved on this by generating a library of probes by click synthesis for activity-based 
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finger printing of matrix MPs [170]. These probes bear a succinyl warhead and a diverse P1 
functionality to achieve enhanced specificities. In addition, these probes were applied to 
high throughput screening of MP activities in a protein array [38]. 
 
Figure 1. 9: Structure of ABPs for metalloproteases and aspartyl proteases. A) Representative photoreactive 
hydroxamate-based ABPs for metalloproteases [168-169]. B) A photoreactive hydroxyethylene-based ABP for 
aspartyl proteases [171].  
ABPs used for profiling aspartic proteases were also started from the template of high-
affinity, reversible inhibitors. Liu et al. at Merck have developed ABPs with similar key 
features as those for MPs, which contain a hydroxyethyl moiety to serve as a transition state 
mimic, a peptide-based scaffold possessing affinity to aspartic proteases, a benzophenone 
for photo-induced cross-linking and a biotin or fluorophore group for visualisation and 
identification [171-172]. These probes selectively labelled the solubilised γ-secretase from 
Hela cell lysates. As with MP probes, the generated probes labelled only the active form of 
γ-secretase.  
1.5 Mass spectrometry analysis 
Mass spectrometry (MS) plays a crucial role in chemical proteomics due to its wide 
applicability in biology, for example in the  characterisation of protein complexes [6], 
providing information about the localisation of proteins in cells and tissues [173], classifying 
bacterial species and subspecies [174], cataloguing the sub-cellular content of structures 
 
A)
B)
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and organelles [175], defining protein interactions and identifying sites of protein 
modification or post-translational modification (PTM) [176]. The use of MS for chemical 
proteomics is supported by rapid advances in MS instrumentation, fragmentation methods 
and computational analysis. In this section, the physical principles of each element of the 
mass spectrometer and its advances are introduced to provide an overview and an 
understanding of the methods used for the present study (described later).  
1.5.1 MS instruments 
MS measures accurately the mass-to-charge ratio (m/z) of a molecule. A general mass 
spectrometer is composed of three elements [173]: an ion source ensuring that sample 
molecules are ionised and brought into the gas phase, a mass analyser(s) separating the gas-
phase ions on the basis of mass-to-charge ratio using electromagnetic fields in a vacuum, 
and a detector responsible for recording the presence of ions (Figure 1. 10). 
Ion sources 
There are two well established ionisation sources commonly used in proteomics: matrix-
assisted laser desorption/ionisation (MALDI) [177] and electrospray ionisation (ESI) [178]. 
MALDI sources are typically based on a pulsed nitrogen UV laser and generate singly 
charged peptide ions, while ESI sources typically heat a  needle to between 40 °C and 100 °C 
to assist nebulisation and evaporation of samples, thereby generating singly and multiply 
charged peptide ions (2+, 3+, 4+ ). Both methods are sensitive, but MALDI is more tolerant 
than ESI to small amounts of contaminants, such as salts and detergents [5]. 
Mass analyser 
The mass analyser is the core of MS technology. There are four commonly used types of 
analyser: quadrupole (Q) [179], ion trap (IT) [180], time-of-flight (ToF) [181] and Fourier 
transform ion cyclotron resonance (FT-ICR) [182-183]. Each of the analysers possesses 
distinct advantages and limitations due to their physical principles and performance 
standards, as well as their mode of operation. Depending on the purpose of the proteomics 
study, one can choose the appropriate analyser to support the chosen analytical strategies. 
Because no instrument can currently offer all capabilities simultaneously, the determination 
of which platform and strategy is preferred is restricted from the outset: the focus is either 
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on identification or quantification. In the case of prioritising identification, resolving power 
(to obtain improved separation of the various components) and mass accuracy are 
important. On the other hand, sensitivity, dynamic range and multiple reaction monitoring 
(MRM) capability are the emphasis in the case of an experiment focusing on quantification.  
In ToF analysers, the velocity of the ion through a tube of specific length is related to the 
mass-to-charge ratio and therefore mass separation can be achieved by different time of 
flight of ions towards the detector [181]. ToF analysers can be operated with both MALDI 
and ESI ion sources and their performance has significantly improved in the last few years 
[5]. Several combinations of ToF with other analysers, such as Q-Q-ToF and ToF-ToF have 
been used to improve the sensitivity, resolution and mass accuracy [5, 184]. 
In IT analysers, effective trapping of ions in an oscillating electrical field leads to 
accumulation of these ions over time in a physical device [180]. Mass separation is acquired 
by tuning the oscillating field to eliminate only ions of a specific mass. IT possesses 
unrivalled sensitivity and fast data acquisition but is limited by low resolution and ion 
trapping capacity [185]. The dynamic range and overall sensitivity of IT instruments was 
improved by the development of the linear ion trap (LIT or LTQ), as this instrument offers a 
unique capability for analysis of PTMs [186]. 
In the quadrupole analyser, which consists of four rods forming two pairs running different 
current modes, ions are filtrated by high-pass mass between the first pair of rods and by 
low-pass mass between the other pair of rods. This filtration can be fine-tuned to overlap 
only in a specific mass-to-charge ratio interval. Ions with m/z values outside this interval will 
be excluded. Quadrupoles are usually applied in conjunction with other analysers (e.g.: Q-Q-
ToF, Q-Q-Q, QQ-LIT) to expand either sensitivity or selectivity [5, 184]. 
In the FT-ICR analyser, the ions are trapped in orbits by a very strong magnetic field in a 
particle accelerator called a cyclotron, while being accelerated by an applied voltage [182-
183]. The cyclotron frequency is related to m/z and Fourier transformation is required to 
extract individual ion frequencies. This technique allows measurement to accuracies in the 
low ppm to sub-ppm range. High resolution leads to better quality data and boosts the peak 
capacity, therefore this instrument can detect more signals compared to low resolving 
power instruments.  
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Figure 1. 10: Mass spectrometry instruments. The basic physical principles of each component of the mass 
spectrometer are shown. MALDI and ESI are ionisation sources and introduce sample into the analyser. Q 
analyser select by time-varying electric fields between four rods, which permit a stable trajectory only for ions 
of a particular desired m/z. In the IT, ions are trapped in an oscillating electrical field leading to accumulation 
of these ions over time. The FT-MS instrument also traps the ions, but does so with the help of strong 
magnetic fields. In Orbitrap, ions are captured and form an orbital harmonic oscillation along the axis of the 
field with a frequency characteristic of their m/z values. In TOF, the ions are accelerated to high kinetic energy 
and are separated along a flight tube as a result of their different velocities. At the detector (EM) ions are 
impinged on several Faraday cup dynodes, amplified and counted. Figure adapted from the lecture of Dr. 
Martens, EBI, Cambridge, UK. 
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In recent times, a new type of mass analyser, the Orbitrap [187], based on a new physical 
principle, was introduced to the field of proteomics [188]. It consists of an outer and inner 
coaxial electrode, which generate an electrostatic field. In the Orbitrap, ions are captured 
and form an orbital harmonic oscillation along the axis of the field with a frequency 
characteristic of their m/z values. This frequency is measured with very high precision and 
can then be calculated by Fourier transform. The performance of the Orbitrap is similar to 
the FT-ICR, but this instrument is cheaper (because it does not require an expensive 
superconducting magnet), much more robust and simpler to maintain [189-190]. Used in 
conjunction with a linear ion trap (LTQ), a new  mass spectrometer named the LTQ-Orbitrap 
(introduced by Thermo Fisher Scientific [191]) demonstrated the combined advances of 
both techniques in robustness, sensitivity and MS/MS capability, possessing very high mass 
accuracy and high resolution capabilities, and has become a powerful tool in proteomics 
studies.  
Detector 
The most common type of detectors are electron multipliers (EM) [192], which are based on 
several Faraday cup dynodes with growing charges to generate an electron cascade based 
on a few incident ions.  
MS mode of operation 
Both MS mode and MS/MS mode are widely applied in proteomics. In MS mode, only one 
MS selection takes place and provides peptide mass spectra that allow subsequent 
identification of the parent proteins using peptide mass fingerprinting (PMF) [176, 193]. In 
contrast, MS/MS, also known as tandem-MS, employs two mass analysers in series (tandem) 
with some form of fragmentation taking place in between each MS selection [5]. The first 
mass analyser serves as an ion selector, by selectively passing through only ions of a given 
m/z. The second mass analyser positioned after fragmentation is triggered and exerted in its 
normal capacity as a mass analyser for the fragments. Tandem-MS allows determination of 
the amino acid sequence of a specific peptide, which can also be used for identification of 
parent proteins by PMF but with more confidence in the identification results. Various types 
of tandem-MS experiments are reviewed in several publications [5, 103, 175, 190, 194].  
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Fragmentation methods 
Several fragmentation techniques are utilised in proteomics, such as collision-induced 
dissociation (CID) [195], post-source decay (PSD) [196], electron-capture dissociation (ECD) 
[197-198] and electron-transfer dissociation (ETD) [199]. CID is the most widely used 
method and relies on multiple collisions events of a gas-phase peptide with rare gas atoms 
to provide the peptide precursor with sufficient energy to fragment. CID typically causes 
backbone fragmentation [195]. On the other hand, PSD is based on a single unimolecular 
event activated by laser energy, in which a highly energetic (metastable) ion spontaneously 
fragments [196]. PSD also typically causes backbone fragmentation. ECD and ETD rely on a 
single impact of an electron with a peptide precursor either by capture of a thermal electron 
or transfer of electrons from radical anions to the protonated peptide/protein. This high-
speed impact immediately imparts sufficient energy to fragment the precursor. Like CID and 
PSD, ETD and ECD also typically produce backbone fragmentation, however ECD is only 
workable in FT-ICR mass spectrometers, whereas ETD is used in traps. 
1.5.2 Bioinformatics/database search approaches 
Mass spectra contain the mass and charge as well as the intensity of the parent ion and its 
fragment ions. These data are submitted to a search engine such as Mascot [200], SEQUEST 
[201], X!Tandem [202] or OMSSA [203], which match the provided data to in silico 
fragmented peptide spectra or a peptide data base containing all experimentally-identified 
peptides and proteins [204]. Despite the huge number of all theoretically possible amino 
acid combinations, there is only a very minor subset of protein sequences that are formed in 
nature, and therefore a short peptide sequence is already highly protein-specific. However, 
it should be noted that the identified peptide can be also matched to several proteins, if 
these proteins are highly homologous. In that case, the number of unique identified 
peptides that are matched unambiguously to only a single protein is important. 
Subsequently, statistical validation of identified peptides and proteins provides scores that 
are used to assess the quality of matches. 
Mascot and SEQUEST are the most widely used search algorithms, but their principles are 
fundamentally different [204]. Several studies had compared these algorithms and others to 
offer a starting point for researcher to choose an appropriate solution for their study [204-
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206]. Mascot scoring algorithm is probability based and scores the best match of the 
observed and predicted spectra with the highest score and a significant match is typically a 
score of the order of 70 [200]. In contrast, SEQUEST algorithm scores the alignment 
between observed and predicted spectra using empirical and correlation measurements 
[201]. Traditionally, TOF-acquired spectra are interpreted with Mascot, whereas SEQUEST is 
used to sequence ion-trap spectra [206]. Both algorithms are fairly comparable and can 
complement each other [206].  
There is a huge number of databases, both public or commercial, available to search 
engines. Some well known databases that are widely used in proteomic studies include 
EMBL Nucleotide DB (European Molecular Biology Laboratory) [207], DDBJ (DNA Data Bank 
of Japan) [208], GenBank [209], NCBI (National Center for Biotechnology Information) [210-
211], Ensembl (Sanger Institute and EBI) [212], UniProt (Universal Protein Resource) [184], 
Swiss-Prot (Swiss Institute of Bioinformatics) [213], and PRIDE (Proteomics Identifications 
Database) [214]. Most of the databases are linked and easily navigated between each other. 
NCBI and EMBL have been used in the present study.  
1.5.3 MS-based proteomic strategies for protein identification and PTM 
characterisation 
Proteomic studies diverge in their objectives: they may focus on the identification of 
proteins in a complex proteome and possible the PTMs of those proteins or they may try to 
address the absolute quantification of proteins or quantitative change in protein abundance 
between samples. Strategies for protein identification and PTM characterisation have 
emerged in two different approaches illustrated in Figure 1. 11: a “top-down” approach 
(whole-protein analysis) and a “bottom-up” approach (analysis of enzymatically or 
chemically digested peptides).  
1.5.3.1 Top-down proteomics 
In this strategy, complex cellular lysates are separated or fractionated, then ionised into gas-
phase intact ions or large protein fragments. Subsequently, these ions and fragments are 
measured by a high resolution mass analyser following their direct fragmentation without 
any pre-digestion. The strengths of this strategy are the potential acquisition of the whole 
protein sequence and the ability to trace and characterise possible PTMs of proteins [190, 
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215]. Furthermore, the possible variations and inconsistencies related with the digestion 
process can be avoided. However, this approach suffers from ambiguous and difficult data 
analysis resulting from the very complex spectra obtained from multiply charged proteins 
[216]. Further limitations such as expensive implementation costs (associated with the 
requirement for high resolving power instruments such as FT-ICR, LIT-FT-ICR or LIT-Orbitrap 
mass spectrometers), the size limit of analysed proteins (not larger than 50 kDa) and 
primitive bioinformatic tools disfavour this strategy compared with the bottom-up strategy. 
However, this approach is relatively young in its development and there is still scope for 
future improvements.  
 
Figure 1. 11 : Workflows for MS-based protein identification and characterisation [190]. Bottom-up or top-
down approaches can be used to analyse proteins. In the top-down approach, a protein mixture is fractionated 
and separated before analysis via either off-line static MS or on-line LC-MS/MS. In the bottom-up approach, a 
protein mixture may be separated before enzymatic (or chemical) digestion followed by either direct PMF-
based acquisition or further peptide separation on-line coupled to tandem MS. Alternatively, the protein 
mixture can be directly digested and then separated by multidimensional chromatography on-line coupled to 
tandem MS analysis (the ‘shotgun’ approach). The highlighted workflow was applied in this study. 
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1.5.3.2 Bottom-up proteomics 
Unlike the top-down approach, analytes for bottom-up proteomics are pre-digested before 
being introduced into the mass spectrometer. Two divergent workflows are commonly 
conducted: “break-then-sort” or “sort-then-break”.  
The break-then-sort approach, also known as shotgun proteomics, deals with analytes that 
are digested without any pre-fractionation/separation [190, 215]. This approach has the 
advantage that it is conceptually and experimentally simple to implement, but it suffers 
from challenging data analysis (due to interfering peptide and protein sequence identities), 
as well as the massive complexity of the samples [216].  
On the other hand, the sort-then-break approach offers samples with a much lower degree 
of complexity, because proteins are separated or fractionated prior to digestion followed by 
direct PMF [193] or further on-line separation using LC interfaced to a tandem-MS [215]. In 
addition, this approach may provide access to physical properties (e.g. approximate mass, 
isoelectric point) of the intact proteins in addition to their identities.  
Peptide mass fingerprinting (PMF) 
PMF [193] allows the identification of proteins by comparing the peptide masses generated 
during the MS analysis to the calculated peptide masses produced by in silico cleavage of 
proteins or gene sequences in the database. This method profits by saving the time and cost 
involved in the de novo peptide sequencing process. 
1.5.3.3 Quantification method 
Protein quantification aims to compare a stressed or perturbed state to an unperturbed 
reference sample. Several reviews describe extensively the strategies for quantification in 
MS-based proteomics [4-5, 173, 175, 194, 217-218]. There are several methods to 
determine the (relative) quantity of a protein using MS. Usually, these methods are 
categorised in three types: metabolic labelling (e.g.: 15N labelling [219], stable isotope 
labelling by amino acid in cell culture (SiLAC) [220]), chemical labelling (e.g.: isotope-code 
affinity tag (ICAT) [221], isobaric tags for relative and absolute quantification (iTRAQ) [222], 
standard peptide [223]) and label free quantification (e.g.: ion intensities [224], spectral 
count [204], divided indices [225-226]).  
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Stable isotope labelling approaches, whether metabolic or chemical labelling, share one 
common characteristic in that they are based on the mass differences of unlabelled and 
labelled peptides with stable isotopes, as these peptides exhibit the same properties during 
chromatography [218]. Metabolic labelling and chemical labelling are distinguished in their 
methodology: chemical labelling is introduced to the proteins or tryptic digested peptides 
through a chemical reaction, whilst metabolic labelling is achieved in the whole cell or 
organism during growth via the growth medium or feed. 
Label-free quantification is based on the number of acquired spectra for each protein or on 
the ion intensities of identical peptides. These approaches are inexpensive, quick and 
effective for relative quantification of proteins [194, 218]. Spectral counting is one of the 
most applied, which operates under the assumption that if a protein is more abundant in 
one sample than another then the number of spectra corresponding to this protein will 
correlate linearly with its abundance during analysis [194, 218]. This is attainable if sample 
treatment is unbiased and samples equally represented. Although this quantitative 
approach is reliable for determining the relative abundance of proteins identified with many 
spectra (peptides), it is important to note that this approach is relatively unreliable for 
quantifying low-abundance proteins because such proteins will produce very few spectra 
leading to low spectral counts and consequently lower reproducibility [227]. For example, if 
only one spectrum was found for protein A in sample one and four spectra for protein A in 
sample two, it is not valid to conclude that the abundance of protein A is four-fold higher in 
sample two compared to sample one since the run-to-run variability in spectral count for a 
given protein is frequently of the same order of magnitude.  
There are many ways to compare spectral abundance, such as unweighted spectral counting 
(a method of counting peptides in all instances when they are shared between proteins), 
quantitative value (a normalised version of the unweighted spectral count), number of 
unique spectra or unique peptides, number of assigned spectra (the total number of spectra 
that matched to a peptide in the protein), percentage of total spectra (the number of 
spectra matched to the protein as a percentage of the total number of spectra in the 
sample) and the relative abundance or fold change (the spectral count ratio of the 
sample/protein to the control sample/protein).  
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1.6 Clostridium difficile 
Clostridium difficile is an anaerobic Gram-positive bacterium and produces spores that can 
survive for a long time in the environment. It was first isolated by Hall and O'Toole in 1935 
and named  Bacillius difficilis due to difficulties of isolation and culture [228]. However in 
the late 1970s this bacterium was identified as the cause of diarrhoea and colitis occurring 
mostly as a complication of antibiotic therapy [229]. During the past few years there has 
been renewed interest in C. difficile, due to the recognition that the disease is more 
common, more severe, and more resistant to standard treatment than previously thought 
[230-231]. Recognised now as the main cause of infectious diarrhoea, C. difficile is the most 
frequent nosocomial (hospital acquired) pathogen. It causes a wide range of gastrointestinal 
diseases ranging from mild diarrhoea to more life threatening pseudomembranous colitis 
(Figure 1. 12) [232].  
C. difficile is resistant to many antibiotics and infection is associated with antimicrobial 
therapy. Many individuals are asymptomatically colonised with C. difficile, but it is thought 
that the resident microflora restricts growth of C. difficile and limits bacterial growth and 
toxins expression. Antibiotic treatment can disrupt the normal bacterial gut flora, allowing 
C. difficile growth and toxin production. The acquisition of C. difficile infection (CDI) is 
through spread and transmission of spores, usually by the faecal-oral route through contact 
of the patients with the hospital environment or health care workers. C. difficile spores are 
highly resistant to heat and disinfectants and can persist in the hospital or nursing home 
environment for months or even years. Heat-resistance even helps spores to survive typical 
hospital laundering cycles and cross-contamination of bed linen during the wash cycle can 
occur. Once spores are ingested, they pass through the stomach unscathed because of their 
acid-resistance, and then germinate to form vegetative cells. The colonised C. difficile strain 
can be either non-toxigenic or toxigenic. Toxigenic C. difficile strains produce and secrete at 
least one of the two major toxins, toxin A (TcdA) and toxin B (TcdB) [233-237], which are the 
main pathogenicity factors of the bacterium. If the patients are infected by a non-toxigenic 
strain or their body can mount an antibody response to the toxin, they are protected from 
CDI.  
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The drugs of choice for treatment of CDI remain orally administered metronidazole or 
vancomycin, despite the dramatic increases in the severity and incidence during the past 
decade. About 20-25 % of patients will have a recurrence of symptoms when either therapy 
is discontinued [238], and the risk of a recurrent infection increases to about 40 % after the 
first recurrence and to more than 60 % after a later recurrence. In severely complicated 
cases, surgical removal of the colon is the only remaining life-saving measure. Recurrent 
infections can also be treated by regenerating the normal intestinal microbiota with a faecal 
transplant. Although this appears to be a highly effective treatment, it is logistically very 
complicated and rarely performed. 
 
Figure 1. 12: A) Normal colon viewed with endoscope; B) Endoscopic view of pseudomembranous colitis, 
showing typical yellow pseudomembranes on the colonic mucosa; C) Cross section of a colon with 
pseudomembranous enterocolitis. Yellow-green plaques partially cover a hyperaemic mucosa, which itself is 
not eroded. Images are from The Internet Pathology Laboratory for Medical Education, Florida State University 
College of Medicine at http://www.medlib.med.utah.edu/WebPath/ORGAN.html 
There is no doubt that C. difficile infections are increasing in frequency and severity. 
Prevalent endemic CDI and outbreaks have been reported in many hospitals in the UK and 
internationally. Reports on epidemic outbreaks of infection with hypervirulent C. difficile 
strains (ribotype 027) have shown that the rising rate of CDI has been largely assigned to the 
50 
 
presence of this strain. In US hospital and long-term care facilities, cases of CDI increase 
each year. The current estimate is ca. 500,000 cases a year, increased from <150000 in 
2000. From these 500,000 CDI cases, 15,000 to 20,000 patients are estimated to die from 
CDI each year. The extra costs associated with infection are around £4000 per patient, by 
reason of treatment and tests required, and extra time spent in hospital [239], amounting to 
an estimated $1.1 billion per year in US alone [240]. Increasing infection levels also found in 
Europe. For example, incidence of CDI in Saxony, Germany increased up to threefold 
between 2002 and 2006. In England and Wales, the number of deaths involving C. difficile 
rose by 28 % between 2006 and 2007. However, in the last few years, a marked decrease of 
CDI cases in England was observed due to recent national mandatory reform in hospitals 
including environmental decontamination, reducing the cross-infection opportunities by 
hand hygiene and barrier precautions. 
The main group of people who are at high risk of CDI are elderly hospitalised patients. 
However C. difficile is not always a pathogen. It is one of dozens of Clostridial species that 
can be found in a low percentage in the healthy human colon and widespread in the 
environment [241-242]. Asymptomatic carriage is even more common in children [243], 
perhaps reflecting the different conditions in the immature intestine which might lead to 
less advantageous environmental conditions for bacterial pathogenicity. Molecular 
microbiologists have not paid great attention to C. difficile in the past, partly because of 
difficulties in handling anaerobes and more specifically the lack of genetic tools. However, 
this is changing with more laboratories intensively scrutinising C. difficile, aiming to 
understand in more detail the properties of this organism and its pathogenesis. For 
example, directed mutagenesis in C. difficile is more difficult than in other well studied 
species such as E. coli. There is no reliable technique for conditional gene deletion, however 
constitutive gene knockouts can be achieved using the ClosTron system, utilising a bacterial 
retargeted mobile group II intron [244]. This allows creation of stable mutants in Clostridium 
species in a few steps including intron design, plasmid cloning, plasmid transfer to the C. 
difficile and integrant isolation. Notably, the complete genome sequence of C. difficile strain 
630, a virulent and multidrug-resistant strain, was published in 2006 [245], enabling the use 
of standard bioinformatic and genetic analyses. Further sequencing projects are ongoing 
51 
 
with other virulent strains which will hopefully improve our understanding of this 
challenging organism. 
1.6.1 C. difficile virulence factors 
The main virulence factors of C. difficile are toxins A and B. These toxins catalyse the 
glucosylation and inactivation of Rho-GTPases, which are regulatory proteins with many 
functions in the eukaryotic cell. Both toxins are virulence factors, as permanent gene knock-
out of either one or both toxins showed significantly reduced virulence activity, at least in 
the hamster model tested [246]. Biochemical, genetic and structural studies of these toxins 
have improved our understanding of their important role in pathogenesis. As this lies 
outside the scope of this thesis, details of the toxins are not discussed in this literature 
review but further reading can be found in the following publications: [246-249]. 
Other virulence factors have also been described, such as adhesins and hydrolytic enzymes 
[233, 250-251]. Among these, the surface layer proteins (SLPs) are additional potential 
virulence factors. They are proposed to aid the colonisation of the bacteria induce both 
inflammatory and antibody responses in the host. These proteins may adhere directly to the 
host cell or compete with the host flora.  
1.6.2 The S-layer of Clostridium difficile  
The S-layer of C. difficile has been studied by a number of groups. As in several other 
bacteria, the surface layer proteins are the predominant surface proteins in C. difficile. 
However, in contrast to most other species, where the S-layer is composed of one protein, 
the S-layer of C. difficile constitute of two distinct proteins: a low molecular weight (LMW) 
SLP and high molecular weight (HMW) SLP [252-254]. Interestingly, the sizes of these 
proteins vary between strains. The LMW SLP is  32–38 kDa and the HMW-SLP  42–48 kDa in 
size. Both the high and low molecular weight subunits are derived from a single gene, slpA, 
confirmed by sequencing of S-layer proteins and comparison with the C. difficile genome 
[255-256]. This gene is strongly transcribed during the entire growth phase [257] and it is 
estimated that up to 400 molecules of SlpA per cell per second are produced, translocated, 
and cleaved during the exponential growth phase. The translated gene product SlpA 
undergoes two rounds of post-translational cleavage, firstly to remove the signal sequence 
that targets the nascent chain for translocation across the cytoplasmic membrane, and then 
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internally (at position 355 in SlpA from strain 630) to release the two mature SLPs, LMW–
SLP and HMW–SLP [258-260] (Figure 1. 13). It is presumed that removal of the signal 
peptide occurs prior to or during translocation across the plasma membrane, while the 
second cleavage takes place either within the plasma membrane or external to the 
membrane, i.e. within the cell wall. After cleavage, the mature proteins form a complex and 
reassemble to build the S-layer with a square symmetric outer layer and a hexagonal 
symmetric inner layer [252].  
 
Figure 1. 13: Processing of the C. difficile S-layer. The SlpA precursor  is synthesised in the cytoplasm as a 
single polypeptide and, after targeting to the membrane (A), is translocated to the cell wall where proteolytic 
cleavage occurs (B) forming the two components of the S-layer, HMW SLP  and LMW SLP . Finally, the 
S-layer is assembled on the surface of the bacterial cell wall (C).  indicates an unidentified cysteine protease. 
 designates other cell wall proteins with cell wall binding domains (unspotted) and surface exposed domains 
(spotted). 
Recently, the Fairweather laboratory reported the structure of the resultant LMW/HMW-
SLP complex [261]. Using a combination of genetic and structural studies (X-ray 
crystallography of the truncated LMW-SLP and SAXS of full length LMW-SLP and 
LMW/HMW-SLP complex), several important points were identified. Firstly, the interaction 
between the two matured proteins, LMW- and HMW-SLPs, is non-covalent but very tight 
with an estimated affinity of 10 nM as the dimer. Gel electrophoresis under denaturing 
conditions (i.e. using SDS) breaks the interaction and revealed two distinct proteins on the 
gel after staining, whilst only one band (the complex) was found under native conditions. 
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Secondly, the structure of the LMW-SLP can be divided in three domains: domain 1, domain 
2 and an interaction domain (Figure 1. 14). The interaction domain of the LMW SLP (C-
terminal 62 residues; 260-321) was identified using ELISA (enzyme-linked immunosorbent 
assay) probing a series of deletion derivatives of the LMW SLP with the full length HMW SLP. 
A complementary series of deletions of the HMW-SLP identified the interaction domain of 
this protein. The LMW-SLP was further investigated by study of SAXS and X-ray structure. 
Domain 1 is small and contains both N-terminal (residues 1-88) and C-terminal (residues 
239-249). Domain 2 is much larger and is the part that is exposed to the external 
environment. Thirdly, similar to LMW-SLP, the HMW-SLP also possesses an interaction 
domain, which is essential for the complex formation. However, this domain is located 
within the first 40 N-terminal residues. Therefore, the LMW- and HMW-SLPs bind to each 
other via their C- and N-terminal respectively (see Figure 1. 14). 
 
Figure 1. 14: A) Model of the interaction between the HMW SLP and LMW SLP. B) Proposed structure of the 
LMW/HMW-SLPs complex on the cell wall. A low resolution SAXS structure of the complex is shown overlaid 
with the crystal structure of the truncated LMW SLP. Three different domains of LMW-SLP are indicated. 
Figure is adapted from Fagan et al. [261]. 
A) 
 
B) 
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Sequence analysis of slpA genes from several strains shows that the LMW–SLPs have a 
remarkable degree of variability, which could play a role in the antigenic variation of the 
bacteria as the LMW–SLP is immuno-dominant [252, 255, 262-263]. Despite the low level of 
sequence homology (largely in the sequence of domain 2) seen in the LMW–SLP across 
different strains, a highly conserved GKR motif is seen located near to the predicted 
cleavage site that generates the two mature SLPs [264-265]. This motif may be essential for 
the recognition by the protease which mediates this cleavage or it may perhaps be involved 
in formation of the two-dimensional lattice. The identity of the protease that performs this 
internal cleavage was unknown at the outset of the present study, and studies directed 
towards its identification are the topic of this thesis. 
Strains   SlpA cleavage sequence 
  N-terminal Cleavage position C-terminal 
 ....  P8 P7  P6  P5  P4  P3  P2  P1  P’1  P’2  P’3  P’4  P’5  P’6 P’7  ...  
R8366  .... G K  R  V  T  T  K  S  A  A  K  A  S  I  A  .... 
R7404 .... G K  R  L  E  T  K  S  A  D  I  I  A  D  A  .... 
R13702  .... G K  R  L  E  T  K  S  A  D  I  I  A  D  A  .... 
Cd630  .... G K  R  L  E  T  K  S  A  N  D  T  I  A  S  .... 
R12882  .... G K  R  L  E  T  K  S  A  N  D  T  I  A  S  .... 
R13550  .... G K  R  L  E  T  K  S  A  N  D  T  I  A  S  .... 
Cd 959 .... G K  R  L  T  T  K  G  A  T  G  T  L  A  D  .... 
SE528  .... G K  R  L  D  T  K  G  A  T  D  I  E  N  T  .... 
R13540  .... G K  R  L  T  T  K  S  A  T  Q  A  S  K  T  .... 
R13549 .... L  N  T  A  S  T  Y  A  S  S  N  Y  P  E  L  ....  
R13699  .... G K  R  L  N  T  L  S  A  S  S  A  K  T  I  .... 
R12884  .... L  Q  G  F  S  T  Y  R  A  T  N  Y  N  E  G  .... 
Cd 167 .... L  Q  G  F  S  T  Y  R  A  T  N  Y  N  E  G  .... 
Cd Y  .... R L  Q  F  S  S  Y  G  K  F  S  T  D  E  A  .... 
Table 1. 2: Alignment of SlpA sequences at the LMW-HMW cleavage locus. 
The HMW–SLPs are considerably more conserved in sequence, and all display significant 
homology to the cell wall-anchoring domain of autolysin CwlB of Bacillus subtilis [252, 264]. 
Using antisera to the HMW– and LMW–SLPs, it was shown that the anti-LMW–SLP 
antibodies do not always cross-react with the LMW–SLPs of other strains, whereas the 
HMW–SLPs are more antigenically conserved [252, 254-255, 266]. Antibodies to the LMW–
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SLP are found in the sera of CDI patients whereas the HMW–SLP seems to be poorly 
immunogenic in C. difficile infections [262, 267-268].  
Despite the increasing number of C. difficile strains isolated from clinical cases, only a few 
slpA genes have been sequenced and characterised [264-265, 269]. Alignment of slpA 
sequences, and in particular of the N-termini of a small number of HMW–SLPs as 
determined by Edman degradation and/or mass spectrometry, reveals sequence homology 
at the cleavage locus. Sequence analysis of approximately 20 strains (from different sources) 
reveals the putative cleavage site between the LMW and HMW subunits. Based on this 
homology, the SlpA cleavage sites of other C. difficile strains were predicted (Table 1. 2).  
Methods to isolate the S-layer 
Surface proteins can be isolated from the cell by various methods including treatment with 
LiCl, EDTA, urea or low pH glycine [270-274]. All of these treatments act on the cell wall but 
with different mode of actions. Therefore, they have different impact on the type and 
number of the released proteins. In a study undertaken by Anne Wright, a past member of 
Fairweather group, a comparison of these extraction methods was performed and revealed 
that LiCl and EDTA treatments are rather an inefficient approach to remove all surface layer 
proteins compared to urea and low pH glycine, judging by the released amount of LMW- 
and HMW-SLPs and other proteins [275]. Urea treatment released a significant number of 
other proteins besides the LMW- and HMW-SLPs, some of which may be due to cell lysis. 
Low pH glycine treatment resulted in equimolar amounts of LMW- and HMW-SLPs and 
fewer background proteins.  
1.6.2.1 Other cell wall proteins 
Whilst the SLPs are the most abundant in the surface layer, many other cell wall proteins 
have been postulated by analysis of the C. difficile 630 genome. These proteins belong to a 
family of genes related to slpA (about 29 genes) and share one common feature: all of these 
genes contain two or three Pfam 04122 motifs ( known as putative cell wall binding motifs) 
and a signal sequence (Figure 1. 15) [255, 263, 276-277]. In addition to these common 
features, some of these proteins bear another domain which may confer a known or 
putative function. Among them, a protein of ~70 kDa was consistently co-purified in all 
strains [266, 272] and is now recognised to be Cwp2 [264]. Another cell wall protein, Cwp66, 
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has a two-domain structure: the C-terminal domain is exposed to the cell surface, and has 
been described as an adhesin, while the N-terminal domain has homology to the cell wall-
anchoring domain and is thought to anchor Cwp66 to the cell wall of C. difficile [278]. 
Another putative adhesin is the cell wall protein CwpV, which is phase-variable [279]. About 
5 to 7 % of C. difficile cells express CwpV. Finally, Cwp84 is identified as a cysteine protease 
[280], and is discussed in details in later section.  
 
Figure 1. 15: Cell wall proteins (CWP) in C. difficile 630 [255]. Cysteine protease homolog domains in Cwp84 
and Cwp13 are shown in green, and other conserved domains are coloured according to the key shown above 
(alignment performed and figure generated by Dr Jenny Emerson). SH3_3, Src homology (SH) regions; PepSY, a 
regulator of peptidase activity; CAP, pathogenesis-related
 
1 proteins, Big_3, brefeldin A-inhibited guanine 
nucleotide-exchange protein 3; YkuD, spores protein; DUF187, domain of unknown function 187. 
1.6.3 Proteases in C. difficile 
Despite the importance of C. difficile as a pathogen, apart from its two toxins and S-layer 
proteins, the organism is very poorly characterised. Currently, construction of mutants in C. 
difficile is very challenging, and alternative biochemical approaches towards 
characterisation of enzymes are employed. Only a few protease activities of C. difficile have 
been reported to date. Proteolytic activity has been observed in ten strains of C. difficile, 
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with degradation of gelatine, collagen and azocoll observed in all of those isolates [281]. 
Similar results were reported by Steffen and Hentges concerning production of gelatinase, 
collagenase, hyalurodinase and chondroitin sulfatase activities in C. difficile [282]. However 
the proteases responsible are not characterised in vitro, and their identities remain 
unknown. 
The MEROPS database lists 139 known and putative peptidases in C. difficile with both 
known or unknown functions, and in addition 63 non-peptidase homologues. This database 
also classifies the peptidases in predicted protease classes where possible. Table 1. 3 
compiles the number of these peptidases in the corresponding classification.  
Protease class Number of peptidase found 
Aspartic protease 5 
Cysteine protease 17 
Metalloprotease 112 
Serine/Cysteine protease 17 
Serine protease 41 
Threonine protease 1 
Unknown 7 
Table 1. 3: Peptidases and non-peptidase homologues classified in the MEROPS database. 
As noted previously, C. difficile synthesises two major toxins, toxin A and toxin B, both of 
which are responsible for the clinical manifestations of the disease. These toxins are large 
multi-domain proteins, whose actions depend on a complex uptake mechanism, including 
auto-proteolytic processing to release an N-terminal glycosyltransferase domain [283]. Both 
cysteine [283] and aspartate [284] protease activity have been proposed as responsible for 
the cleavage process of the toxin.  
1.6.3.1 Putative cysteine proteases in the S-layer: Cwp84 vs. Cwp13 
One interesting finding from studies of cell wall proteins of C. difficile was the presence of 
two proteins, Cwp13 and Cwp84, that have high homology to cysteine proteases (Figure 1. 
15) [285]. Cwp13 remains uncharacterised, whereas recombinant (E. coli produced) Cwp84 
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was experimentally characterised in vitro as a cysteine protease with degrading activity on 
extracellular matrix proteins [280].  
Comparison of both proteases reveals that they have relatively similar size of about 87 kDa. 
Both proteins possess a cysteine protease domain and three repeated cell wall binding 
domains Pfam 04122 [286] (Figure 1. 15). The genes have 63.2% nucleotide sequence 
identity. However, their locations in the genome are situated approximately 1.2Mb apart 
from each other. Cwp84 is found in the same genomic region as slpA and a number of other 
cell wall proteins including cwp2, cwp66 and cwp6, while cwp13 is not included in this gene 
cluster (Figure 1. 16 A and B). Sequence alignment of these proteases with well-known 
papain-like cysteine proteases such as human procathepsin L (1CS8) [287], rat cathepsin C 
(1JQP) [288], rat procathepsin B (1MIR) [289], procaricain (1PCI) (in the latex of Carica 
papaya) [290], cysteine protease Der p 1 (from a house dust mite allergen) (1XKG) [291], the 
Plasmodium falciparum cysteine protease Falcipain-2 (1YVB) [292], human procathepsin S 
(2C0Y) [293], procathepsin L1 from Fasciola hepatica (2O6X) [294], human procathepsin B 
(3PBH) [295] and human procathepsin K (7PCK) [296] revealed that the catalytic triads of 
both proteases are located in the same region of the polypeptide chain, even though the 
amino acid numbering is not identical for the two proteases (Figure 1. 16B). The Cwp84 
catalytic triad is predicted to consist of C116-H263-S295, whereas the one for Cwp13 is 
predicted to be C109-H256-N288. 
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Figure 1. 16: A) Genomic region of Cwp13 and Cwp84. B) SlpA locus. C) Sequence alignment of Cwp84 and 
Cwp13 with well-known papain-like proteases. The cysteine residue in the catalytic triad is indicated in red. 
ClustalW was used to align the amino acid sequences which was obtained from RCSB protein data bank 
website.  
1.7 Project aims and outline 
Recognising the need for novel therapies for the drug-resistant C. difficile, this project aims 
to identify and characterise potential therapeutic targets in this bacterium using ABPP. As 
the synthesis and processing of the S-layer are key steps in the biogenesis of the cell wall, 
this thesis describes an in-depth chemical proteomic investigation of SlpA processing as a 
target for therapeutic intervention.  
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Procathepsin B (1MIR) 62 -LPESFDAREQWSNCP---TIAQIRDQGSCGSSWAFGAVEAMSDRICIHT 108
Human procathepsin B (3PBH) 63 -LPASFDAREQWPQCP---TIKEIRDQGSCGSCWAFGAVEAISDRICIHT 109
Human procathepsin K (7PCK) 94 EWEGRAPDSVDYRKKG---YVTPVKNQGQCGSCWAFSSVGALEGQLKKKT 141
Human procathepsin S (2C0Y) 93 NPNRILPDSVDWREKG---CVTEVKYQGSCGAAWAFSAVGALEAQLKLKT 140
Procathepsin L (1CS8) 91 PLFYEAPRSVDWREKG---YVTPVKNQGQCGSCWAFSATGALEGQMFRKT 138
Procathepsin L1 (2O6X) 87 N-NRAVPDKIDWRESG---YVTEVKDQGNCGSGWAFSTTGTMEGQYMKNE 133
Procaricain (1PCI) 101 EDIVNLPENVDWRKKG---AVTPVRHQGSCGSCWAFSAVATVEGINKIRT 148
Cysteine Protease Falcipain-2 (1YVB) 16 ----FDHAAYDWRLHS---GVTPVKDQKNCGSCWAFSSIGSVESQYAIRK 59
Cwp84 86 PSAYKSSVAYNPMDLG---LTTPAKNQGSLNTCWSFSGMSTLEAYLKLKG 133
Cwp13 84 -----APTSYDPRKLG---LMTSIKNQEDLGICWDFAAMATLESFLKLNN 126
Cathepsin C (1JQP) 200 QQILSLPESWDWRNVRGINFVSPVRNQESCGSCYSFASLGMLEARIRILT 250
Cysteine protease Der p 1 (1XKG) 84 SINGNAPAEIDLRQMR---TVTPIRMQGGCGSAWAFSGVAATESAYLAYR 131
C)
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1.7.1 Structure of this thesis 
Chapter 1: The first chapter introduces ABPP and relevant techniques that can contribute 
towards a chemical and microbiological toolbox for investigation the S-layer of C. difficile.  
Chapter 2: This chapter describes the screening of commercial inhibitors leading to the 
discovery of the first inhibitors of S-layer processing. E-64 is discussed as a starting point for 
inhibitor design. 
Chapter 3: Based on E-64, a series of inhibitors is designed, synthesised and tested in vivo.  
Chapter 4: In this section active inhibitors are transformed into ABPs. Subsequently, the 
condition of bio-orthogonal ligation using these probes is developed and optimised.  
Chapter 5: Direct label probes are developed and employed for target identification. 
Chapter 6: The labelled target enzymes are enriched and identified using mass 
spectrometry.  
Chapter 7: This chapter describes the exploration of further cysteine protease inhibitors in 
C. difficile. 
Chapter 8: The main conclusions drawn from the work are presented and potential 
directions for future investigation are summarised in this section.  
Chapter 9: This chapter records the experimental methods used throughout the thesis. 
Chapter 10 and Chapter 11: These chapters contain the references and appendix figures.  
The results generated by this study have two potential outcomes. Firstly, they may provide a 
new route to develop therapeutic targets against C. difficile. Secondly, the advances in 
chemical technology employed here may enable comparable insights into related species 
(e.g. C. tetani, the bacterium that causes tetanus) and related pathogenic processes (e.g. 
release and processing of bacterial toxins). 
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Chapter 2 Discovery of E-64 and leupeptin as the first inhibitors 
of S-layer processing in C. difficile  
 
C. difficile secretes a family of proteins that are held in place on the cell wall by non-
covalent forces, forming the S-layer, which surrounds the entire cell. These S-layer 
proteins (SLPs) are immunogenic in humans and play a role in binding to host cells 
[258]. Synthesis of the C. difficile S-layer involves site-specific proteolytic cleavage of the 
precursor SlpA into two components by one or more C. difficile proteases, that were 
unknown at the outset of the work reported here [255]. We hypothesised that 
processing of SlpA would be inhibited by addition of a protease inhibitor to a growing 
culture of C. difficile. The focus of this chapter is the series of experiments that led to 
the discovery of the first inhibitors of SlpA processing, and preliminary classification of 
the protease(s) involved in the cleavage of SlpA. As part of this work, an assay was 
developed to monitor the inhibition of SlpA cleavage, and this was used as the basis for 
inhibitor optimisation (Chapter 3) and ABP development (Chapter 4).  
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2.1 Screening of commercial inhibitors  
2.1.1 Inhibition assay 
As described in the previous chapter, the initial aim of the current project was to investigate 
S-layer biogenesis, and in particular the SlpA maturation events that lead to the LMW and 
HMW SLPs. In order to assign the protease(s) involved in the cleavage of SlpA to one of the 
protease families, a general method was developed to monitor directly the cleavage 
products. This measured the effect of the inhibitors on SlpA processing in vivo and provided 
the essential inhibition assay for this study. Ideally, an untreated culture will show only SlpA 
cleavage products, namely HMW-SLP and LMW-SLP, whereas a culture treated with 
inhibitor should reveal the presence of full-length SlpA.  
Working with C. difficile presents certain challenges such as strictly anaerobic conditions for 
culturing the bacteria, the requirement for blood agar plates and inherent variability in the 
growth of cultures. These challenges were overcome as much as possible during the 
experiments undertaken. C. difficile was grown on a blood agar plate under anaerobic 
conditions for at least three days before use. However, this plate required renewal after ten 
days to ensure subsequent culture viability. Furthermore, all equipment such as tips, 
pipettes, microcentrifuge tubes and brain heart infusion (BHI) broth used for bacterial 
culture required incubation in an anaerobic cabinet prior use to allow any oxygen to be 
replaced with an anaerobic gas mixture ( 80% N2, 10% CO2, 10% H2).  
For the inhibition assay, a single colony of C. difficile was inoculated into BHI broth and 
grown anaerobically for 1 hour with vigorous shaking to obtain a homogeneous suspension. 
This culture was then aliquoted into microcentrifuge tubes containing specific inhibitors 
(usually at 100 µM, stock solution was in H2O or DMSO). This ensured an equal starting 
point for all samples and limited culture variation at the early stage. The cultures were 
allowed to grow overnight (16–18 h) with agitation. Cells were harvested by centrifugation, 
fractionated when appropriate and analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting against LMW-SLP antibody.  
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Figure 2. 1: The flow diagram of a general in vivo inhibition assay.  
2.1.2 Protease inhibitors 
Protease inhibitors are molecules that bind to a protease to reduce its activity. They are 
ubiquitous and are found in multiple forms in all living organisms [297]. Protease inhibitors 
can be small non-proteinaceous molecules (typically found in microorganisms), peptides or 
proteins. Their gross function is to regulate undesirable protease activity, but protease 
inhibitors can be used as a powerful tool in basic as well as applied research, for example in 
the characterisation of binding sites, catalytic functional groups and transition-state 
geometries of proteases [298]; investigation of the physiological function of particular class 
of proteolytic enzymes within an organism [299]; and in drug discovery [300-301]. 
Because protease inhibitors can be used to target proteolytic enzymes crucial for disease 
propagation, development of such protease inhibitors into drugs has generated 
considerable research interest. Generally, protease inhibitors are developed from natural 
product screening or combinatorial library screening with subsequent lead optimisation 
[302] or by using substrate/transition state mimetic methods, including the truncation of a 
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peptidic substrate or substituting the cleavable amide bond by a non-cleavable isostere 
[303]. Substrate-based development can be taken further using receptor-based design, 
which requires the availability of three-dimensional structural information for the protease. 
With the aid of in silico modelling, protease inhibitors can be designed to fit into the active 
site of the receptor to gain higher selectivity [304]. 
Protease inhibitors are usually presented in two contrasting classes: reversible and 
irreversible. These two forms differ in their mode of inhibition (Figure 2. 2). Reversible 
protease inhibitors bind non-covalently to the protease to form an enzyme-inhibitor 
complex (EI), which is in equilibrium with the individual species; for example, these non-
covalent interactions can include hydrogen bonds, van der Waals interactions and ionic 
bonds. These weak interactions combine to generate strong and specific binding between 
enzyme and inhibitor. There are three kinds of reversible inhibitors differentiated by their 
inhibition mode. Competitive inhibitors cannot bind to the enzyme (E) at the same time as 
the substrate (S) due to competition for access to the same binding site of the enzyme. The 
inhibition can be overcome by addition of excess substrate to disturb the equilibrium. 
Uncompetitive inhibitors are only able to bind to the enzyme-substrate complex (ES). Finally, 
non-competitive inhibitors are able to bind to the enzyme as well as the enzyme-substrate 
complex and does not affect binding of the substrate. Reversible inhibition can be overcome 
by dilution or dialysis, as it depends on the concentration of the inhibitor. In contrast, 
irreversible protease inhibitors also form an initial enzyme-inhibitor complex or enzyme-
substrate-inhibitor complex, but subsequently react with the enzyme to form a covalent 
bond (EI*) and inactivate the enzyme permanently. Irreversible inhibitors often contain an 
electrophilic functional group, which reacts with a nucleophile in an amino acid side chain of 
the protease to form a covalent adduct. Furthermore, irreversible inhibitors act in a time-
dependent manner, as the amount of active enzyme is reduced with the inhibitor-enzyme 
incubation time. 
 
65 
 
 
Figure 2. 2: Kinetic schema for reversible and irreversible inhibitors. 
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With regards to the protease(s) involved in SlpA cleavage in C. difficile, at the outset of this 
project little was known and the identification of these enzymes remained unclear. 
However, there are potential candidates such as Cwp84 and Cwp13, one of which is 
encoded in the same gene cluster as SlpA, that possess a cysteine protease domain (Section 
1.6.3.1). Clues as to the correct classification of these proteases may be derived from their 
inhibitory activity in the presence of broad-spectrum protease inhibitors. For this purpose, a 
panel of commercially available protease inhibitors was selected. These inhibitors cover 
most of the protease families and clans. Figure 2. 3 illustrates the structures of the chosen 
protease inhibitors and the details about each inhibitor are summarised in Table 2. 1.  
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Figure 2. 3: Structure of chosen commercially available protease inhibitors (Sigma Aldrich library). Crystal 
structure of trypsin inhibitors are shown in green and disulfide bonds are highlighted in red. 
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Inhibitor Type of target 
proteases 
Inhibition 
mode 
Origin Application 
ε-Aminocaproic acid 
(EACA) 
Serine [17] Reversible 
[305] 
Synthetic  Marketed as Amicar [306] for treatment of 
bleeding disorders (fibrogenemia postoperative 
bleeding).  
Benzamidine Serine [307-309] Reversible 
[307-309] 
Synthetic  As effective as aprotinin in the prevention of 
glucagon degradation in human plasma (see 
below) [310]; additive in protein crystallography 
to prevent degradation of a protein of interest. 
4-(2-Aminoethyl) 
benzenesulfonyl fluoride 
hydrochloride (AEBSF) 
Serine [311-313] Irreversible 
[311-313] 
Synthetic Preferred over other serine protease inhibitors 
(PMSF, DIFP) due to low toxicity and improved 
water solubility; used in preparation of tissue 
lysates in molecular biology [314-316]. 
Chymostatin Serine [317] Reversible 
[307-309] 
Streptomyces 
hygroscopicus 
and S. 
lavendulae 
Inhibits human leukocyte elastase [318], the 
cytosolic Ca2+-dependent proteinase calpain 
[319], and other cytosolic multicatalytic 
proteinases [320] involved in antigen 
presentation [321] and in the degradation of 
ubiquitin-protein conjugates [322] 
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Aprotinin Serine [323] reversible[323] bovine lung and 
bovine pancreas 
[324] 
Marketed as Trasylol (Bayer) for treatment of 
various diseases including reducing bleeding 
during complex surgery. Withdrawn worldwide 
due to increased risk of complications or death 
(Bayer press release 2007).  
Kunitz soya bean trypsin 
inhibitors 
Serine [325-326] Reversible 
[325-326] 
soybean [327-
328] 
Inhibit plasma kallikreins and coagulation Factor 
Xa by a mechanism similar to trypsin inhibition. 
Leupeptin Serine and cysteine 
[329] 
Reversible 
[329] 
Actinomycetes 
[330] 
Inhibits plasmin, trypsin [331], papain [332-333], 
thrombokinase and kallikrein, produces a curative 
effect for inflammation in oedema [333] 
Bestatin Serine and cysteine 
[334] 
Reversible 
[334] 
Streptomyces 
olivoreticuli 
[335] 
Marketed as Ubenimex and used in the treatment 
of acute myelocytic leukemia [336] 
Antipain Serine and cysteine 
[308] 
Reversible 
[308] 
Actinomycetes 
[337] 
Used in studies demonstrating the role of 
proteases in the process of cell transformation 
[338], and identifying proteases.[339] [340] 
E-64  Cysteine [341] Irreversible 
[341] 
Aspergillus 
japonicus [155] 
Used in in vivo studies due to specific inhibition, 
good cell permeability in cells and tissues, 
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stability and low toxicity [342] 
Pepstatin Aspartyl [329] Reversible 
[343] 
Actinomyces 
[344] 
Inhibits γ-secretase [308] and retroviral protease 
[345]; used to exploit proteases from several 
sources [346-347] 
Phosphoramidon Metalloendoproteinases 
[348] 
Reversible 
[349] 
Actinomycetes 
[348] 
Inhibits many bacterial metalloendoproteinases, 
thermolysin and elastase [348], collagenase [308, 
348, 350]. Does not inhibit trypsin, papain, 
chymotrypsin or pepsin [348] 
Ethylenediaminetetraacetic 
acid (EDTA) 
Metalloendoproteinases 
[351] 
Reversible 
[352] 
synthetic Used as an anticoagulant in hematology [353],  
and in chelation therapy for treatment of 
atherosclerotic cardiovascular diseases [354] 
Table 2. 1: Summary of selected commercially available protease inhibitors. 
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2.1.3 First inhibition results 
Screening a panel of commercially available protease inhibitors at 100 µM in the in vivo 
assay described above against the reference strain 630 revealed some three striking results 
(Figure 2. 4). First and foremost, a new band at 74 kDa apparent molecular weight appeared 
in the samples treated with E-64 and leupeptin (lanes 6 and 8); since this band cross-reacts 
with the anti-LMW-SLP antibody this was assumed to be an unprocessed SlpA band. This 
result strongly suggests that E-64 and leupeptin have a modest inhibitory effect on SlpA 
processing, and therefore, E-64 and leupeptin would represent the first ever reported 
inhibitors of S-layer processing in C. difficile. Secondly, EDTA disturbs bacterial growth at the 
given concentration completely, which might be due to removal of Ca2+ ions responsible for 
holding the S-layer/cell wall together [261], consequently it was not included in the gel. 
Thirdly, it is interesting to note that trypsin inhibitor caused extensive cell lysis compared to 
other inhibitors; this is visible on the Coomassie stained gel, which shows the release of 
proteins not normally found in the S-layer (Figure 2. 4, compare lanes 1 and 13). However, 
trypsin inhibitor does not inhibit SlpA processing under the conditions tested due to the 
absence of a strong band for full-length SlpA in the Western blot against LMW-SLP antibody.  
It should be noted that there is a weak SlpA band in most lanes, visible by western blotting. 
This could be SlpA that has yet to be cleaved, or could reflect that fact that the bacteria may 
grow with a slight excess of unprocessed SlpA. However, it may be supposed that 
comparison of the amount of SlpA with the untreated sample (Figure 2. 4, lane 1) is a 
reliable (though rough) guide to inhibition level. In addition Western blot may be not 
suitable for precise quantitative analysis in the absence of a control band since the intensity 
of a particular band on the blot varies from one membrane to the next, and also depends on 
the length of the exposure time during imaging. This problem is reflected in the case of 
leupeptin and E-64, as the leupeptin coomassie band is actually at least as strong as E-64 but 
appeared weaker on Western blot. As a direct total protein stain the Coomassie gel could 
provide more comparable data, however unlike a Western blot it does not provide 
confirmation of protein identity. 
Leupeptin is known as a reversible, competitive inhibitor of serine and cysteine proteases 
[329] (Section 2.1.2). Its activity applies to a wide range of proteases from trypsin [331], 
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thrombokinase and kallikrein to papain [332-333] and cathepsins B [355], H and L [356-357]. 
Leupeptin was determined to be N-acetyl(N-propionyl)-L-leucyl-L-leucyl-DL-argininal [358] 
and possesses an aldehyde group at the C-terminal position that is considered to be 
involved in the mechanism of inhibition [332].  
E-64, on the other hand, is an irreversible cysteine protease inhibitor. It also inhibits papain 
and cathepsins B, H and L [341], but it does not have any inhibitory effect toward serine 
proteases like other cysteine protease inhibitors such as leupeptin and antipain [359]. 
Specifically, the functional thiol group of non-protease enzymes, such as L-lactate 
dehydrogenase or creatine kinase are not affected by E-64 [155]. Based on these data it 
seems likely that the protease (or proteases) involved in SlpA processing is a cysteine 
protease. Indeed, it later emerged that further in-depth investigation into structure activity 
relationships and binding modes provide sufficient evidence for classification of the target 
protease into a subfamily of cysteine proteases (see Chapter 6).  
Having discovered the first inhibitors of S-layer processing in C. difficile, we next considered 
which should be selected as an initial lead compound for further investigation, taking into 
account the ease of access to the initial scaffold for inhibitor design, and potential for 
inhibitor optimisation to fine-tune reactivity for the target protein. Usually, small 
compounds that modulate target proteins reversibly are favoured as chemical tools or 
potential drugs because these compounds possess in most cases an attractive toxicity 
profile due to their elimination from the body/cell by dilution, excretion and metabolism. 
Irreversible inhibitors, on other hand, are seen as less useful for developing as drugs as they 
would be expected to modify a range of tissue constituents possessing amino or thiol groups 
besides the target proteins due to their alkylating or acylating chemistries. The undesired 
modification could lead to potentially serious side effects (e.g. DNA alkylation, 
carcinogenesis, immune response to modified proteins). Furthermore, these inhibitors 
inactivate the enzyme permanently and stay in the cell/body until the protein is degraded. 
Despite these potential problems there are many instances where irreversible inhibitors 
were successfully developed as drugs, sometimes inadvertently, and reached the market 
[360-362] (see Potashman and Duggan for an extended review on successful irreversible 
inhibitors as drugs [363]). Furthermore, irreversible inhibitors can be very useful for probing 
the catalytic nature of the enzyme concerned and can assist in identification by forming a 
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stable covalent bond with the functional group of the active site of the enzyme, labelling it 
irreversibly. In addition, irreversible inhibitors can sometimes be designed directly from the 
specific substrate of a particular enzyme. Combining these considerations, irreversible 
inhibitors are well-suited as starting points for the development of inhibitor analogues and 
activity based probes aiming at target identification. For this purpose, E-64 was chosen over 
leupeptin as the lead candidate due to its generally specific inhibitory effect and irreversible 
character.  
 
Figure 2. 4 : In vivo activity of inhibitors in C. difficile S-layer processing assay. A) Coomassie Blue stained gel. B) 
Western blot using anti-LMW SLP. Lanes of the gel show assays for the following inhibitors: Lane 1, no 
inhibitor; 2, 6-Aminohexanoic acid; 3, Benzamidine hydrochloride; 4, 4-(2-aminoethyl) benzenesulfonyl 
fluoride hydrochloride; 5, Chymostatin; 6, Leupeptin; 7, Bestatin; 8, E-64; 9, Pepstatin; 10, Phosphoramidon 
disodium salt; 11, Aprotinin; 12, Antipain; 13, Trypsin inhibitor from Glycine max (Soybean) type I-S. 
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2.2 E-64 
2.2.1 Isolation, characterisation and structure determination 
Inspired by the discovery of an aspartic protease inhibitor from Penicillium cyclopium [364] 
and the work of Umezawa et al. on a low molecular weight and highly reactive protease 
inhibitor from actinomycetes [337], Hanada and his co-workers isolated E-64 from a fungus, 
Aspergillus japonicas TPR-64 in 1977 [155]. E-64 was isolated as white needles with physico-
chemical properties as summarised in Table 2. 2. The structure of E-64 was determined by 
breaking the compound down in three parts using pronase E, each component analysed 
separately and confirmed by comparison with synthesised compounds. In addition, positive 
colour test and IR analysis provided further evidence for the guanidyl group, epoxide, 1,2-
dicarboxyl motif and peptide bonds. The absolute structure was revealed to be N-[N-(L-3-
trans-carboxyoxiran-2-carbonyl)-L-leucyl]-agmatine [365]. Hanada also found that E-64 
reacts only with proteolytic enzymes possessing a functional thiol group such as papain, 
bromelains and ficin. In addition, his kinetic study suggested strongly that E-64 reacts 
irreversibly and almost stoichiometrically with the active thiol group [155].  
Form White needle 
Mp 231–234 °C 
Molecular formula C15N5H27O5 (MW: 357) 
Optical rotation  [α]  
 
 = +24.4 (c = 1, 0.1 N HCl) 
Stability Stable at pH range from 2 to 10 
Solubility Soluble: H20–MeOH, acetic acid, pyridine, DMSO. 
Insoluble: Acetone, EtOAc, CHCl3, diethylether, benzene, petroleum 
ether. 
Table 2. 2: Physicochemical properties of E-64. 
2.2.2 Inhibitory activity and specificity 
Continuing the characterisation of E-64, Hanada et al. investigated the structure activity 
relationship (SAR) of E-64 and its analogues with papain [366]. Their study revealed that the 
epoxydyl moiety is required for the activity against papain and the guanidyl moiety is not 
necessary for the inactivation of papain. Further modification of the leucyl moiety and 
esterification of the epoxydyl acid turned out to increase the papain inhibitory activity. This 
information was very useful; however knowledge of the enzyme-inhibitor interaction at the 
atomatic level is more valuable for designing E-64 analogues with increased potency and 
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selectivity. For this purpose, Matsumoto et al. analysed the epoxysuccinyl inhibitory 
mechanism [367]. His study suggested a SN2-like reaction for the covalent bond formation 
between E-64 and the active thiol group. The nucleophile of the active thiol group (Cys-25) 
attacks from the backside of the E-64 epoxide on the C2 atom causing ring opening and 
changing the S-chirality of C2 atom to the (R)-form (Figure 2. 5A). This feature was found in 
most of cases of binding of E-64 to papain family proteases.  
 
Figure 2. 5: A) Suggested SN2-like attack of the Cys-25 Sγ atom to an E-64 epoxy carbon atom. B) Chemical 
structure of E-64 and its analogues. 
To date, several crystal structures of cysteine proteases inactivated by E-64 and its 
analogues e.g.: papain [368], cathepsins K [369] and B [370], mexicain [371], ervatamin 
[372] and actinidin [373], have been reported and it was confirmed that E-64 can bind to the 
active site of the enzymes in two different orientations. In most cases, E-64 binds into the S-
subsite of the enzyme with a peptide backbone orientation opposite to that of the 
substrate. However, it can also bind into the S prime subsite as proposed in the cases of 
CA030 or CA074 with cathepsin B [370]. Figure 2. 6 illustrates some examples of E-64 and its 
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analogues (chemical structures are displayed in Figure 2. 5B) bound to the active site of 
cysteine proteases derived from different sources, such as mammalian cells (human 
cathepsin K, 1ATK; rat mu-calpain, 1TLO), plant (papain, 1PE6; mexicain, 2BDZ; ervatamin-C, 
2PRE; actinidin, 1AEC) and parasite (cathepsin B, 3HHI). It is interesting to note that the 
binding orientation of the inhibitors is very similar despite the dissimilarity of the binding 
pocket of each protease. Later work produced the so-called double-headed epoxysuccinyl 
inhibitors that can modulate the protease specificity, even at a high degree of similarity in 
the binding pocket [50, 303, 374-375]. Because the binding of E-64 is mostly at the S- 
subsite, the Sn-Pn main/side chain interaction plays an important role in determining the 
binding specificity of papain-family cysteine proteases. It was found that the P2 position of 
the substrate/inhibitor contributes significantly to the specificity towards peptide 
substrate/inhibitor. This amino acid is usually aromatic (Tyr, Phe, Trp) [371], as the S2 
binding site is a deep hydrophobic pocket [376]. In contrast, the S1 and S1 primes site of 
papain-like proteases provide a binding surface rather than a pocket, therefore they allow a 
relatively broad spectrum of substrate/inhibitor with no amino acid restrictions at the P1 
and P1 prime sites [376-377]. One other interesting aspect is the stereochemistry of the 
epoxide moiety. A switch from an (S,S)- configuration, as present in E-64, to an (R,R)-form 
results in a dramatic change to the overall potency and specificity of inhibition [50, 359, 366, 
374]. Usually the (S,S)-form shows significantly higher inhibitory activity than the 
corresponding (R,R)-diastereomer.  
With the birth of chemical biology and its quickly evolving technology, E-64 became a 
favourite candidate for use as scaffold for ABP design. Its development for studying cysteine 
proteases was pioneered by the groups of Cravatt, Ploeg, Overcleeft and Bogyo. There is still 
a lot of interesting work on-going based on this single molecule. 
2.3 Conclusions 
In this chapter the establishment of an assay that is effective for monitoring the inhibition of 
the SlpA cleavage process has been described. Using this assay, the first inhibitors of SlpA 
processing, E-64 and leupeptin, were discovered and reported. Furthermore, E-64 proved to 
be a more suitable candidate than leupeptin as an initial “lead”, which was taken further 
into inhibitor design and development as described in the next chapter. 
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Figure 2. 6: Superposition of E-64 at the active site of different cysteine proteases. A, Cathepsin K – E-64 
(mammalian cell, 1ATK); B, Mexicain – E-64 (plant, 2BDZ); C, papain – E-64c (plant, 1PE6); D, Ervatamin-C – E-
64 (plant, 2PRE); E, Cathepsin B – CA074 (parasite, 3HHI); F, calpain – E-64 (mammalian cell, 1TLO). E-64 is 
presented as sticks (warhead is indicated in red and specificity element in gray), and the enzyme surface is 
represented as coloured by element C (green), N (blue), O (red) and S (gold).  
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Chapter 3 Synthetic inhibitors of S-layer processing in C. difficile 
 
As discussed in Chapter 2, E-64 proved to be the most suitable starting point for 
inhibitor design. In Chapter 3, an in depth analysis of novel synthetic inhibitors is 
described. Starting from the E-64 scaffold and the cleavage site of the SlpA substrate, a 
series of inhibitors were designed. Analogues of E-64 were developed via versatile 
synthetic routes and tested for their activity and stability in order to identify more 
potent inhibitors of S-layer processing. These optimised inhibitors provided the basis for 
subsequent activity-based probe (ABP) development in this study (Chapter 4). 
Furthermore, the challenge of tracking down the target protease in a highly 
multifarious proteome mixture after cell lysis was simplified by implementing a 
technique for fractionating bacteria after inhibition into the S-layer and the remainder 
of the cell.   
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3.1 Potential protease targets in SlpA maturation 
Cells possess a multitude of different enzymes and each of them catalyses a reaction of one 
substrate or a group of substrates. A range of enzymes takes part in a pathway and each 
enzyme activates one specific step in the pathway up to the final step reaching the desired 
product (Figure 3. 1A). Regulation results in a harmonious arrangement governed by the 
requirements of the cell. During development of enzyme inhibitors as drugs, the typical aim 
is maximal inhibition of a suitably selected target enzyme, causing either an accumulation of 
the substrates or a corresponding decrease in concentration of the products, which could 
result in a useful clinical response. 
During biogenesis of SlpA in C. difficile, there are at least two proteases expected as the 
translated gene product SlpA undergoes two rounds of post-translational cleavage: the 
cleavage of the signal sequence (SP) that targets the nascent chain for translocation across 
the cytoplasmic membrane to the cell surface, and the internal cleavage that releases the 
mature LMW and HMW-SLPs. The protease involved in the first cleavage is presumably a 
signal peptidase [255]. Provided that signal peptide cleavage precedes and is essential for 
final maturation, inhibition of either of these proteases could cause the accumulation of full-
length SlpA.  
 
Figure 3. 1: A) Multi-enzyme pathway, e.g. in a cell. B) Cleavage of SlpA: removal of the signal peptide by 
protease1 (a signal peptidase) and cleavage by protease2 (the target enzyme for this study) to generate the 
LMW- and HMW-SLPs. 
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As all surface localised proteins in C. difficile contain a typical signal sequence in the 
precursor including SlpA [255, 277], there might be a general secretory pathway for surface 
proteins to export them across the plasma membrane. There are two pathways commonly 
responsible for general extracellular secretion: using N-terminal signal peptide as substrate 
for either a type I signal peptidase (SPase), a membrane-bound serine peptidase [379-380] 
after passing through a pore in the membrane with the support of the Sec machinery or a 
twin arginine transport (TAT) pathway [381]. Because the signal peptide of SlpA does not 
contain a twin arginine motif required for the TAT pathway, it is more likely that the signal 
peptidase is involved in the first cleavage.  
At this stage of the project, it was not clear whether E-64 and leupeptin inhibited the signal 
peptidase (protease1 in Figure 3. 1B) or the second protease (protease2 in Figure 3. 1B). 
However, E-64 inhibits specifically only cysteine proteases, while signal peptidase are 
generally  serine proteases [379]. It is tempting to speculate that E-64 and leupeptin target 
the second protease. As the aim of the project is to disrupt the specific cleavage of SlpA into 
LMW and HMW-SLPs, protease2 was targeted for inhibitor design.  
3.2 Inhibitor design 
The aim of this part of the project was to develop a more potent inhibitor than E-64 that 
could be converted into an ABP for future study. Chapter 2 revealed two key factors that 
should be taken into consideration during inhibitor design. Firstly, the protease(s) involved 
in the cleavage process may be cysteine proteases, since the natural products E-64 and 
leupeptin (both known as cysteine protease inhibitors) can disrupt S-layer formation when 
the bacterium is grown in the presence of these inhibitors, whereas inhibitors of other 
protease classes cannot. Secondly, the cleaved locus of SlpA shows high homology between 
most strains sequenced to date, and it is thought that the protease involved in SlpA cleavage 
into LMW- and HMW-SLPs in these strains have the same mode of action. This implies the 
presence of a specific recognition element enabling binding into the active site of the 
proteases.  
Examination of the structure of E-64 (Figure 3. 2A), reveals that this compound can be 
divided in two parts: an electrophilic epoxysuccinyl moiety (the warhead) and a short 
peptidic sequence (the specificity element). Similar to the canonical E-64 mode of action 
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discussed in Chapter 2, it was hypothesised that the warhead acts to alkylate the 
nucleophile of the active cysteine residue of the protease whereas the specificity element 
allows protease recognition. The influence of each of these two components on activity was 
thoroughly investigated. 
A versatile synthetic route to E-64 mimics (Figure 3. 2B) was developed using solid phase 
peptide synthesis (SPPS), leading to a generic structure for these inhibitors (Figure 3. 2C) 
consisting of the two moieties previously described. The electrophilic warhead (indicated in 
red) in Figure 3. 2C is the epoxysuccinyl moiety and the specificity element (indicated in 
black) is the peptidic moiety thought to be mainly responsible for protease recognition. The 
peptidic chain terminates in a carboxamide group rather than a carboxylate group to avoid 
the associated negative charge in a cellular environment. This should act to minimise the 
possibility of metabolism and aid cell penetration and thus might enable the inhibitor to 
reach the site of the target protease. For future ABP development, a tag could be appended 
onto the peptidic unit, also on solid phase.  
 
Figure 3. 2: Structures of inhibitors. A) E-64. B) EP-LR-NH2, a mimic of E-64. C) Generic structure of inhibitors. 
Warheads are indicated in red and the specificity element is indicated in black. 
For simplicity, a short and general nomenclature was applied to all inhibitors. The epoxide 
will be abbreviated as EP, whereas the EtEP presents the ethyl ester form. All EPs have an 
(S,S) configuration unless otherwise stated and all amino acids of the specific peptidic chain 
are represented by their single letter code. Hence under this nomenclature the E-64 mimic 
(Figure 3. 2B) will be named EP-LR-NH2. E-64 and EP-LR-NH2 differ from each other only in 
the carboxamide group indicated in blue (Figure 3. 2 A and B). To examine the space 
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requirement for the binding of the specificity element to the active site, glycine was inserted 
into the sequence to act as a spacer to extend the peptidic chain adding EP-LGR-NH2 into 
the new design inhibitor list.  
In order to assess the relative importance of these features of E-64 in facilitating cysteine 
protease inhibition, a series of modified E-64 mimics were synthesised. First, the warhead 
was modified, while the specificity element was kept as LR (Figure 3. 4). This included 
replacing the epoxysuccinyl moiety by an acetyl group to investigate the significance of the 
warhead motif (Ac-LR-NH2); esterification of the epoxy carboxylate group with a view to 
improving cell penetration and potency (EtEP-LR-NH2) [155]; removing the peptide 
appendage to demonstrate the necessity for a specificity element (EtEP-OH); and inverting 
the (S,S) stereochemistry present in E-64 to the (R,R) configuration since the 
stereochemistry of the epoxide has been shown in other studies to have a critical 
contribution to the inhibitory effect [155, 342, 366-367, 374]. It should be noted that this 
type of inhibitor has never previously been tested on C. difficile. 
Second, the specificity element was tailored, while the warhead was kept as epoxysuccinyl. 
Since the discovery of E-64, research has primarily focused on the variation of the specificity 
element with the intention of improving the selectivity and potency [366, 371], and these 
studies suggest that the specificity element usually binds at and beyond the P2 position of 
the substrate as the epoxysuccinyl moiety occupies the P1 position. Figure 3. 3 illustrates 
the binding mode of E-64 in actinidin [373] as an example of various other papain-like 
protease co-crystal structures and the suggested binding mode for the novel synthetic 
inhibitors designed in this study. It has been found that the Sn region varies in size from S2 
to S5 across the cysteine proteases [367, 377, 382]. In the majority of cases, the inhibitor is 
bound in the Sn-subsite of the active centre and is positioned in the opposite sense to the 
substrate, i.e. the inhibitor binds in a C-to-N fashion along the S1-S2...Sn pocket whereas the 
substrate binds in an N-to-C fashion [366, 371]. Taking these findings into consideration, 
several inhibitors were synthesised in which the length of the peptidic chain mimicking the 
cleavage locus in SlpA was varied (EP-K-NH2, EP-KT-NH2, EP-KTE-NH2, EP-KTEL-NH2 (by 
reference to strain 630) and EP-KTT-NH2, EP-KA-NH2, EP-YT-NH2 (by reference to strains 959 
and 167) as shown in Figure 3. 4.  
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Figure 3. 3: Binding mode of E-64 and E-64 based inhibitors to cysteine proteases A) actinidin-E64 complex 
(1AEC). B) General binding mode of E-64. It should be noted that the backbone of E-64 binds to the S subsites 
in the opposite sense to the substrate. C) Proposed binding mode of E-64 based inhibitors. 
It has usually been found that the P2 position of the substrate has a more significant effect 
than subsequent positions on the activity [50, 373], thus further inhibitors were produced in 
which the lysine in the AA1 position which is corresponding to the P2 position of the 
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substrate was substituted by an alanine (a technique commonly applied to neutralise the 
effects of a particular residue side-chain); EP-A-NH2, EP-AT-NH2 and EP-ATT-NH2); by a 
threonine ((present in the P3 position in the substrate, K-to-T); EP-T-NH2); and by leucine or 
arginine ((inspired by the structure of E-64, K-to-L/R); (EP-R-NH2, EP-L-NH2, EP-LT-NH2, EP-
LTT-NH2 and EP-LTTL-NH2)).  
To summarise, the inhibitor library designed consisted of 22 analogues covering most 
aspects of known E-64 structure-activity relationships (SARs) –These inhibitors were 
synthesised as described in the following section.  
 
Figure 3. 4: Inhibitor design. Both components of the inhibitor, the warhead and the specificity element, were 
varied to investigate the influence of each components on the activity. Modification of warhead was 
concentrated on stereochemistry, while the one of specificity element was based on cleavage site locus of 
SlpA. 
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3.3 Synthesis of E-64 analogues 
The designed inhibitors discussed above were synthesised with the intention of turning 
them into ideal tools to evaluate the potency and selectivity towards the target protease. E-
64 and its derivatives have historically been prepared using a short and flexible route in 
which the epoxysuccinyl moiety was synthesised using a modified method of Mori and 
Iwasawa [383]. This epoxide portion was subsequently appended to a peptide, where many 
modifications have also been reported [59, 151, 384-385].  
 
Scheme 3.1: Synthesis of inhibitors. Reagents and conditions: i) HBr-HOAc, 0ºC to RT, 16 h; ii) HCl-EtOH, Δ, 5 h; 
iii) DBU, Et2O, 2 h; iv) KOH (1 eq), EtOH, 0 ºC, 3 h; v) HCTU, DiPEA, 1 h; vi) TFA, TIS, H2O (95:2.5:2.5), 2 h; vii) 
NaOH, 30 min. Yields of VII vary from 1 to 87% depending on the sequence. 
The general route employed for the preparation of the E-64 analogues is illustrated in 
Scheme 3.1. The synthesis is a combination of solution and solid-phase chemistries. For 
simplicity, Scheme 3.1 displays only the synthesis of (S,S)-configuration of epoxysuccinyl 
inhibitors, derived from (-) diethyl-D-tartrate, whilst (+) diethyl-L-tartrate yielded the 
analogue possessing an (R,R)-configuration.  
Diethyl tartrate (1) was converted into the bromo ester (2) using HBr-HOAc, and this was 
subsequently deacetylated by HCl-EtOH treatment to yield the bromohydrin (3). A second 
Walden inversion was achieved by treatment with DBU in Et2O at 4 °C to force ring closure 
and this afforded the epoxide (4) in 77 % yield. The di-ester was saponified with an 
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equimolar amount of KOH in EtOH, and after a dilute HCl work-up and EtOAc extraction, the 
desired epoxy mono-ester (5) was generated. Subsequent attempts at coupling the crude 5 
onto the resin-bound peptide were unsuccessful despite what was previously reported to be 
a facile coupling step [59-60]. The coupling failure implied that even a small amount of 
acetic acid, formed during the work up by hydrolysing EtOAc through HCl, could be in 
competition with the epoxide mono-ester to prevent the coupling reaction from taking 
place. Hence the epoxide mono-ester was purified via HPLC and lyophilised to remove most 
residual water before coupling onto the resin-bound peptide. In addition, the mono-ester 
was seen to decompose over time even when stored at -20 °C, thus the warhead was stored 
as the epoxide di-ester and hydrolysed to the monoacid when required. 
Standard automated Fmoc/tBu solid-phase peptide chemistry was exploited in order to 
generate the peptide component of the E-64 mimics, where the amino acids were pre-
activated in situ with HBTU and DiPEA. This provides a flexible system to enable the 
production of inhibitors with peptidic elements containing any combination of amino acids. 
However, this is not the only advantage to this strategy as once the desired peptide element 
has been made this also enables the straightforward incorporation of the epoxide warhead 
onto the peptide N-terminus and hence generate the desired inhibitors in a small number of 
steps in a typically high overall yield.  
The key step in the synthesis was the coupling of 5 to the peptide portion of the inhibitors, 
and in particular, the activation of 5 prior to this step. Several strategies employed for the 
activation of such unusual compounds include the utilisation of DCC-HOBt [386-388] or DCC-
p-nitrophenol [59], conversion to the NHS or pentafluorophenyl ester [389], and the use of 
phosphorous-based reagents such as diethylphosphoryl cyanide, BOP and PyBOP [365, 384]. 
During this study, it was determined that pre-activation using HCTU and DiPEA led to 
improved yields and required shorter coupling times (1h) in comparison with other coupling 
reagents e.g. PyBOP (5h). 
Once the epoxide peptide (6) was formed, the resin was washed thoroughly and dried 
before cleavage to obtain better yields. HPLC or LC-MS analysis revealed the crude material 
contained predominantly the ethyl epoxysuccinyl compound (7) however the hydrolysis 
product (8) was also isolated on occasion. When the epoxide mono-ester (5) used for 
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coupling to the peptide moiety contained a trace of acetic acid, an acetylated product of this 
pseudo peptide was also found. 7 was purified via HPLC and lyophilised to yield the ethyl 
epoxysuccinyl coupled peptidic inhibitors. 
In E-64 the epoxysuccinyl moiety contains a free carboxylic acid, and thus the ester 
functionality in 7 was also hydrolysed with NaOH to give the acid (8) in quantitative yield. It 
was thought that it would be advantageous to eliminate the hydrolysis step to obtain the 
epoxy acids directly via coupling the epoxide di-acid to the free N-terminus of the resin-
bound peptide instead of 5. Unfortunately, the di-acid proved to be insoluble in DMF, 
contrary to the literature precedent [390]. This may be due to the difficulty of removing all 
the remaining water formed during epoxide di-acid precipitation, which was shown to 
remain despite heating and lyophilisation. The subsequent coupling was therefore not 
accessible.  
Unfortunately, compounds possessing a single amino acid bearing a small or hydrophobic 
side chain such as alanine or leucine were also not accessible using the described method 
despite ESI-MS detection in the crude material since isolation by preparative HPLC proved 
problematic. Alternative approaches employed alaninamide or leucinamide hydrochloride 
with preactivated epoxide monoacid using either PyBop/DiPEA in DMF at room temperature 
or HOBt/DiPEA/EDC in chloroform/DMF at 0 °C [150]. However, these reactions were 
unsuccessful, and no product was observed in the crude ESI-MS spectrum. No further 
attempt was made to synthesise these compounds. 
Stocks (10 mM or 25 mM) of the desired inhibitors accessible via the aforementioned 
synthetic route were prepared in water, or in a water/DMSO mixture for more hydrophobic 
compounds. It should be noted that the proportion of water/DMSO is depend on the 
hydrophobicity of the inhibitors and varied among inhibitors. However, the final level of 
DMSO in the culture was always less than 1% v/v. At this level DMSO does not have any 
influence on SlpA inhibition or cell growth (Figure 3. 7). Stock concentration calculations 
were based on the mass of the freeze-dried product, which may be inaccurate due to the 
accuracy of weighing relatively small amounts of material (±0.1 mg) and potential additional 
mass of residual water or salts.  
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No. Warhead AA1 AA2 AA3 AA4 Abbr. Name 
TD 1 EP Leu Arg - - EP-LR-NH2 
TD 2 EtEP - - - - EtEP-OH 
TD 3 Ac Leu Arg - - Ac-LR-NH2 
TD 4 (R,R)EP Leu Arg - - (R,R)EP-LR-NH2 
TD 5 EtEP Leu Arg - - EtEP-LR-NH2 
TD 6 EP Lys - - - EP-K-NH2 
TD 7 EP Lys Thr - - EP-KT-NH2 
TD 8 EP Lys Thr Glu - EP-KTE-NH2 
TD 9 EP Lys Thr Glu Leu EP-KTEL-NH2 
TD 10 EP Lys Ala - - EP-KA-NH2 
TD 11 EP Lys Thr Thr - EP-KTT-NH2 
TD 12 EP Tyr Thr - - EP-YT-NH2 
TD 13 EP Leu Thr - - EP-LT-NH2 
TD 14 EP Leu Thr Thr - EP-LTT-NH2 
TD 15 EP Leu Thr Thr Leu EP-LTTL-NH2 
TD 16 EP Leu Gly Arg - EP-LGR-NH2 
TD 17 EP Thr - - - EP-T-NH2 
TD 18 EP Ala Thr - - EP-AT-NH2 
TD 19 EP Ala Thr Thr - EP-ATT-NH2 
TD 20 EP Arg - - - EP-R-NH2 
Table 3. 1: Inhibitors synthesised at this stage in this study. 
Attempts were made to circumvent this problem by normalising the stock concentration to 
a known concentration using UV-absorption of the peptide bond at 223 nm via analytical 
HPLC. However, this measurement was found to be ambiguous since amino acid side chains 
also absorb UV light at this wavelength but to differing degrees depending on the amino 
acid present, leading to a complex absorption spectrum and thus the normalisation strategy 
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was unreliable. Moreover, potential variation in the amount of sample injected during each 
LC-MS run was a further limitation for this approach, and thus the freeze-dried mass was 
used despite its potential inaccuracies. Consequently, the stock concentration 
determination based on the product weight is reported in this study, and the absolute 
concentration of the stock solution generated for testing is likely to be somewhat lower. For 
the purpose of finding specific inhibitors that only label the protease involved in the SlpA 
cleavage process in the presence of many other bacterial proteases, this potential mass 
inaccuracy is not a major problem. In summary, a library of 20 compounds was generated 
for initial in vivo testing; the library members are presented in Table 3. 1.  
3.4 Activity of E-64 analogues 
As discussed, the purpose of the study at this stage was to find potent inhibitors that can act 
as precursors to aid the identification of the target protease(s). The inhibitors presented in 
Table 3. 1 were tested in vivo using the assay described in section 2.1.1, but before 
discussing the results it is worth reiterating some of the limitations of the chosen assay 
technique that should be taken into consideration during interpretation. Firstly, the growth 
rate of C. difficile is rather inconsistent despite the application of some technical 
improvements (discussed in section 2.1.1). Secondly, because the compounds do not 
directly inhibit growth, the observed effect may appear relatively insignificant as the 
samples were normalised by OD. However the behaviour of the bacterium in the presence 
of the inhibitor could be affected in a subtle way. Secondly, the small inaccuracy in the stock 
concentration may affect the relative potencies when comparing different inhibitors. 
Nevertheless, a given compound may be reliably assayed and compared at various 
concentrations from the same stock solution. Thirdly, a Western blot is not suitable for 
precise quantitative analysis in the absence of a control band since the intensity of a 
particular band on the blot varies from one membrane to the next and also depends on the 
length of the exposure time during imaging. Furthermore, this intensity is judged by eye, 
which further reduces the accuracy. Despite this, it is usually reliable to compare bands on 
the same membrane, and a negative and positive control on each membrane acts as a 
useful reference. As mentioned in the assay section 2.1.1, the band for full length SlpA 
appears when the target protease is inhibited since there is no longer full cleavage of SlpA 
by the protease. The extent to which this cleavage is inhibited correlates well with the full 
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length SlpA band intensity, because the better the inhibitor inactivated the target protease 
the less it cleaves SlpA and therefore the more intense the band becomes. Thus, within the 
limitations noted above, this band can be exploited as a semi-quantitative scale for a lower 
limit of inhibitor potency, where the stronger the band the more potent the inhibitor. 
Initially, the inhibitor EP-LR-NH2 was compared side-by-side with the natural product itself 
(E-64) at two different concentrations (50 µM and 250 µM). The anti-LMW Western blot of 
this comparison is shown (Figure 3. 5, includes a negative control lane in which no inhibitors 
were added). It is readily noticeable that EP-LR-NH2, which retains the key stereochemical 
and functional features of the natural product, is probably somewhat more potent than E-
64 since the full length SlpA band is clearly visible at 50 µM in EP-LR-NH2 but not present in 
E-64. This was very encouraging as it implies that to some extent the considerations taken 
and assumptions made during inhibitor design were justified and with optimisation could 
potentially lead to more potent inhibitors. The fact that all the LMW-SLP bands are equal 
indicates that the same amount of sample was loaded on each lane and suggests the results 
can be interpreted reliably. Comparing inhibition at 250 µM, there is no significant 
difference between EP-LR-NH2 and E-64. It was decided to introduce a concentration of 
100 µM in order to improve the interpretation of results when comparing different 
inhibitors on Western blot. 
 
Figure 3. 5: Activity of EP-LR-NH2 vs. E-64, as measured by Western blot using anti-LMW SLP. C. difficile 630 
cultures were treated with each compound at 50 µM and 250 µM.  
 
E-64           EP-LR-NH2
N
o
 in
h
ib
it
o
r 
   
   
   
 
5
0
µ
M
2
5
0
µ
M
5
0
µ
M
2
5
0
µ
M
SlpA
LMW-SLP
91 
 
The importance of the warhead was next investigated. EtEP-OH, Ac-LR-NH2, EtEP-LR-NH2, 
(R,R)EP-LR-NH2 were tested alongside two positive controls (EP-LR-NH2 and E-64) and the 
negative control, with all compounds at 100 µM (Figure 3. 6). Figure 3. 6 demonstrates that 
both positive controls possess similar activity at 100 µM which is in line with previous 
observations. It is also evident that the substitution of the N-terminal 
trans-(S,S)-epoxysuccinyl warhead with an acetyl group or a trans-(R,R)-epoxysuccinyl 
warhead leads to a complete loss of activity. This validates the hypothesis that the epoxide 
warhead is not only critical for inhibition but its binding to the protease is also highly 
stereoselective. Furthermore, the warhead on its own without any appended specificity 
element was determined to be inactive, illustrating that both parts, the warhead and the 
specificity element, are essential for achieving inhibition.  
Finally, no significant difference was identified in the extent of inhibition at this 
concentration between the free acid and the ester form of the epoxide warhead. It is 
difficult to speculate on which of the analogues are more likely to accomplish superior cell 
penetration or reach the target protease more easily and thus it is challenging to 
differentiate between them at this stage with regards to their relative activities. Another 
speculation is that the ethyl ester compound might be hydrolysed to the acid form in the 
culture and therefore it possesses similar potency. Further investigation to answer these 
intriguing questions fell outside the principal focus of this research and hence this further 
work will be carried out in subsequent studies.  
 
Figure 3. 6: Activity of inhibitors, as measured by Western blot of S-layer fractions using anti-LMW SLP. C. 
difficile 630 cultures were treated with compound at 100 µM. The warhead was modified and a specificity 
element was kept as LR-NH2, as present in the parent precursor.  
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The effects of the variation of the specificity element on inhibition were examined, and the 
warhead was kept in its acid form (as seen in E-64) for all inhibitors to ease directly 
comparison (Figure 3. 7). The data suggests that increasing the peptide length to mimic P2 
up to P5 of the substrate for strain 630 enhanced inhibition (EP-KTEL-NH2 was more active 
than EP-KT-NH2). However, EP-K-NH2 and EP-KTE-NH2 were found to be unexpectedly 
inactive at the concentration tested. The activity of EP-KT-NH2 and inactivity of EP-K-NH2 
might imply that at least two amino acids are required for binding, but it is difficult to 
suggest why EP-KTE-NH2 was inactive whilst EP-KTEL-NH2 was active. Maybe the glutamic 
acid is unfavoured in the binding, but this unfavourableness is compensated by adding a 
leucine in the chain. On the other hand, EP-KA-NH2, EP-KTT-NH2 and EP-YT-NH2 (refer to 
strain 959 and 167) all show some level of activity. EP-YT-NH2 is the most potent compound 
from the entire series as measured by Western blot. The variation of the AA1 leads to highly 
intriguing results as can be seen for EP-KT-NH2, EP-YT-NH2, EP-LT-NH2 and EP-KT-NH2 in 
Figure 3. 7. These inhibitors carry the same AA2 residue, threonine, but a different AA1 
residue. An alanine at AA1 position causes a consistent loss of activity, a phenomenon 
further confirmed by EP-ATT-NH2. The activity increases dramatically from leucine to 
tyrosine. EP-KT-NH2 and EP-KA-NH2, where the AA
1 residue is the same but the AA2 amino 
acid is different, are observed to have similar activities. Furthermore, if threonine is shifted 
to the P2 position (as in EP-T-NH2), inhibition is lost.  
 
Figure 3. 7: Activity of inhibitors, as measured by Western blot of S-layer fractions using anti-LMW SLP. C. 
difficile 630 cultures were treated either with compound at 250 µM or 1% DMSO. The specificity elements 
were varied and the warhead was kept as EP, as present in E-64.  
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Regarding the inhibitors designed through inspiration from the structure of E-64 (i.e. AA1= 
leucine: EP-LT-NH2, EP-LTT-NH2, EP-LTTL-NH2), only moderate activities were observed 
compared to EP-KTEL-NH2. The addition of a spacer in the middle of the peptidic sequence 
of the parent inhibitor did not affect its activity. Unfortunately EP-L-NH2 was not readily 
accessible using the routes described above, so a direct comparison with the related EP-R-
NH2 was not possible.  
Accumulating the knowledge gained from the comparison between EP-AA1XX-NH2 and EP-
XXAA2-NH2 (where XX is the varied amino acid), the inactivity of EP-T-NH2 and the increased 
potency of EP-R-NH2 is compelling evidence that the AA
1 position plays the decisive role in 
contribution towards binding whereas variation in the AA2 position does not affect the 
activity within the range of compounds explored here. Extending the length of the peptidic 
chain from AA3 to AA4 does not gain substantial additional activity. On the contrary, the 
potency of EP-R-NH2 indicates that even one amino acid in combination with the warhead is 
enough to support a relatively effective inhibition.  
Looking at the unanticipated inactivity of EP-K-NH2 and EP-KTE-NH2, this could be associated 
with the limitation of the assay discussed above. The stock concentration of EP-K-NH2 and 
EP-KTE-NH2 might be much lower than determined by mass, consequently their real 
concentration in this particular experiment could be significantly below 100 µM which may 
suggest why no activity was detected. 
3.5 Determination of the location of the target protease(s)  
E-64, discovered as one of the first SlpA cleavage inhibitors, does not have a noticeable 
effect on bacterial growth in rich BHI media (section 2.1.3). It was found that the inhibitors 
synthesised in this study also do not have an obvious effect on bacterial growth due to 
similar OD measured before harvesting. Nevertheless, an impact on cell integrity was found. 
Boiling C. difficile cells in a buffer containing strong anionic detergent (0.7% SDS, 100 °C) 
does not typically induce lysis because under normal culture conditions (described in section 
2.1.1) C. difficile possesses an extremely stable cell wall in addition to the S-layer. However, 
cells treated with inhibitor are less robust under the same conditions and cause a detectible 
effect on lysis as can be seen in Figure 3. 8A. One could speculate, therefore, that inhibition 
has a marked effect on cell integrity even when bacteria are cultured under optimal 
94 
 
conditions (e.g. BHI medium). From the aspect of future drug development based on this 
type of inhibitor, S-layer processing might be a potential therapeutic target, if possibly this 
impact on integrity might increase significantly, when the bacteria suffer under general 
stress such as antibiotic treatment or attack by the host immune system.  
 
Figure 3. 8: A) Coomassie blue-stained gels of protein released from cells untreated and treated with inhibitor 
(100 µM EP-LR-NH2) after boiling in 0.7% SDS at 100 :C for 5 min. Cells treated with inhibitor release a large 
quantity of intracellular protein, whilst untreated cells release proteins mainly or exclusively from the S-layer; 
Coomassie stained gels and anti-LMW-SLP Western blot of protein derived from fractions: 1 = glycine fraction; 
2 = soluble faction; 3 = insoluble fraction. B) C. difficile cell without treatment with inhibitor. C) C. difficile cell 
treated with EP-LR-NH2.  
The protein mixture derived from whole cell lysis is highly complex as it contains proteins 
from the S-layer, the cell wall, cytoplasmic proteins and other cell components. This 
complexity would present an additional challenge to locate the target enzyme. We next 
sought to determine the location of the active target protease in live cells (surface layer, 
membrane or intracellular) with the aim of reducing the complexity of the identification 
process. The cell was separated into three fractions. Firstly, the S-layer was stripped using 
low pH glycine following the standard extraction protocol [391]. The remaining cells were 
treated with lysozyme (to digest the polysaccharide component of bacterial cell walls) and 
DNase (to reduce the viscosity causing by released nucleic acid material) followed by 
centrifugation, based on the method of Jonquires [392]. Cell lysis was further enhanced by 
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additionally treating the cells with glass beads in order to facilitate the breakdown of cell 
walls after lysozyme treatment. As a result, the stripped cells were collected in two further 
factions: the soluble fraction (containing cytoplasmic proteins) and the pelleted insoluble 
fraction (containing membranes and insoluble cell components). The proof of principle of 
this technique for achieving effective cell separation was demonstrated in a sample without 
any inhibitor shown in Figure 3. 8B, highlighted by different bands in each fraction (only 
LMW- and HMW-SLPs, Slp2 in the S-layer fraction, distinctive bands for soluble and 
insoluble fractions). This experiment was repeated with EP-LR-NH2 inoculation before the 
bacteria were grown. Figure 3. 8C indicates that the inhibitory effect occurs after (or 
possibly during) delivery of SlpA to the S-layer fraction as no SlpA band was observed in the 
soluble and insoluble fractions.  
As previously shown and discussed in section 3.4, it was not clear which protease was 
targeted by this type of inhibitor. However, looking at Figure 3. 8C, it can be concluded that 
the inhibition most probably follows translocation to the cell surface and that the synthetic 
inhibitors target the putative protease involved in the internal cleavage to produce mature 
LMW and HMW-SLPs. This suggests the hypothesis that the putative target protease resides 
in the S-layer of the bacteria and is probably readily accessible to inhibitors present 
externally in the cell growth medium. If this is the case then inhibitors do not require 
intracellular uptake through the dense S-layer/cell wall, lending further support to the 
potential of this process as a therapeutic target. However, further study is required to 
provide concrete evidence that this is indeed the case, as described in the next chapter.  
3.6 Activity vs. concentration 
The dependence of in vivo inhibition on inhibitor concentration was investigated. To 
examine the maximal concentration of inhibitor required for an absolute inhibitory effect 
the concentration series tested ranged from 250 µM to 5 mM. Consequently, this 
experiment required a larger amount of inhibitor. EP-LGR-NH2 was found to have similar 
activity to that of the parent inhibitor EP-LR-NH2, and was relatively high-yielding, therefore 
it was chosen for this trial experiment. Remarkably, the amount of full length SlpA 
accumulating in the S-layer increased with increasing EP-LGR-NH2 concentration until 0.5 
B) 
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mM at which point a plateau was reached where increases in concentration had no further 
effect (Figure 3. 9).  
 
Figure 3. 9: Inhibitor activity vs. concentration, as measured by Western blot of S-layer fractions using anti-
LMW SLP.  C. difficile 630 cultures were treated with EP-LGR-NH2 at different concentrations. 
While examining the supernatant of cultures treated with inhibitor, it was found that SlpA is 
shed from cells. Although the level of the shedding is relative high, eventually exceeding the 
total SLPs retained on the cell wall, it does not reach a point where S-layer processing is 
completely inhibited. This striking result suggests a potency plateau in the cell and suggests 
that the S-layer probably has an important function for C. difficile. Unprocessed SlpA above 
a certain threshold may be not permit a tight matrix of S-layer and furthermore the 
production of SlpA appears to have been up-regulated to counteract the inhibitory effect. 
This response to the inhibitory stress is in agreement with papers that report increased SlpA 
expression in C. difficile exposed to various general stresses [393-394].  
3.7 Conclusion 
This chapter has detailed the development of improved inhibitors starting from a design 
based on E-64 through the synthesis and characterisation of activity in live cells. The 
synthetic route exploited during this study was adapted and optimised from literature 
methods to achieve high yields and enable facile access to a variety of inhibitor analogues. 
This can be used as a general platform for generating future generations of inhibitors.  
Both efficacy and selectivity of the synthesised inhibitors was explored, showing that the 
warhead and the specificity element are essential in combination to obtain an inhibitory 
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effect. Moreover, the inhibition is highly stereoselective with respect to the warhead. The 
results of this work also point to the important role of the AA1 position in contributing 
towards the activity, and that having only one amino acid with the warhead is sufficient for 
effective inhibition. This work formed the basis for a deeper structure activity relationship 
(SAR) study described the next chapter. 
Finally, resistance to lysis and inhibition dependence on inhibitor concentration were 
explored. In addition to weakened resistance to lysis, shedding behaviour was found to 
counteract the inhibitory effect at higher concentration suggesting an important structural 
role of the S-layer in C. difficile. 
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Chapter 4 Inhibitor analogues and bioorthogonal ligation 
 
To date, little work has been done involving the characterisation of proteases in C. 
difficile and only a few protease activities have been reported. Recent developments in 
genomics have provided the complete genome sequence of the C. difficile strain 630 
[277] and proteomic characterisation of its spore [395]. In these previously reported 
studies, sequence alignment algorithms and transcriptional profiling were applied to 
create a better understanding of the potential role of specific gene products. However, 
these technologies do not reveal the functional complexity of an enzyme such as the 
protease involved in the SlpA cleavage process because they do not provide direct 
information on protease activity in vivo, which is typically regulated at the post-
translational level. To address the functional complexities of this protease, activity 
based probes (ABPs) were applied.  
In this chapter, the development of ABPs is described. Epoxysuccinyl inhibitors were 
appended with a small chemical tag, an alkyne, with the objective of identifying their 
target. The chemical tag was expected to have a minimal effect on binding to the 
protease and cell distribution and could be ligated bioorthogonally with a fluorophore 
to visualise labelled enzymes after gel-based separation. Furthermore, a structure 
activity relationship (SAR) was generated by correlating AA1-modified epoxysuccinyl 
inhibitors with their inhibition potencies. The results of this work are important as they 
provide a starting point for protease identification (Chapter 6). 
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4.1 ABP design and synthesis 
Having established that the newly synthesised epoxysuccinyl inhibitor possesses improved 
potency over E-64 and that the AA1 position contributes significantly to its activity, we 
explored the SAR for this class of inhibitor with the putative protease. For the sake of easy 
evaluation, all inhibitors possessed the same warhead and the AA1 position was varied with 
different amino acids. The warhead chosen was ethyl epoxysuccinate, eliminating the last 
hydrolysis step in the synthesis route (see section 3.3). Previous data suggested that there is 
no difference in inhibitor potency between the ethyl ester and the carboxylic acid at the N-
terminus (section 3.4). The amino acids chosen for variation at the AA1 position featured 
different side chain motifs for the target binding: lysine, arginine and histidine were selected 
due to their basicity, while glutamic acid was chosen for its acidic side chain. Hydrophobicity 
and aromaticity were covered by valine, isoleucine, leucine, phenylalanine and tyrosine, 
whilst neutral hydrophilicity was covered by threonine and serine. Furthermore, the effect 
of altering the structural motif of the inhibitor was addressed by proline and glycine.  
 
Figure 4. 1: Structures of the chemical tag (Pra) and newly generated ABPs. 
As discussed in section 3.3, synthesis with only one amino acid after the warhead was 
problematic in some cases. Furthermore, the results of Chapter 3 also indicated that the AA2 
position does not affect potency. In addition, the inhibitors should be readily converted into 
ABPs with the objective of visualising their labelled target, and thus a chemical tag, an 
alkyne embedded in L-propagyl-glycine (Pra), was appended to each inhibitor at the C-
terminus. The Pra tag motif is used widely in chemical biology and found to be almost 
completely unreactive toward biological molecules [36]. Its small size, relatively nonpolar 
character and inability to form significant hydrogen bonds mean it does not change the 
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properties of the structure of the enzyme it labels. Moreover, it can be inserted 
straightforwardly into the peptidic chain using SPPS, as with normal amino acids.  
 
Nr. WH AA1 AA2 AA3 Abbr. Name 
TD 21 EP Leu Arg Pra EP-LR-Pra-NH2 
TD 22 EtEP Leu Arg Pra EtEP-LR-Pra-NH2 
TD 23 EtEP Ala Pra - EtEP-A-Pra-NH2 
TD 24 EtEP Phe Pra - EtEP-F-Pra-NH2 
TD 25 EtEP Ile Pra - EtEP-I-Pra-NH2 
TD 26 EtEP Leu Pra - EtEP-L-Pra-NH2 
TD 27 EtEP Val Pra - EtEP-V-Pra-NH2 
TD 28 EtEP Tyr Pra - EtEP-Y-Pra-NH2 
TD 29 EtEP Ser Pra - EtEP-S-Pra-NH2 
TD 30 EtEP His Pra - EtEP-H-Pra-NH2 
TD 31 EtEP Lys Pra - EtEP-K-Pra-NH2 
TD 32 EtEP Arg Pra - EtEP-R-Pra-NH2 
TD 33 EtEP Glu Pra - EtEP-E-Pra-NH2 
TD 34 EtEP Gly Pra - EtEP-G-Pra-NH2 
TD 35 EtEP Pro Pra - EtEP-P-Pra-NH2 
TD 36 EtEP Thr Pra - EtEP-T-Pra-NH2 
TD 37 (R,R)EtEP Leu Arg Pra (R,R)EtEP-LR-Pra-NH2 
TD 38 EtEP Pra - - EtEP-Pra-NH2 
TD 39 EtEP (D)Ala Pra - EtEP-(D)A-Pra-NH2 
TD 40 EtEP (D)Lys Pra - EtEP-(D)K-Pra-NH2 
TD 41 EtEP (D)Arg Pra - EtEP-(D)R-Pra-NH2 
TD 42 EtEP (D)Tyr Pra - EtEP-(D)Y-Pra-NH2 
Table 4. 1: ABPs synthesised in the work described in this chapter. 
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To confirm the properties of a Pra-appended inhibitor, EtEP-LR-Pra was synthesised to 
compare with the parent compound EtEP-LR-NH2. With regard to the stereochemistry, apart 
from creating an (R,R) configuration in the epoxide warhead, D-amino acid analogues were 
made of some inhibitors (A, K, R and Y) in the expanded library. Using the synthetic method 
described in section 3.3, the expanded library of 21 compounds, listed in Table 4. 1, was 
generated with the general structure shown in Figure 4. 1.  
4.2 Activity of chemical tag appended analogues 
To confirm that the Pra group did not affect the potency and that the ethyl ester N-terminal 
of the epoxide possessed identical activity to the corresponding free carboxylic acid, EtEP-
LR-Pra-NH2 and EP-LR-Pra-NH2 were compared with the parent compounds EtEP-LR-NH2, EP-
LR-NH2. As expected, the potencies of all these inhibitors appear identical (Figure 4. 2). 
Next, a panel of ABPs (Table 4. 1) was tested in vivo against strain 630 at 100 µM. The 
results from this experiment are striking (Figure 4. 3): both tyrosine and arginine as the AA1 
amino acid showed significantly improved potency over EtEP-LR-Pra-NH2, which is in good 
agreement with previous results (section 3.4); phenylalanine also showed strong activity 
compared to tyrosine and arginine. Other analogues such as X = alanine, valine, serine, 
lysine, glutamic acid, glycine, proline and threonine remained inactive at the concentration 
tested, while histidine, isoleucine and leucine were slightly active.  
 
Figure 4. 2: Activity of (Et/)EP-LR-Pra-NH2 vs (Et/)EP-LR-NH2, as measured by Western blot against anti-LMW 
SLP. C. difficile 630 were treated overnight with 100 µM inhibitors and whole cells were boiled in loading 
buffer prior to SDS-PAGE analysis. 
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Consistent with our previous finding, the opposite stereochemistry of the warhead ((R,R) 
configuration) remained inactive. Interestingly, a switch of the stereochemistry of the amino 
acid from L- to D-isomers in the specificity element moiety also caused complete loss of 
potency. The correlation between potency and amino acid structure was divided into two 
different tendencies. In one of the trends, the large positively charged side chain of arginine 
was permitted, while in the other large hydrophobic/aromatic side chains (phenylalanine 
and tyrosine) were tolerated. Aliphatic hydrophobic side chains tended to reduce the 
potency dramatically as found in the case of isoleucine and leucine. In addition, inhibitors 
with an (R,R)-configured warhead or D-amino acid were not active suggesting a highly 
stereoselective mode of action on the putative protease. The inhibitor containing only the 
epoxide warhead and the chemical tag, EtEP-Pra-NH2, was also inactive. Examining the 
conserved sequence of the SlpA cleavage locus across C. difficile strains (Table 1. 2) offers a 
better understanding of this interesting SAR. According to this, the AA1 position 
(corresponding to the second residue upstream of the scissile bond) is either lysine or 
tyrosine. In the case of EtEP-Y-Pra-NH2, the result suggested that it bound to the protease in 
a similar manner as the substrate, in which the epoxide warhead occupied the S1 pocket 
and tyrosine the S2 pocket. However, this hypothesis was not maintained for EtEP-K-Pra-
NH2. It is possible that EtEP-K-Pra-NH2 was not active at the concentration tested, but could 
be active at higher concentration. Indeed, it emerged in later studies (section 4.3), that 
lysine possessed a higher activity threshold. Figure 4. 3 also illustrates the correspondence 
of SlpA bands on the Coomassie stained gel and Western blot as reflected by their 
intensities. 
 
Figure 4. 3: Activity of ABPs, as measured by Coomassie stain and Western blot of S-layer fractions using anti-
LMW SLP. C. difficile 630 cultures were treated with compounds at 100 µM. Indicated bands are 1) SlpA; 2) 
Slp2; 3) HMW-SLP; 4) LMW-SLP. 
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4.3 Activity vs. Concentration 
We next revisited the dependence of in vivo inhibition on inhibitor concentration. 
Comparing the E-64 mimic ABP, EtEP-LR-Pra-NH2, with the most potent compound, EtEP-Y-
Pra-NH2, revealed remarkable results. The tendency of reaching a plateau at about 500 µM 
on the S-layer and the shedding behaviour in the cultured supernatant of the unprocessed 
SlpA were found as expected (Figure 4. 4). However, at 5 mM EtEP-Y-Pra-NH2 almost 
exclusively SlpA and almost no LMW-SLP were detected in the cultured supernatant. 
Furthermore, the ratio of SlpA and LMW-SLP was significantly lower when C. difficile was 
treated with EtEP-LR-Pra-NH2. 
 
Figure 4. 4: Activity of inhibitors, as measured by Coomassie stain and Western blot of S-layer fractions using 
anti-LMW SLP. C. difficile 630 cultures were treated with compounds at different concentrations, as indicated. 
To compare inhibitor potency at lower micromolar concentrations, a panel of ABPs (X=A, L, 
Y, K, R) was tested at various concentrations, from 10 µM to 500 µM. As can be seen in 
Figure 4. 5, the inhibitor containing alanine at the AA1 position remained inactive, even at 
500 µM. Compared with the previous result shown in Figure 4. 3, a slight lack of 
reproducibility was observed as EtEP-L-NH2 was active at 100 µM previously but not in this 
experiment; this is likely a result of inconsistencies in the Western blot detection of SlpA. 
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Thus, moderate activity was observed for lysine and leucine at this position above 250 µM. 
On the other hand, substitution at the AA1 position with arginine increased the potency to 
50 µM and with tyrosine to 10 µM. Further testing of EtEP-Y-Pra-NH2 at much lower 
concentrations showed that it retained some activity down to 5 µM. This indicates a 
significant improvement in in vivo activity over the initial hit E-64.  
 
Figure 4. 5: Activity of inhibitors, as measured by Western blot using anti-LMW SLP. SlpA is shown. C. difficile 
630 cultures were treated overnight with compounds at different concentrations, as indicated and whole cells 
were boiled in loading buffer prior to SDS-PAGE analysis. 
4.4 Chemical labelling 
4.4.1 Click ligation in labelled C. difficile 
Click reactions are often used to ligate a labelling reagent to a bioorthogonally tagged 
molecule. The details of click reaction and its application in chemical biology have been 
described in section 1.3.2. The application of CuAAC in C. difficile is reported in this study 
using CuAAC as it was found to be more suitable for detecting alkynes in protein lysates 
rather than on live cells because of its cytotoxicity [94]. In addition, this method is known to 
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be relatively sensitive and useful for the detection of low-abundance proteins [94] and its 
extensive application in the Tate group provided access to strong local expertise and 
reagents. Moving towards the identification of the target protease involved in SlpA 
cleavage, although the ABP inactivates (and therefore should tag) this protease in vivo, 
labelling with capture reagent probes can take place in vitro. 
Conditions suitable for performing CuAAC in different mammalian cell lines (e.g. Hela and 
HEK cell lines) and parasite lysates (e.g. Trypanosoma brucei) had already been established 
by members of the Tate group, and the same conditions were employed in the C. difficile 
system. Once the designed ABP (Figure 4. 1) has been introduced into the target protease in 
vivo by virtue of its inhibition effect, the capture reagent should label the ABP after lysis 
using the highly selective CuAAC (Figure 4. 6). The capture reagent (AzK(TAMRA)G-PEG3-
Biotin) used in this study was synthesised by Megan Wright (Tate group, Imperial College 
London, UK) and contains three functionalities: an azide group enabling ligation to the 
alkyne, a biotin group permitting subsequent affinity pull down for enrichment and a 
TAMRA group for in-gel fluorescence detection of labelled proteins.  
4.4.2 Click assay development 
As mentioned above, work in the Tate group has directed considerable effort toward 
optimisation of click conditions for various systems. These reagents and conditions were 
employed to develop a protocol for click ligation in C. difficile. The bacteria were grown in 
the presence of an ABP, allowing the tagging of the target protease in vivo. Afterwards, the 
bacteria were harvested and treated with low pH glycine to strip off the S-layer (the ‘S-layer 
fraction’). The remaining cells lacking S-layer proteins were termed the ‘cell fraction’. 
Subsequent ligation was carried out on aliquots of these fractions. The initial click conditions 
applied were: 
1. 10 µl of prepared protein fractions (from a 200 µl of a 5 mL culture) 
2. 10 µMfinal of azide capture reagent (from a 1 mM stock in DMSO) 
3. 2 mMfinal CuSO4 (from a 40 mM stock in H2O) 
4. 10 mMfinal sodium ascorbate (from a 400 mM stock in H2O) 
5. 500 µMfinal BCS ligand (Figure 4. 7; from a 50 mM stock in H2O) 
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Figure 4. 6: A) Cu(I)-catalysed azide-alkyne cycloaddition reaction of the ABP with AzK(TAMRA)G-PEG3-Biotin. 
B) Bioorthogonal labelling in C. difficile. 
A) 
 
B) 
 
O
3
N
H
O
N
H
H
N
S O
2 H
H
N
H
O
H
N
O
N
H
NH
O
N
N
O
O
O
O
N3
+
Cu(I)
labelled protease Capture reagent
O O
O N
H
H
N
O
NH2
OR
S
OH
O O
O N
H
H
N
O
NH2
OR
O
3
N
H
O
N
H
H
N
S O
2 H
H
N
H
O
H
N
O
N
H
NH
O
N
N
O
O
O
O
N
N N
OH
S
C. difficile
proteins extracted
Click ligation
= Warhead
= specificity element
= alkyne tag 
= azide
= TAMRA
= biotin
In-gel 
fluorescence
- + - +
Total proteins
107 
 
Components were added in the order above and mixed thoroughly at each addition step. 
The reaction mixture was agitated at room temperature for a further 20 minutes, before 
quenching with MeOH (0 °C) and storage at -80 °C overnight to promote protein 
precipitation. The precipitated protein was analysed by SDS-PAGE and in-gel fluorescence 
imaging. Unfortunately, no bands were observed, apart from excess capture reagent at the 
bottom of each lane (Figure 4. 8A). This could be due to the low concentration of the 
labelled protein or of the azide capture reagent, or the short reaction time. Therefore, the 
click reaction was further optimised as follows: 
 Increasing the amount of the prepared protein in each fraction from 10 µl to 50 µl 
 Increasing the azide concentration from 10 µM to 50 µM 
 Increasing the reaction time from 20 minutes to 1 hour 
The results remained disappointing as no labelled bands were observed. The click ligation 
proved to be challenging for C. difficile and required further optimisation, perhaps indicating 
the complexity of the extracted proteome which demands more robust protocols and 
reagents.  
Examining and comparing each component of the click reaction mixture to examples of click 
ligation in the literature led to the realisation that the prepared protein fractions (S-layer 
and cell fractions) contained relatively high concentrations of salts (glycine in the S-layer 
fraction and PBS in the cell fraction). These salts could interfere with the click reaction. 
Glycine could act as a weak ligand for Cu(I) and outcompete the BCS ligand when it is in 
large excess. Consequently, the stability of Cu(I) might be sufficient to catalyse cyclisation. 
Therefore, buffer replacement by ultrafiltration in Ultrafree 0.5 mL centrifugal filter devices 
(Millipore) with a 10 kDa molecular weight cut-off limit was proposed to try and eliminate 
the problem.  
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Figure 4. 7: Ligands and reducing agents used in this study.  
The reducing agent used to generate the copper (I) catalyst was one of the next concerns. 
Although only small differences between the effect of ascorbate and TCEP on the ligation in 
mammalian cell lines and parasite lysates were found [396], sodium ascorbate was replaced 
by TCEP to avoid addition of further salt to the reaction mixture. Furthermore, the BCS 
ligand was switched to TBTA. Both ligands were known to stabilise the copper (I) oxidation 
state, however TBTA better stabilises Cu(I) against oxidation and disproportionation and 
reduces the background signals better than BCS [397-398]. The optimised click ligation 
conditions were:  
1. 50 µl of prepared protein fractions (from a 200 µl of a 5 mL culture) 
2. 50 µMfinal of azide capture reagent (from a 1 mM stock in DMSO) 
3. 1 mMfinal CuSO4 (from a 40 mM stock in H2O) 
4. 1 mMfinal TCEP (from a 400 mM stock in H2O) 
5. 100 µMfinal TBTA ligand (Figure 4. 7; from a 50 mM stock in H2O) 
6. 1 hour reaction time at room temperature. 
Figure 4. 8B shows the results for the click ligation carried out using these optimised 
conditions. A positive control (lane L) was added, which was alkynyl myristate-labelled Hela 
cell lysate containing 50 µg protein prepared by Megan Wright, a student in the Tate group 
(Imperial College London, UK). A few bands were observed in lane DS and the control lane 
(lane L) after a prolonged exposure time. However, the signals were relatively weak and 
lanes S to C remained blank. Increasing the protein amount from 50 µl to 100 µl led to a 
striking result (Figure 4. 8C): clear labelled bands were observed in all lanes. Comparing lane 
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DS (S-layer fraction after buffer replacement) and lane S (S-layer fraction without any buffer 
replacing process) revealed the important role of the buffer replacement step.  
 
Figure 4. 8: Click optimisation, including the optimised conditions for each stage. Gels visualised by in-gel 
fluorescence show ligation of protein extract after treatment with 100 µM of indicated inhibitor. PM = ECL 
Plex™ Fluorescent Rainbow Markers (kDa), S = S-layer fraction, C = cell fractions, DS = buffer replaced S-layer 
fraction, DC = buffer replaced cell fraction, L = alkynyl labelled Hella cell lysates as positive control (50 µg 
protein lysates, prepared by Megan Wright). 
4.4.3 Ligation results 
In order to demonstrate the correlation of protein labelling with S-layer inhibition activity, a 
panel of ABPs was tested using these optimised conditions. The result of this experiment is 
displayed in Figure 4. 9. Generally, labelling was observed in all samples with a more 
complex pattern than previously found in the last optimisation step (Figure 4. 8C). Although 
the intensities of labelled bands varied strongly between samples, the pattern of these 
bands was very similar. Comparing bands in no inhibitor lane with other lanes indicated that 
most of these bands were background labelling. It was difficult to extract meaningful 
information without further optimisation.  
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Figure 4. 9: In-gel fluorescence image showing labelling of S-layer fractions across the ABP series (100 µM) 
after click ligation to AzK(TAMRA)G-PEG3-Biotin. SlpA bands of Western blot against LMW-SLP have been 
added (at top) to facilitate comparison with activity. In the activity assay, cells were treated with ABPs at 
250 µM. 
From a practical aspect, there was still scope to improve the click ligation because problems 
including unpredictable loss of sample resulted in inconsistently loaded protein in each lane 
(Figure 4. 9, lane X=A) and high background labelling made evaluation difficult. Ultrafree 
centrifugal filter devices are useful to reduce the salt concentration, but have one drawback: 
a certain amount of protein sticks to the filter membrane, leading to occasional complete or 
partial loss of samples. In addition, precipitation of protein at -80 °C in MeOH produces 
fluffy protein pellets that are easy to lose during solvent removal and wash steps. To 
circumvent the discussed problems, another precipitation method (MeOH/CHCl3) was 
applied. The precipitated protein concentrated at the phase interface and was easy to 
handle.  
To reduce the degree of background labelling a pull-down step was added to the protocol 
prior to SDS-PAGE analysis. ‘Pull-down’ is the term used for a small scale affinity purification 
technique that utilises the strong affinity binding of two different binding partners, biotin 
and streptavidin in this case. Commercially-available streptavidin immobilised onto solid 
support was used (‘Streptavidin Dynabeads’). After resuspending the prepicipitated protein 
in 30 mM Tris, 30 µL Streptavidin was added and agitated for one hour at RT to allow the 
capture (‘pull-down’) of biotin labelled protein onto the beads. With this method, labelled 
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protein was enriched and physically separated from unlabelled protein, however there was 
also nonspecific binding causing a certain amount of undesired co-purification. Stringent 
washing steps (three times of 50 µl 1%SDS in 30 mM Tris) were added to elute these non-
specific binders, but does not co-elute the biotin labelled protein due to its specific and very 
strong affinity bond. Finally, the beads were heated at 100° C in loading buffer to break the 
streptavidin-biotin bond, eluting labelled protein from the beads.   
 
Figure 4. 10: Optimised click ligation protocol for C. difficile system used in this study.  
To secure relatively equal amounts of protein for each sample in each lane the relative 
concentration of eluted proteins in loading buffer was measured using a spectrophotometer 
and normalised prior loading on the gel. A NanoDrop® ND-1000 UV-Vis Spectrophotometer 
was used as it is designed for quantifying accurately and reproducibly small volumes of 
sample (0.5-2 µL), perfect for limited sample volumes such as those used here. The 
instrument was blanked using loading buffer without any protein, and 1 µl of sample was 
measured on the analyser at 230 nm. The final optimised protocol is displayed in Figure 4. 
10.  
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The results of the final optimised protocol were clearer (Figure 4. 11). In general, the high 
background was eliminated and the gel looked much cleaner; most of the background 
labelling remained in the supernatant. However, some of the abundant HMW and LMW-
SLPs were retained in the pull-down and showed a very strong labelled band on the S-layer 
pull-down gel. Intriguingly, strongly labelled bands at approximately 76 kDa were seen in 
direct correlation with inhibition activity in some cases. However, bands at the same size 
were also observed with some inactive ABPs including all D- amino acid analogues. 
Interestingly, EtEP-R-Pra-NH2, EtEP-Y-Pra-NH2 and EtEP-F-Pra-NH2 labelled a second band 
slightly higher than 76 kDa. Further labelled bands below 38 kDa appeared to be present in 
most samples but with different intensity, indicating that they were also background 
labelling. As the cell lysed differently after treatment with different inhibitors due to 
inhibition of SlpA processing, the level of this background labelling might be depend on the 
total protein in cell lysate. Cell fractions revealed only background labelling, reinforcing the 
previous suggestion that the target protease(s) is/are located in the S-layer, and not inside 
the cell (section 3.5).   
4.5 Conclusion 
The development of alkyne-tagged ABPs has been described in this chapter. Having 
investigated more than 40 inhibitors/ABPs (Chapter 3 and 4) covering most aspects of 
known E-64 SARs and of the SlpA cleavage site, a general SAR for epoxysuccinyl inhibitors 
was compiled. This SAR is divided in three parts examining the importance of each unit of 
the designed inhibitors/ABPs, namely the warhead, the specificity element and the 
appended tag. In the inhibition of proteases involved in SlpA cleavage, the warhead was an 
essential unit in contribution towards activity, as replacing the epoxysuccinyl warhead with 
an acetyl group caused a complete loss of activity. Furthermore, the stereochemistry of the 
epoxide also played an critical role in inhibition. The S,S- configuration as found in E-64 was 
active, while the R,R-configuration was not. Although ethyl ester and carboxylic acid 
functions at the N-terminus of the inhibitor differ in their chemical structure and properties, 
they possessed similar inhibitor potency. The epoxysuccinyl warhead was indeed essential 
for inhibition, but not on its own. It required the attachment of the specificity element, with 
even a single specific amino acid resulting in activity, suggesting equal importance of both 
these parts of the inhibitors. 
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Figure 4. 11: Labelling across ABP series seen by in-gel fluorescence after CuAAC ligation to AzK(TAMRA)G-
PEG3-Biotin. Three different fractions are shown: S-layer pull-down, S-layer supernatant and cell pull-down. 
Indicated band in S-layer pull-down gel: 1) HMW-SLP; 2) LMW-SLP. 
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The specificity element was designed to mimic the cleavage locus of SlpA. It was found that 
the first amino acid after the warhead (AA1 in the inhibitor nomenclature adopted here) had 
a significant influence on inhibitor potency. Correlation with activity was divided in two 
groups. In one group a positively charged side chain was permitted, though it appeared that 
a larger or more basic group was preferred over smaller group (e.g.: arginine better than 
lysine, histidine). This effect was observed more clearly in the concentration dependence 
experiment (Figure 4. 5). In the other group, large hydrophobic/aromatic side chains (e.g.: 
phenylalanine, tyrosine) were accepted. In this group, aliphatic hydrophobic side chains 
seemed to be disfavoured as they significantly reduced the potency (e.g.: leucine, 
isoleucine). 
Inhibitors bearing a small side chain (alanine), acidic side chain (glutamic acid) or neutral 
hydrophilic side chain (threonine, serine) as well as structure-altering side chains (glycine, 
proline) at AA1 remained inactive. Stereoselectivity was also observed within the specificity 
element as L-amino acids were active and D-amino acids not.  
Examining the importance of the second amino acid after the warhead (AA2) brought more 
questions rather than answers. If AA1 was moderately active and kept consistent while AA2 
was varied, the inhibition activity could be barely distinguished (e.g.: EP-KT-NH2, EP-KA-NH2, 
EP-KPra-NH2), suggesting that the AA
2 position does not affect the activity. Indeed, further 
work in the Tate and Fairweather research groups (Vladimir Turek, Imperial College 2008, 
unpublished results) building on the data reported here demonstrated that a wide range of 
amino acids at AA2 are tolerated when AA1 is Tyr or Lys. However, this trend did not appear 
to extend to leucine. As shown above, leucine possessed a relatively poor activity on its own 
as AA1, but in combination with arginine ((Et/)EP-LR-NH2) at AA
2 the potency increased 
significantly, suggesting that, on the contrary, the nature of AA2 can have an effect on 
inhibition. Further extension of the length of the specificity element to AA3 or AA4 did not 
result in substantial additional activity within the limited set of inhibitors investigated here. 
The chemical tag appended to the C-terminus of the inhibitor did not appear to interfere 
with inhibition. This was further confirmed by the ABPs described in the next chapter.  
Taken together, these data suggest that the epoxysuccinyl inhibitors inactivate a papain 
class cysteine protease in a canonical manner to that found for E-64, in which the epoxide 
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warhead probably binds to the S1 pocket and the first amino acid after the warhead 
(corresponding to the second residue upstream of the scissile bond in the cleavage locus) 
binds to the S2 pocket. This being the case, binding to the S3 pocket was uncertain, as the 
effects of AA2 on inhibition were ambiguous.  
The work of Chapter 4 also describes the optimisation of two-step labelling in the C. difficile 
system. The practical challenge was overcome and very distinct labelling of proteins was 
seen. Despite the still ambiguous correlation between these labelling with the activity of the  
corresponding ABP, the labelled proteins could be identified (Chapter 6), and later verified 
as including the target protease (Chapter 7). Furthermore, the results of protein labelling 
confirmed that the target protease(s) is/are located in the S-layer and should therefore be 
readily accessible in the medium. This observation led to the development of directly 
labelled ABPs, as described in the next chapter (Chapter 5).   
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Chapter 5 Directly labelled activity-based probes 
 
Verification that the putative proteases are located in the S-layer of C. difficile 
eliminates any cell penetration issues associated with the inhibitors/ABPs, as they can 
readily reach their targets in the medium. It was then speculated that switching from 
two-stage ABPs to directly-labelled ABPs would simplify the target identification 
process due to abolishing the challenged click ligation and its requirements, as well as 
its interference in the labelling step. This chapter is divided in two parts: the first part 
explores the work with ABPs bearing a direct affinity label (a biotin tag), while the 
second part addresses ABPs possessing single and dual direct fluorescent labels (a 
fluorescent dye and a biotin tag). The results of this chapter served as foundation for 
the target identification process, discussed in the next chapter.  
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5.1 Biotinylated ABPs 
Biotin is the most widely used reporter unit (see 1.3.1.3). In this study, biotin was attached 
to the C-terminus of inhibitors via a hydrophilic PEG linker, which improves solubility of the 
ABP and reduces the chance of interference between warhead and affinity tag. The general 
structure of these ABPs is displayed in Figure 5. 1.  
 
Figure 5. 1: General structure of biotinylated ABPs. 
To generate a new series of PEG-biotinylated ABPs, SPPS using the method described in 
section 3.3 was performed using Biotin-Novatag resin instead of Rink amide resin, 
permitting the PEG-Biotin to be introduced at the outset of the synthesis. With the aim of 
confirming the correlation of activity and labelled effect found previously, a similar series of 
ABPs to those discussed in Chapter 4 were synthesised, and are listed in Table 5. 1.  
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EP-AA1-AA2-PEG3-Biotin 
No. WH AA1 AA2 Abbr. Name 
TD 43 EP Leu Arg EP-LR-PEG3-Biotin 
TD 44 EtEP Leu Arg EtEP-LR-PEG3-Biotin 
TD 45 (R,R)EtEP Leu Arg (R,R)EtEP-LR-PEG3-Biotin 
TD 46 EP Ala - EP-A-PEG3-Biotin 
TD 47 EP Phe - EP-F-PEG3-Biotin 
TD 48 EP Ile - EP-I-PEG3-Biotin 
TD 49 EP Leu - EP-L-PEG3-Biotin 
TD 50 EP Val - EP-V-PEG3-Biotin 
TD 51 EP Tyr - EP-Y-PEG3-Biotin 
TD 52 EP Ser - EP-S-PEG3-Biotin 
TD 53 EP His - EP-H-PEG3-Biotin 
TD 54 EP Lys - EP-K-PEG3-Biotin 
TD 55 EP Arg - EP-R-PEG3-Biotin 
TD 56 EP Glu - EP-E-PEG3-Biotin 
TD 57 EP Gly - EP-G-PEG3-Biotin 
TD 58 EP Pro - EP-P-PEG3-Biotin 
TD 59 EP Thr - EP-T-PEG3-Biotin 
TD 60 EP - - EP-PEG3-Biotin 
Table 5. 1: Biotinylated ABPs synthesised in the work described in this chapter. 
5.1.1 Activity of biotinylated analogues 
Similar to pervious work in Chapter 4, a comparison of the parent compounds (Et/)EP-LR-
NH2 with different generations of ABPs (the directly-labelled EtEP-LR-PEG3-Biotin and the 
alkyne-tagged EtEP-LR-Pra-NH2) was performed. As shown in Figure 5. 2, these compounds 
possessed essentially identical potency (at 100 µM) to the parent inhibitors, strongly 
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suggesting that the tag does not change or interfere with the inhibition activity. This may be 
due to the fact that the target proteases are located in the S-layer and are readily accessible 
for inhibitors/ABPs in the medium.  
 
Figure 5. 2: Activity of EP-LR-PEG3-Biotin and EP-LR-Pra-NH2 vs. EP-LR-NH2, as measured by Western blot 
against LMW SLP. C. difficile 630 cultures were treated with compounds at 100 µM. 
Testing selected ABPs against strain 630 in vivo at 100 µM produced similar results as those 
found in Chapter 4 (Figure 5. 3). The tendency for the tolerance of two different 
characteristic amino acids located in the AA1 position with improved potency was also 
observed. Tyrosine (representative of a large aromatic side chain group) or arginine 
(possessing a large, positively-charged side chain) at the AA1 position retained higher 
potency, other ABPs remained moderate or less potent. The appearance of a weak SlpA 
band in most lanes was also observed, as previously discussed (section 2.1.3). 
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Figure 5. 3: Activity of biotinylated ABPs, as measured by Western blot of whole cell against LMW SLP. C. 
difficile 630 cultures were treated with compounds at 100 µM. 
5.1.2 Labelling effect of biotinylated ABPs 
To investigate the utility of directly-labelled ABPs, C. difficile overnight cultures were grown 
in the presence of the panel of ABPs at 100 µM (Table 5. 1) and harvested before the whole 
cell was boiled in loading buffer. SDS-PAGE analysis (on glycine-tris gel) and Western 
blotting against NeutrAvidin revealed the interesting results presented in Figure 5. 4.  
 
Figure 5. 4: Labelling effect of biotinylated ABPs, as measured by Western blot of whole cell against 
NeutrAvidin-HRP. C. difficile 630 cultures were treated with compounds at 100 µM. SlpA bands of ABPs from 
previous section (Figure 5. 3) are shown to aid the evaluation of correlation between activity and labelling. 
Intriguingly, the labelling of these probes appeared very specific. A single band, at 
apparently 70 kDa, was observed for all probes, except EP-R-PEG3-Biotin that labelled two 
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bands, one of similar size to the other ABPs and the other located slightly higher on the gel. 
The band at 70 kDa (apparent m.w.) on the NeutrAvidin blot is probably the same band as 
was observed with the two-step labelling method at approximately 76 kDa (Figure 4. 11). 
The small difference in size is the result of differing behaviour of the protein on the different 
gel types (glycine-tris gel and Bis-tris gel (see section 9.1.3) and the less accurate estimation 
of protein size in the higher molecular weight region by using different protein markers 
(fluorescent and biotinylated protein markers). The labelling of proteins of apparently the 
same size with both the inactive and active inhibitor is in agreement with the results of the 
two-step labelling and is likely to be the same protein labelled. However, all labelled bands 
were equally intense and consistent throughout the whole series of ABPs, regardless of 
whether these ABPs are active or not in inhibition of SlpA processing. It was hypothesised 
that there may be two possibilities explaining this phenomenon. The first possibility is that 
both active and inactive ABPs label one single protease. However, in this case the inactive 
ABP must presumably bind to the protease at a site other than the active site (Figure 5. 5A). 
The second possibility is that this type of inhibitor targets at least two proteases, in which 
case only the active ABPs label the protease involved in the internal SlpA cleavage, whilst 
the inactive ABPs (and possibly also the active ABPs) label some other protease of C. difficile 
of similar size, running at the same position on the gel after SDS-PAGE analysis (Figure 5. 
5B). Furthermore, these proteases could be closely related and belong to the same protease 
family since they are targeted by the same type of inhibitor, but tolerate different binding 
motifs and so would respond to different specificity elements in the ABPs. The identification 
of these proteins would reveal which hypothesis is more likely in C. difficile.  
To examine the minimal concentration of ABP required for a labelling effect, EP-LR-PEG3-
Biotin was tested over a range of 0 to 50 µM. As shown in Figure 5. 6, only slight activity was 
observed at 50 µM and at lower concentrations no activity was observed. However, the 
labelling effect could be detected at concentrations as low as 2 µM. This result implies that 
the minimal concentration required for detection of labelling of the target protease(s) is 
much lower than that required for detectable activity against SlpA processing. It is possible, 
that C. difficile produces an excess of the active protease(s), so that only a fraction of 
available protease is required for cleaving SlpA. Consequently, inactivating (and labelling) 
the excesses protease with an ABP will not result in inhibition of SlpA cleavage, and 
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therefore the concentration threshold for labelling/detection is much more sensitive than 
detection of activity (via detection of SlpA).   
 
Figure 5. 5: Hypothesis of labelling of epoxysuccinyl ABPs. A) Both active and inactive ABPs target one single 
protease, but at different binding sites. B) Only active ABPs target label the target protease involved in SlpA 
cleavage, while inactive and possibly also active ABPs bind to another protease which have similar size to the 
target protease. 
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Figure 5. 6: Activity and labelling effect of biotinylated ABPs, as measured by Western blot of whole cell 
against LMW-SLP (A) and NeutrAvidin-HRP (B). C. difficile 630 cultures were treated with EP-LR-PEG3-Biotin at 
the indicated concentrations, as per standard inhibition assays (see section 2.1.1).  
Presumably the labelling effect correlates directly with the amount of protease(s) bound by 
the ABPs regardless whether the ABPs inactivate the protease(s). Furthermore, the labelling 
signals seem to saturate at 20 µM, as the intensity of the labelling from 20 µM to 50 µM is 
similar. This saturation effect is one drawback of a non-linear visualisation method such as 
NeutrAvidin-HRP (using chemiluminescence detected with an automated gel reader), which 
tends to enhance the detection of strong signals and decrease weaker signals, frustrating 
the detection of proteins at lower concentration. Furthermore, it makes the quantitative 
evaluation of labelling more difficult, especially at higher concentrations required for 
detectable potency. Nevertheless, the fact that the designed ABPs tag target protease(s) at 
relatively low concentration encouraged further investigation in protein enrichment and 
identification, as discussed in the next chapter.  
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5.1.3 Stability of inhibitors in culture  
Epoxides were reported to be stable under biologically relevant conditions by the Koide 
group [399]. However, under the condition tested, it might be that denaturised proteins 
contained in the BHI broth could cross react with the epoxide part of the inhibitors at 37  C in 
the anaerobic cabinet. 
It was assumed that if the epoxide reacts or degrades in BHI broth its effective 
concentration would decrease significantly and therefore a much lower activity would be 
expected at later time points. To address this concern, EP-LR-PEG3-Biotin was pre-incubated 
in BHI broth for 1.5, 16 or 24 hours prior to inoculating a single C. difficile colony for 
performing the activity assay. The result of this experiment is shown in Figure 5. 7A. Both 
full-length SlpA on Western blot against LMW-SLP and the characteristic labelled band at 
approximately 70 kDa on a NeutrAvidin-HRP blot were found in all three samples, 
suggesting that the epoxide inhibitor was stable in BHI broth under the conditions tested. 
Thus the lifetime of active inhibitor/ABP in BH  broth at 37  C is certainly greater than 24 h. 
However, it is unclear if the concentrations of inhibitor in the growth medium after different 
incubation times are identical or slightly lower compared to the initial concentration added, 
as the similar potency and labelled activity in all samples does not reflect small changes of 
inhibitor concentration.  
It was noted that there was a high molecular weight band at approximate 140 kDa found on 
the NeutrAvidin blot. This band is presumably either a natively biotinylated protein or is 
detected non-specifically, as it is also found in negative control which was not treated with 
any of the biotinylated ABPs.  
In addition, a growth curve of active and inactive ABPs (EP-LR-PEG3-Biotin and EP-A-PEG3-
Biotin) was monitored (Figure 5. 7B) showing that these ABPs did not affect the growth of 
bacteria. Samples OD600 were identical at all time points, except the one measured after 
overnight inhibition which may be due to growth variation rather than any effect of the 
inhibitors.  
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Figure 5. 7: Inhibitor stability test. A) Stability test of epoxide-based inhibitor over time in growth medium. EP-
LR-PEG3-Biotin was pre-incubated in BHI broth for a given time before a C. difficile colony was inoculated. The 
SlpA band on a Western bolt against LMW-SLP antibody reveals the inhibition activity level for each sample. 
Labelled bands on NeutrAvidin-HRP blot show the labelling effect. B) Measurement of C. difficile growth by 
treating with active ABP (EP-LR-PEG3-Biotin) and inactive ABP (EP-A-PEG3-Biotin). Optical density at 600 nm 
(OD600) was measured at each time point.  
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5.1.4 Minimal inhibition time required for detectable labelling or inhibitory 
effects 
The time dependency of in vivo inhibition and labelling was investigated and the results are 
described in this section. In order to obtain a sufficient amount of bacteria for SDS-PAGE 
analysis and visualisation at each time point, all treated samples were grown and harvested 
at the same time with inhibitor added at different stage of the growth curve in each case. 
Briefly, a 1 hour pre-grown C. difficile culture was divided into six aliquots and grown for 10 
hours. During growth, EP-LR-PEG3-Biotin was added to the aliquot at sequential time points 
to vary the length of inhibitor incubation time. All samples were stopped simultaneously by 
centrifugation after 10 hours. 
 
Figure 5. 8: Time dependency analysis of biotinylated ABP. Cultures of C. difficile 630 were incubated with EP-
LR-PEG3-Biotin at 250 µM for the indicated time. Cell pellets and concentrate of culture supernatant were 
analysed by Western blot against LMW-SLP and NeutrAvidin-HRP.  
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The whole cell pellet and the concentrate of the culture supernatant were analysed by 
Western blot against LMW-SLP and NeutrAvidin to reveal the results displayed in Figure 5. 
8. It was found that inhibition of S-layer processing occurred continuously and the longer 
the inhibitor was present in the culture, the more SlpA was found. Interestingly, the shed 
SlpA in the culture supernatant obeyed the same tendency as that found in the cell pellet, 
however unprocessed SlpA was not found in the culture supernatant until at least 4 hours of 
inhibitor incubation time whilst this was only 2 hours for SlpA found in the cell pellet.  
Labelling of protein occurs only in the cell and not in the culture supernatant suggesting that 
the protease(s) involved in the cleavage remain in the S-layer. Furthermore, a similar 
tendency was observed as for inhibitory activity; that 2 h of inhibitor incubation time is 
sufficient for the labelling process to take place. 
5.1.5 Strain dependence 
Based on the labelling effect and inhibitory activity on SlpA processing, it was hypothesised 
that epoxysuccinyl inhibitors/ABPs targeted at least two proteases in C. difficile. One is 
involved in SlpA cleavage (inhibited by active inhibitors) and one is not (bound by inactive 
inhibitors and possibly also active inhibitors). It was decided to investigate this phenomenon 
further by looking at different C. difficile strains. 
The cleavage locus of different strains still varies despite the relatively high homology 
around this locus, as revealed by an alignment of SlpA sequences from 35 strains from 
different sources (see section 1.6.2.). It is more unlikely that one specific protease can 
recognise all the different proteins. To address this topic, a collection of ten different strains 
of C. difficile which possess less homology at the cleavage site was investigated.  
A panel of non-tagged and biotinylated inhibitors was chosen for this experiment. E-64 and 
its mimic EP-LR-NH2 and EP-LR-PEG3-Biotin were selected as positive controls, while EtEP-
OH, EP-PEG3-Biotin and EP-A-PEG3-Biotin served as negative controls. EP-LGR-NH2 and EP-
KTEL-NH2 were chosen to satisfy both design considerations (based on the parent 
compound EP-LR-NH2 and cleavage site). EP-K-PEG3-Biotin and EP-L-PEG3-Biotin were 
selected to mimic the P2 position of the majority of substrates (corresponding to the AA1 
position of inhibitors). 
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Figure 5. 9: Strain dependency of inhibitors. Amino acids indicated in red in the cleavage sequence represent 
the P1 position of the substrate at the cleavage site. Raw data of western blot gels are attached in the 
Appendix 1.  
A summary is illustrated in Figure 5. 9, SlpA bands were excised and compiled in the table, 
while the raw data is attached in the appendix. Overall, E-64 and its mimics showed 
moderate activity, whereas EtEP-OH, EP-PEG3-Biotin and EP-A-PEG3-Biotin remained 
essentially inactive in all strains tested. Furthermore, some different levels of inhibition 
were observed for certain inhibitors across different strains. In particular, EP-KTEL-NH2 and 
EP-K-PEG3-Biotin possessed reduced or no inhibitory effects with strains including 167, 
E13540 and SE 538, but good activity with other strains.  
As found in the reference strain 630, all biotinylated ABPs labelled a strong band at 
approximate 70 kDa. In some strains such as CD17, CD167 and Y, additional bands at lower 
molecular weights were found with lower intensity (Figure 5. 10). These bands showed 
similar behaviour as found with the 70 kDa bands; they were present in all samples 
regardless of the activity of the inhibitors. This trend might relate to a degradation process 
of the above mentioned proteins, but it could also result from non-specific labelling of 
cytoplasmic proteins released by cell lysis, as different strains might possess varied 
sensitivity to induce cell lysis in response to inhibitor treatment.  
Results of activity and labelling indicated comparable inhibition behaviour to that found in 
630. Epoxysuccinyl inhibitors may target multiple proteases, but the protease involved in 
SlpA cleavage might also vary between strains. Similarly to SlpA, these proteases might 
possess high homology among each other, but could possess subtly different active sites 
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appropriate for the corresponding SlpA cleavage locus. Due to the possible high homology 
and similarity of these proteases across all strains, a potent inhibitor could be active in most 
of the strains, and hypothetically a single drug could treat all strains related to CDAD if S-
layer processing were to be selected as a therapeutic target. Fortunately, this ambiguity 
regarding the conservation of the target protease(s) was resolved in the later study 
described in Chapters 6 and 7.  
 
Figure 5. 10: Labelling of targets across different strains, visualised by NeutrAvidin blot. Bacteria were grown 
overnight with given compounds at 100 µM. Whole cell pellet was boiled in loading buffer prior SDS-PAGE 
analysis. 
5.2 Fluorescent ABPs 
5.2.1 Design of fluorescent ABPs 
Although biotinylated ABPs proved to be practical due to their elimination of two-step 
labelling by accessing the target protease directly in the medium, they brought a new 
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problem to the assay. Proteins labelled by biotinylated ABPs can only be visualised by 
Western blot e.g. against biotin antibody, streptavidin, avidin, NeutrAvidin, which could not 
be used for precise or semi-quantitative analysis. In addition to the common limitations of 
typical Western blots discussed in section 2.1.3, NeutrAvidin blot signals appeared to 
saturate at very low inhibitor concentrations and therefore the biotin label may not be 
optimal for exploring any correlation between activity and labelling. For this reason, another 
better visualisation label such as a fluorescent dye (Carboxytetramethylrhodamine called 
TAMRA) was considered to replace biotin. 
 
Figure 5. 11: Anatomy of the fluorescent ABPs. A) Singly labelled ABPs warhead and specificity element were 
separated from the fluorescent tag (TAMRA) by a PEG linker. B) Dually labelled ABPs contain an affinity label 
appended on the side chain of a lysine and a fluorescent label appended via a PEG linker. 
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ABPs are not only useful for monitoring labelling and activity, but also for facilitating the 
enrichment of labelled proteins required for the target identification process. The 
enrichment process usually involves affinity or antibody pull-down [103]. The TAMRA-
antibody used for pull down of TAMRA-appended proteins was found to be less effective 
than the NeutrAvidin-biotin system due to weaker binding which did not survive the 
stringent wash step for removing unspecific labelling [400]. Therefore, it was decided to 
keep the biotin tag for subsequent protein enrichment. Consequently, the new generation 
of ABPs described here possess two labels, a TAMRA group for fluorescent detection and a 
biotin group for affinity pull down.  
Combination of the two different labels compensated for their individual limitations, but 
significantly increased the size of the ABPs over the singly-labelled ABPs. It has been 
reported that bulky reporter tags could have a detrimental effect on enzyme/labelling [37, 
75]. To investigate the potential effect of increasing the size of the ABP, singly labelled 
(fluorescent only) ABPs were also synthesised in the present study.  
 
No. WH AA1 Affinity tag Fluorescent tag Abbr. Name 
TD 61 EtEP Ala - TAMRA EtEP-AG-PEG3-TAMRA 
TD 62 EtEP Arg - TAMRA EtEP-RG-PEG3-TAMRA 
TD 63 EtEP Tyr - TAMRA EtEP-YG-PEG3-TAMRA 
TD 64 EtEP Ala Biotin TAMRA EtEP-AK(Biotin)G-PEG3-TAMRA 
TD 65 EtEP Arg Biotin TAMRA EtEP-RK(Biotin)G-PEG3-TAMRA 
TD 66 EtEP Tyr Biotin TAMRA EtEP-YK(Biotin)G-PEG3-TAMRA 
Table 5. 2: Table of fluorescent ABPs. 
The design of epoxysuccinyl inhibitors/ABPs with respect to activity has been described 
extensively in Chapters 3, 4, and 5.1, therefore only the labelling effect is discussed in this 
section. For this purpose, three representative examples which contain different AA1 amino 
acids were chosen: alanine (representing inactive inhibitors), arginine (representative of one 
of the two alternate substrate/inhibitor tendencies for S2 tolerance and the only inhibitor 
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which caused the double band labelling effect) and tyrosine (representing the remaining 
activity trend and the most potent inhibitor so far). The general structure of these ABPs is 
illustrated in Figure 5. 11 and the newly synthesised ABPs are summarised in Table 5. 2. 
5.2.2 Synthesis of fluorescent ABPs 
Similar to the previous generation of inhibitors/ABPs, the synthesis was performed on solid 
phase, however it was more challenging due to the need to incorporate two different labels 
(biotin and TAMRA) on a single molecule and the instability of the TAMRA group to the 
conditions employed in Fmoc/tBu SPPS [68]. For this reason, an orthogonal protection 
strategy was applied on Universal PEG Novatag resin (9) (Novachem, UK). This resin enables 
peptide chain extension on a secondary Fmoc protected amine under standard conditions 
and the coupling of TAMRA occurs following orthogonal deprotection of the 
monomethoxytrityl (Mmt) protected primary amine [68]. The general synthesis route 
employed for fluorescent ABPs is displayed in Scheme 5. 1. 
The synthesis was performed as follows: the Fmoc protecting group was removed using 20% 
piperidine in DMF. Afterwards, the resin was washed thoroughly before the first amino acid 
was loaded onto the resin. As mentioned previously, the coupling involved is acylation of a 
secondary amine and therefore stronger coupling conditions were needed. Several 
activation strategies for the first amino acid coupling were explored including the utilisation 
of HBTU, HCTU, HATU or HOBt/DIC, but only activation using HOBt/DIC was efficient. 
Furthermore, HOBt/DIC preactivation is a harsh condition and could possibly cause 
racemisation of a coupled chiral amino acid. To prevent this potential problem, glycine was 
chosen as the first amino acid for initial loading on the resin. Glycine is small and achiral, 
and could act as additional spacer extension to the PEG linker; in itself, it should not 
interfere with inhibition/labelling. As glycine was the initial loading for all ABPs, the resin 
was loaded on a large scale and aliquoted subsequently for the next coupling.  
Much effort was put into optimisation of the first loading, because it is very important to 
occupy as much as free amine as possible. Unreacted amines were capped by acetic 
anhydride; without capping, short-peptidic by-products e.g.: EtEP-PEG3-TAMRA, TAMRA-
PEG3-TAMRA, caused dramatic purification problems.  
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Secondly, the desired peptide was extended on the preloaded resin using standard 
conditions with HBTU and DiPEA: alanine/tyrosine/arginine was the second loaded amino 
acid in the case of single label ABPs, whilst in the case of dual label ABPs biotin appended 
lysine was inserted prior in order to introduce the biotin label. Chain extension was 
completed by coupling of the warhead using HCTU and DiPEA, followed by an intensive resin 
wash with DFM and DCM.  
Lastly, the Mmt group, stable during the chain extension under basic conditions but 
unstable in mildly acidic media [401], was removed with 1%TFA in DCM. This deprotection 
procedure was repeated twice and was relatively quick (2 min) to prevent possible cleavage 
of the pre-synthesised peptide still attached on the resin. TAMRA pre-activated with 
HOAt/DIC was coupled to the resin via the PEG linker. It was important to get rid of the 
excess TAMRA by thoroughly washing with DCM-DMF-DCM-MeOH-Et2O. The resin was 
dried and cleaved to obtain the final products. 14 was purified using LC-MS and lyophilised 
to yield the fluorescent inhibitors. It is worth noting that the more by-products the synthesis 
contained, the more challenging the purification of the crude material was. In some cases 
the purification had to be repeated several times with appropriate gradient settings to 
obtain the final pure products. For this reason, the whole synthesis was implemented 
manually by hand with extra care in each step rather than using an automated synthesiser. 
Unfortunately, the yield of each inhibitor was very poor due to substantial losses during the 
purification process, and no attempt was made to calculate the overall yield.  
Similar to other inhibitors/ABPs, stock solutions of 10 mM were prepared in DMSO. The 
stock solution calculation was based on the mass of the freeze-dried product. An attempt to 
minimise the limited accuracy of the stock concentration determination discussed in section 
3.3 was made by normalising the stock solution against a standard solution of TAMRA. It 
should be noted that the standard solution was prepared by the same manner as the 
inhibitors (i.e. by mass), but at greater dimension (ca. 5 mg) to minimise the inaccuracy of 
weighing, followed a dilution to 10 mM. After normalising, the concentration of most 
inhibitors dropped from 10 mM (by mass) to 4 mM or 2 mM, thus it was estimated that the 
true inhibitor concentrations were four or five fold lower. 
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Scheme 5. 1: Synthesis of fluorescent ABPs using Universal PEG Novatag
TM
 resin (I). Reagents and conditions: i) 
Fmoc deprotection with 20% piperidine/DMF, 5 min; 3   coupling of glycine (5 eq) preactivated with DIC, HOBt 
and DiPEA, 30 min, capping the unreacted amine with acetyl anhydride/DiPEA/DMF (2:1:7); ii) Fmoc 
deprotection with 20% piperidine /DMF, 5 min; 2   coupling of either AA1 (5 eq) or K(Biotin) (2.5 eq) then AA1 
(5 eq) preactivated with HBTU and DiPEA, each coupling 30 min; coupling of EtEP-OH (3 eq) preactivated with 
HCTU and DiPEA, 1h, capping the unreacted amine with acetyl anhydride/DiPEA/DMF (2:1:7) after each 
coupling step; iii) Mmt deprotection with DCM/TFA/TIS (94:1:5), 2 min; iv) 2   coupling of TAMRA (2 eq) 
preactivated with DIC, HOAt and DiPEA, 1h; v) cleavage from the resin with TFA/TIS/H2O (95:2.5:2.5), 2h. 
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5.2.3 Activity and labelling effect of fluorescence appended ABPs 
Although the focus of this section is not the potency of inhibitors, newly synthesised 
fluorescent ABPs were tested at 100 µM to ensure that they were still active despite the 
expanded size. As can be seen in Figure 5. 12A, the activity of this new ABP generation 
remained, though at a modified degree: alanine in AA1 position was inactive as previously 
found; tyrosine and arginine at the same position were active, but arginine appeared to be 
significantly more active than tyrosine (in both type of ABPs), which is contradictory to the 
previous findings with other ABPs/inhibitors (sections 4.2). Counting all possible limitations 
in each step, starting from the synthesis to the stock solution determination, in vivo assay 
and western blotting, the observed inverted potency of tyrosine and arginine in AA1 position 
is certainly subject to some uncertainty. This difference could arise from the altered 
structure of TAMRA labelled ABPs vs. previously described ABPs, but on the basis of the 
observations to date this seems unlikely. 
Looking at the in-gel fluorescence (Figure 5. 12B), one single band at approximately 76 kDa 
was found in all samples which is in agreement with the labelling effect of biotinylated ABPs. 
However, the degree of labelling differed significantly among these ABPs. For singly-labelled 
fluorescent ABPs, EtEP-AG-PEG3-TAMRA gave the distinct impression that it labelled the 
protein less strongly than EtEP-RG-PEG3-TAMRA and EtEP-YG-PEG3-TAMRA. The labelling of 
EtEP-RG-PEG3-TAMRA and EtEP-YG-PEG3-TAMRA were equally strong, though any ‘double 
band’ effect of EtEP-RG-PEG3-TAMRA (as previously seen with analogous Arg-containing 
ABPs) was apparently minor, as only a faint band on top of the 76 kDa band was observed.  
In the case of dually labelled fluorescent ABPs, all three ABPs possess similar labelling 
effects, which might arise from the interfering effect of biotinylated lysine adjacent to the 
AA1 amino acid. The ‘double band’ effect of was also missing for EtEP-RG-PEG3-TAMRA.  
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Figure 5. 12: Activity and labelling of fluorescent ABPs, as measured by A) Western blot using anti-LMW SLP 
and B) in-gel fluorescence. C. difficile cultures were treated with compound at 100 µM. 
Given that the size of ‘first’ labelled bands with fluorescent ABPs were similar to the size of 
labelled bands with alkyne-tagged ABPs (both on Bis-Tris gel at ca. 76 kDa) and the tendency 
of all bands being labelled at one size in all three generation of ABPs, it could be supposed 
that these labelled bands were the same protein(s) in each case. Therefore, enrichment and 
proteomics using one type of ABPs may be representative of the other types.  
Combining the changed behaviour of dual label ABPs in activity (inverted potency of EtEP-
RG-PEG3-TAMRA and EtEP-YG-PEG3-TAMRA) and labelling (all ABPs seemed to labelled 
double bands equally), it was supposed that the expansion in size could have an effect on 
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activity and labelling of the ABPs. Therefore, it was decided to apply the previous (single 
label) biotinylated ABPs for initial target identification, rather than the fluorescent ABPs. 
 
Figure 5. 13: Labelling of dual label fluorescent ABPs (S-layer fractions), visualised by in-gel fluorescence. C. 
difficile 630 was grown overnight in the presence of 50 µM ABPs. S-layer fraction was extracted using glycine 
at low pH.  
5.2.4 Strain dependence 
Investigation of strain dependence with biotinylated ABPs provided useful information 
(section 5.1.5), but the results were rather difficult to analyse. The cell contains a certain 
amount of protein that carries biotin, and these are also visualised by streptavidin blotting 
causing a certain level of background signals. These background signals increased where the 
cell lysed and released more cytoplasmic protein. The visualisation method itself also varied 
between blots causing different intensity of bands, and made comparison between 
membranes problematic. Fluorescence detection does not suffer from these problems and 
therefore fluorescent ABPs might provide clearer results.  
Because most of the stocks of dual label fluorescent ABPs were consumed in previous pull 
down experiments only single label ABPs were tested in this case. Bacteria were treated 
with ABP at 100 µM overnight, then were harvested and boiled in loading buffer. Whole cell 
was loaded on the gel for SDS-PAGE analysis and in-gel fluorescence imaging. All ABPs 
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labelled the 76 kDa band very strongly across all strains tested. EtEP-RG-PEG3-TAMRA 
showed clearly the double band effect in all strains. While the 76 kDa bands appeared to 
have the same size and same intensity in all strains, the upper band (of the double band) 
varied in size slightly and in intensity more so. Background labelling remained relatively 
weak and more consistent in all three ABP treatments.  
 
Figure 5. 14: Labelling across different strains visualised by in-gel fluorescence. C. difficile was treated with 
100 µM overnight. Whole cell was boiled in loading buffer and loaded on the gel.  
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5.3 Conclusion 
This chapter has described the development of directly-labelled ABPs that carry either a 
biotin or a fluorescent group (TAMRA), or both. The synthesis of these ABPs was similar to 
the synthesis described in section 3.3 with some important modifications. It was more 
challenging to synthesise fluorescent ABPs than biotinylated ABPs because of the 
application of an orthogonal protection strategy and more challenging purification.  
Efficacy and selectivity of biotinylated ABPs were explored and the result was in line with 
previous observed SAR (section 4.5), while the dual label ABPs showed some variance. 
Labelling of directly-labelled ABPs was clean and specific, as generally only one band was 
labelled in all ABPs, except ABPs bearing an arginine in AA1 position.   
As part of this work, the labelling effect across different strains that possess alternative 
homology at the cleavage locus was also investigated. It showed that the potency varied 
somewhat among strains but that labelling was consistent across all strains. These results 
suggest that the target enzyme(s) in different strains have both a similar mode of action 
(mechanism) and similar size.  
The clean and mostly specific labelling given by biotinylated ABPs, coupled with ease of 
synthesis, resulted in their selection for testing in the enrichment and target identification 
experiments described in the next chapter.  
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Chapter 6 Target enrichment, identification and proteomic study 
 
Whilst previous chapters described in detail the synthesis of chemical probes and their 
biological effects on C. difficile, this chapter focuses on the methods to identify the 
target proteases labelled by the developed probes, starting with affinity enrichment 
and moving on to different mass spectrometric methods. In the first reported 
application of ABPP to Clostridia, two putative cysteine proteases were identified in the 
S-layer of C. difficile, Cwp84 and Cwp13; further study was then performed on the 
potential functions of these proteases, seeking the candidate responsible for internal 
cleavage of SlpA to mature the two surface layer proteins (HMW- and LMW-SLPs). 
Furthermore, the effect on other cell wall protein members was investigated to 
increase our understanding of the role of SlpA proteolysis in S-layer integrity.  
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6.1 Enrichment of labelled proteins in C. difficile 
Having established that the target proteases were located in the S-layer and were readily 
accessible for direct labelled ABPs, the labelling experiment was scaled-up to provide 
sufficient protein for subsequent mass spectrometry analysis. The probes used in this 
experiment contained a biotin label allowing for the affinity purification, in which the highly 
specific interaction of biotin with avidin and its modified forms (NeutrAvidin and 
streptavidin) was exploited.  
6.1.1 Pull down of labelled proteins with NeutrAvidin agarose resin 
Aiming for a sufficient protein amount for mass spectrometry analysis, a 5 ml C. difficile 
culture was grown overnight in the present of EP-LR-PEG3-Biotin or EP-A-PEG3-Biotin at 
100 µM. After treatment of the bacterial cell pellet and dividing in three fractions (S-layer, 
soluble and insoluble) as described in section 3.5, NeutrAvidin agarose suspension was 
added to each fraction and the mixtures agitated gently at 4 °C for 1 hour to allow 
immobilisation of biotin-labelled protein onto the beads. Afterwards, the mixture was 
centrifuged and the supernatant removed. The beads were washed three times with PBS-T 
buffer to aid in removing potential non-specifically bound proteins and then boiled in the 
loading buffer at 100 °C. At these conditions (0.7% of SDS in loading buffer and high 
temperature) NeutrAvidin is denatured, thereby breaking the interaction with biotin, eluting 
the labelled proteins in the loading buffer readily for SDS-PAGE analysis.  
The result of this experiment is shown in Figure 6. 1. Coomassie stained gels and 
NeutrAvidin-HRP blotting of all three fractions are shown to demonstrate the correlation of 
the pull down bands and the labelling effects. The Coomassie stained gel of the supernatant 
fraction after S-layer pull-down also confirmed the activity of the ABPs through the presence 
of the SlpA band (band 1 in S-layer fraction).  
In the S-layer fraction, several bands were observed on the Coomassie stained gels in the 
pull down samples. These bands were enriched, since they were not readily detectable 
before (cf. the supernatant gels). Comparing bands from samples treated with active and 
inactive probe (EP-LR-PEG-Biotin and EP-A-PEG-Biotin respectively), it can be seen that the 
pattern of the pulled down proteins in both cases was similar. However, the intensity of the 
active sample was far greater than the inactive one. The same effect was observed in the 
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NeutrAvidin-HRP blot. There were about 6-7 bands enriched at different levels, but only the 
band at approximately 70 kDa was detected in the NeutrAvidin-HRP blot of both samples. 
Two further bands similar in size were observed in the EP-LR-PEG3-Biotin sample, but with a 
much lower intensity.  
 
Figure 6. 1: Pull down experiment with biotinylated ABPs using NeutrAvidin agarose resin. C. difficile was 
treated with 100 µM indicated ABP overnight, and then divided in subcellular fractions. Coomassie stained gels 
(CO) and NeutrAvidin-HRP blotting (NB) are shown for each fraction. The supernatant of the pull down of the 
S-layer fraction is shown to demonstrate the activity through the present of SlpA band. The lanes are: 1= SlpA; 
2= Slp2; 3= HMW-SLP; 4= LMW-SLP.  
Examination of the soluble fraction shows that no real enrichment occurred; bands were 
very faint and hardly detectable. The same tendency was found on the NeutrAvidin-HRP 
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blot. In contrast, many more bands were observed in the sample deriving from the insoluble 
fraction. However, in terms of the bands detected, the two samples were barely 
distinguishable. Furthermore, no bands on the Coomassie stained gel were found to 
correspond to those on the NeutrAvidin-HRP blot, suggesting that these bands might 
represent proteins ‘sticking’ on the beads non-specifically and therefore not related to the 
labelling.  
Combining all the observations discussed above, the labelling only occurred in the S-layer, 
which is in agreement with previous observations (Chapters 4 and 5). Only a few enriched 
bands were correlated with the labelling, suggesting that co-precipitation occurred. These 
bands could be bound either to the beads or to the labelled proteins. Because no real 
correlation between enriched proteins and labelling was found in the soluble and insoluble 
fractions, only bands from the S-layer fraction were excised and prepared for mass 
spectrometry analysis. As a result, only the S-layer fraction was considered in the 
subsequent experiments.    
 
Figure 6. 2: Pull down experiment of S-layer fractions with biotinylated ABPs using NeutrAvidin agarose resin. 
C. difficile was treated with 100 µM of indicated ABPs overnight. A) Western blot against LMW-SLP. B) 
Coomassie stained gels (CO) and NeutrAvidin-HRP blotting (NB) are shown. Supernatant of the pull down of 
the S-layer fraction was added to demonstrate the activity through the presence of the SlpA band. The lanes 
are: 1= SlpA; 2= Slp2; 3= HMW-SLP; 4= LMW-SLP. 
Revisiting the labelling results described in Chapters 4 and 5, it was noted that the labelling 
effects of epoxysuccinyl ABPs was very specific. In most cases, a strongly labelled band at 
approximately 70 kDa was observed with both active and inactive ABPs. However, in some 
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cases a further labelled band above this 70 kDa band was found. The intensity of this band 
varied between samples, but it appeared significantly stronger when AA1 was an arginine 
residue. In particular, in the case of biotinylated ABPs, only EP-R-PEG3-Biotin gave rise to this 
‘double labelled band’ effect, while all other ABPs labelled (mainly) one single band.  n this 
experiment, the focus shifted to identifying this second band. Therefore, the pull down 
experiment with the S-fraction described above was repeated with EP-R-PEG3-Biotin, and 
including EP-LR-PEG3-Biotin as a positive control. As can be seen in Figure 6. 2, the double 
labelled band characteristic of EP-R-PEG3-Biotin was observed in line with previous results. 
The upper band was less intense, but easily distinguishable compared with EP-LR-PEG3-
Biotin. A similar pattern of nonspecific co-purification was also observed, as in Figure 6. 1. 
6.1.2 Pull down of labelled proteins with Streptavidin Dynabeads 
It was noticed during implementation of the pull down experiment that it was practically 
difficult to remove all the supernatant from the NeutrAvidin agarose resin without 
accidentally withdrawing some resin. If a small volume of supernatant was left to ensure 
that the resin was not touched, then the final volume of the samples after adding loading 
buffer varied slightly. Consequently, there was a degree of inconsistency among the 
prepared samples, which might affect any quantitative analysis. To avert this potential 
problem, NeutrAvidin was replaced by streptavidin Dynabeads, which provide several 
advantages over the agarose resin, such as:  
 Easy separation of the protein-bead complex from the supernatant with a Dyna 
magnet by collecting the beads on the tube wall; this provides a quick and gentle 
method, as centrifugation was avoided. 
 According to the supplier’s product data [402], batch consistency and reproducibility 
of results were aided by the presence of a streptavidin monolayer (covalently 
coupled on the hydrophobic bead surface) whose leakage was negligible and which 
contained no excess adsorbed streptavidin 
The beads were first trialled with EP-R-PEG3-Biotin labelled sample. Compared with the 
previous method of using NeutrAvidin agarose resin, the level of background pull down was 
very high, which indicated a higher level of non-specific binding to the streptavidin beads 
(Figure 6. 3A). Matching up bands in the not treated sample with those in the treated 
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sample, only a few additional bands at high molecular weight were observed in the treated 
sample. The experiment was repeated with EP-X-PEG3-Biotin (X=A, Y or R), and more 
stringent wash conditions (1% SDS in PBS) were used to successfully remove some of the 
non-specifically binding proteins (Figure 6. 3B).  
 
Figure 6. 3: Pull down experiment of S-layer fractions using super-paramagnetic Streptavidin Dynabeads, 
visualised by Coomassie staining. C. difficile was treated with 100 µM ABP overnight. Prepared S-layer fractions 
were pulled down with 30 µL of beads. A) The bands in the supernatant are: 1= SlpA; 2= Slp2; 3= HMW-SLP; 4= 
LMW-SLP. Beads were washed three times with PBS-T. B) Only the pull down samples are shown. Beads were 
washed three times with PBS containing 1% SDS. 
6.2 Identification of protease(s) by MALDI-TOF-MS and PMF 
Having successfully enriched the labelled protein(s) from C. difficile, a MS-based proteomic 
analysis was carried out using a bottom-up, sort-then-break approach to identify these 
enriched protein(s) (see section 1.5.3.2). As this study was focussed on the identification of 
the labelled proteins in a relatively less complex peptide mixture (only one band per 
sample), MALDI-TOF-MS with subsequent PMF analysis was chosen as the least complex and 
most matured proteomic approach, simplifying the data analysis and saving time and cost.  
The enriched bands visualised by Coomassie staining prepared in section 6.1.1 were excised 
from the 1D-gel and digested with trypsin. The tryptic digest was then spotted on the 
MALDI-plate readily for MS analysis. This experiment was first implemented by Dr. Len 
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Packman (Protein & Nucleic Acid Chemistry Facility of Biochemistry department (PNAC), 
Cambridge, UK) as an external service (Figure 6. 4A) and then repeated by the author using 
facilities at Imperial College London (Division of Molecular Biosciences) (Figure 6. 4B). 
Because the experiments were practiced using different facilities (although the same type of 
instrument and approach was used in both cases) by different analysers, besides the 
biological variation of samples discrepancies in performance might be expected. The 
resulted peptide masses were processed with the online database search engine MASCOT 
[403] with bacteria (Eubacteria) as selected Taxonomy and the NCBI non-redundant 
database selected for the search. Protein identification was validated when the MOWSE 
score was significant (p<0.05) according to MASCOT [403].  
 
Figure 6. 4: Identified bands on Coomassie stained gels. Samples were prepared and enriched as described in 
section 2.1.1. In-gel digestion with trypsin and subsequently MALDI-TOF-MS and PMF were implemented by A) 
Dr. Len Packman, PNAC Cambridge, UK, B) the author, Imperial College London, UK. Indentified bands are: 1, 5, 
7, 8 and 10) Cwp84; 2 and 11) Cwp19 and Cwp66; 3) Cwp6; 4) LMW-SLP; 6) SlpA; 9) CD2797.  
The PMF of labelled bands successfully obtained and their MASCOT analysis results are 
listed in Table 6. 1. The protein scores (probability scores in Mascot program) were 
relatively high (above 110), except the score for Cwp66 and CD2767 (around 60-70). Higher 
scores indicate more confidence in correct protein identification. Generally, all enriched 
proteins were identified as members of the cell wall protein family. Intriguingly, all the 
bands corresponding to labelling (bands 1,5,7, 8 and 10 in Figure 6. 4) were revealed to be 
the putative cysteine protease Cwp84, regardless of whether the probe was active (EP-LR-
PEG3-Biotin, EP-R-PEG3-Biotin) or inactive (EP-A-PEG3-Biotin). Figure 6. 5 shows an example 
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of the final full spectra and the sequence coverage of the matched protein identified by 
peptide mass fingerprinting (PMF), while raw data can be found in the appendix. That this 
protein gave the highest score in all PMF analyses suggests very strongly that the identity of 
this protein is correct, especially given the relatively high sequence coverage. Variation in 
scores and sequence coverage of Cwp84 reflected possible discrepancies in the biological 
and technical reproducibility; nevertheless, this variation seemed to be minor and in all 
cases the protein identification was high confidence.  
Assuming that biological and technical variation can be neglected by virtue of the near-
identical sample treatment (starting from the same culture, same growth time, running on 
the same gel, identical chemical treatment, practising by the same analyst, processing with 
the same instruments), certain aspects of the results from treatment with active EP-LR-
PEG3-Biotin (band 1 in Figure 6. 4) can be compared directly with the results from treatment 
with inactive EP-A-PEG3-Biotin (band 5 in Figure 6. 4). According to this, although both 
probes labelled Cwp84, the active probe seemed to label Cwp84 in a much more effective 
manner than the inactive probe, reflected in the significantly stronger band on NeurAvidin-
HRP blot and Coomassie stained gel, associated with a larger amount of enriched protein. 
However, no quantitative comparison using MALDI-TOF-MS acquired data could be 
performed, and this will be discussed in detail in section 6.8. 
More interestingly, both labelled bands of EP-R-PEG3-Biotin treated samples (bands 7 and 8 
in Figure 6. 4) were identified as Cwp84, suggesting a specific structure-dependent activity 
of this probe. Comparing the biological replicates with EP-LR-PEG3-Biotin, the identified 
bands were identical, despite the variation in score and sequence coverage which maybe 
the result of technical variation. Bands 1 and 10 were revealed as Cwp84, whereas bands 2 
and 11 were Cwp19 and Cwp66, further increasing confidence in the identification results.  
Co-purified bands that did not correspond to the labelling were identified as Cwp19, Cwp66, 
Cwp6, LMW-SlpA, SlpA and CD2797. LMW-SlpA and SlpA were probably co-purified due to 
their high abundance in the sample. Cwp19, Cwp66, Cwp6 and CD2797 are part of the same 
gene cluster as slpA. However, only Cwp66 has been functionally annotated, as a 
temperature-dependent adhesion protein [256], whilst the other proteins have no known 
function.  
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Band 
No. 
Accession No. Protein Name  Protein 
score 
Calc. 
Protein 
MW 
Sequence 
coverage  
1 gi|145953268 Cwp84 297 87456 45(%) 
2 gi|126700383 
gi|11066029 
Cwp19 (also known as CD2767) 
Cwp66 
263  30(%) 
19(%) 
3 gi|168708027 Cwp6 (also known as CD2784) 206 72964 35(%) 
4 gi|94966244 LMW-SlpA 192 36607 53(%) 
5 gi|145953268 Cwp84 246 87456 38(%) 
6 gi|126700409 SlpA 205  29(%) 
7 gi|126700403 Cwp84 215 87455 35(%) 
8 gi|126700403 Cwp84 314 87455 41(%) 
9* gi|126700413 CD2797 70 221748 9(%) 
10* gi|126700403 Cwp84 657 87227 45(%) 
11* gi|126700383 
gi|11066029 
Cwp19 (also known as CD2767) 
Cwp66 
110 
60 
77782 
66724 
26(%) 
21(%) 
Table 6. 1: Identified proteins using MALDI-TOF-MS and PMF with band number as shown in Figure 6. 4. 
Protein name and accession number (AC) are reported according to the NCBI data base, percentage of 
sequence coverage is generated from experimental PMF; protein score is probability score in Mascot program. 
Proteins in bands 1 to 8 were identified by Dr. Len Packman (PNAC Cambridge, UK), while proteins in bands 9 
to 11 (indicated with a *) were identified by the author using facilities of Imperial College London (Division of 
Molecular Biosciences).  
The activity and labelling data (from the previous chapters 3, 4 and 5) as well as the 
identification data for the labelled bands combine to provide convincing evidence that 
Cwp84 is a key target of this type of inhibitor and the ABPs described in this study. However, 
attempts to identify the tryptic peptide bearing the probe (covalently bound to the cysteine 
of the active side) failed in all samples. It is possible that either this modified peptide did not 
ionise well and therefore could not be detected, or the bond between the probe and the 
peptide was broken by the impact of the high ionisation energy, or during the sample 
preparation process. 
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Figure 6. 5: MALDI-TOF-MS analysis of band 1 in Figure 6. 4, identified as Cwp84. The MALDI-TOF mass 
spectrum is shown on top and the Cwp84 sequence is shown at the bottom. Matched peptides are indicated in 
red.  
6.3 Identification of proteases by LC-MS/MS 
Although MALDI-TOF-MS is the most cost-efficient approach in proteomics today [175, 404] 
it suffers from some fundamental and practical limitations. The identification of a mixture of 
two proteins (Cwp66 and Cwp19 in bands 2 and 11) observed in the work described in the 
previous section may be due to a very distinct protein sequence, however, in general a 
MALDI-TOF-MS based method cannot identify multiple components in a mixture, especially 
if these components are highly homologous or low abundance [216]. This results from lower 
search scoring, which occurs when experimentally derived peptide masses for a given mass 
accuracy tolerance match to more than one protein, especially when these masses are small 
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and the peptide signal intensity is weak [216]. Furthermore, if proteins in the mixture are 
highly homologous, their derived peptide masses are very similar and so the software 
cannot differentiate the identification hits. This limitation may affect the results of this 
study, since in 1D gels a band often contains more than one protein [405]. This missed 
information could be decisive in understanding the similar labelling by active and inactive 
probes. However, this information can be obtained by applying tandem-MS, because during 
MS/MS a peptide can be trapped and sequenced giving unique information about its 
identity.  
Another drawback of MALDI-TOF-MS is encountered when any degree of quantitative 
analysis is required [216, 404, 406-407]. This restriction is the result of multiple contributing 
factors, including variation in the ionisation efficiency due to non-homogeneous application 
of the peptide sample to the MALDI plate by spotting, the quality of the sample crystal, 
initially crystal form of samples and therefore only a diluted amount was ionised, ion 
suppression effects due to the presence of residual surfactant and salts, resulting in 
selective ionisation of certain peptide species over others depending on their amino acid 
sequence. These peptide species exhibit typically poor ionisation potential and small 
peptide masses are beyond the optimum mass range of the MALDI-TOF instrument due to 
interference from matrix. Unfortunately, the limitations discussed above restrict not only 
the quantitative analysis but also the ability to trace PTM modification, which is required for 
detection the probe-modified peptide fragment.  
To circumvent these limitations and aim for a more sensitive method, identification of 
labelled bands with different probes was reproduced using the most recently developed 
technology, LC-ESI-MS/MS with an LTQ-Orbitrap-Velos as mass analyser and with ETD as the 
fragmentation method. The enriched bands visualised by Coomassie staining prepared in 
section 6.1.2 were excised from the 1D-gel, covered with 50 mM ammonium bicarbonate 
solution and frozen on dry ice by the author before sending to the University of Leicester 
Proteomics Facility, UK. There, these gels pieces were digested with trypsin and prepared 
for MS/MS analysis by Dr. Andrew Bottrill, a senior experimental officer at the University of 
Leicester, UK.  
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The resulting tandem mass spectra were analysed using Mascot (Matrix Science, London, 
UK) with Clostridium difficile as selected Taxonomy and the Trembl_39.6 database selected 
for the search. Furthermore, modification of cysteine by the probes was specified in Mascot 
as variable modifications. Scaffold (version Scaffold_3_00_03, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater than 95,0% 
probability as specified by the Peptide Prophet algorithm [408] and contained at least 2 
identified peptides.  
Figure 6. 6: Identified bands on Coomassie stained gels. 
Samples were prepared and enriched as described in 
section 6.1.2. Bands 1 and 2 indicated as red boxes were 
excised. In-gel digestion with trypsin and subsequent LC-
MS/MS analysis were carried out by Dr. Andrew Bottrill, 
University of Leicester, UK.  
The first attempt re-explored the labelled bands 
of EP-R-PEG3-Biotin, therefore two bands 
(indicated in red box, in Figure 6. 6) were excised 
based on the knowledge about the labelling of 
this ABP acquired in various stages of this study. 
There were 13 proteins identified for band 1 
(Figure 6. 6) and 15 proteins for band 2; however, by spectral count only one or two proteins 
were major species, while other proteins were more likely trace species that may co-migrate 
in the gel with the prominent proteins. A summary of the spectral counts of both bands can 
be found in Table 6. 2.  
Intriguingly, in the first band two major proteins were found: Cwp84 and Cwp13 (also 
known as CD1751), both of which are putative cysteine proteases. A few examples of the 
proteolytic activity of Cwp84 had been previously reported in the literature and the function 
of both Cwp84 and Cwp13 were unknown at the time this work was performed. According 
to the spectral count Cwp13 seemed less abundant than Cwp84 in band 1, while in band 2 
Cwp84 was the only prominent species and other proteins including Cwp13 were 
insignificant. Comparing this result with the previous results generated by Dr. Packman 
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using MALDI-TOF-MS, it was clear that Cwp84 is present in both bands, indicating the 
consistency of results regardless of the approach used. However, a few important 
differences were found. Besides the increased amount of Cwp13 in the first band, the 
sequence coverage of the proteins identified using LC-MS/MS – LTQ-Orbitrap was greater 
(almost double) compared with MALDI-TOF-MS; sequence coverage increased from 35% to 
64% for the top band and from 41% to 77% for the bottom band in the case of Cwp84. This 
improvement was expected, since LC-MS/MS by LTQ-Orbitrap is more sensitive and has 
better dynamic range for data acquisition than MALDI-TOF-MS (see section 1.5.1). 
Unfortunately, this improvement was not enough to detect the peptide modified with the 
probe. Generally, at least 80% sequence coverage is desirable for a good chance of 
identifying modified sites [409], if the location of the modification is not known. In our case, 
the location of the probe modification is known (peptide containing the active cysteine 
residue C116), but this peptide was not found in the identified sequences, which might be 
due to less well ionisation property and consequently this peptide is not detectable in MS. 
Identified 
proteins 
Sequence 
coverage (%) 
Quantitative 
Value 
Unique 
peptides 
Unique 
spectra 
Assigned 
spectra 
B 1 B 2 B 1 B 2 B 1 B 2 B 1 B 2 B 1 B 2 
Cwp84 64 77 83 134 36 49 43 59 65 164 
Cwp13 37 13 40 7 23 6 24 6 30 6 
SlpA 30 18 17 7 13 8 13 9 13 9 
Cpw66 15 27 8 7 6 9 6 9 6 9 
CD2767 27 24 14 9 11 11 11 11 11 11 
CD2784 7 19 5 7 4 9 4 9 4 9 
Table 6. 2: Spectral counts of identified proteins of bands in Coomassie stain gel Figure 6. 6A. B 1= band 1, B2 = 
band 2. 
6.4 In-depth proteomic study using LC-MS/MS with the wild type 630 
The appearance of Cwp84 in the top band and the presence of Cwp13 raised further 
questions. Did epoxysuccinyl ABPs intercept these putative cysteine proteases at multiple 
stages of their self-processing, assuming that they undergo a self-processing like that of 
recombinant Cwp84 [410], and therefore label different sizes of Cwp84 (and maybe Cwp13 
as well)? If so, does inactivation occur in an ABP structure-dependent fashion, as only ABPs 
with arginine at the AA1 position seemed to grant the strong double-labelled band effect? 
Furthermore, why do inactive ABPs also label proteins in the lower band?  
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Figure 6. 7: Identified bands on Coomassie stained gels. Samples were prepared and enriched as described in 
section 6.1.2. Bands 1 and 2 indicated as red boxes were excised. In-gel digestion with trypsin and subsequent 
LC-MS/MS analysis were carried out by Dr. Andrew Bottrill, University of Leicester, UK 
Seeking an answer to those questions, the proteomic experiment was re-run with a panel of 
ABPs. EP-R-PEG3-Biotin was chosen as an interesting candidate due to its ability to generate 
two strongly labelled bands, whilst EP-Y-PEG3-Biotin was selected as the most potent ABP 
and EP-A-PEG3-Biotin as an inactive ABP. EP-LR-PEG3-Biotin was added to compare the 
labelling between moderately active and potent ABPs. E-64 treated samples served as 
controls. The experiment was implemented as described above with one additional step: 
before loading onto the MS instrument, the tryptic digested samples were mixed with a 
standard peptide digest (ADH- alcohol dehydrogenase from yeast – with Uniprot accession 
P00330) as an internal standard to aid with quantitative analysis, and to correct for run-to-
run variations in the instrumentation. Two bands at the same gel location (labelled as 1 and 
2 and corresponding to the two labelled bands in samples treated with EP-R-PEG3-Biotin) 
were excised for each sample. Unfortunately, protein amount loaded on the Coomassie 
stained gel was not equal between samples (Figure 6. 7). Judging by the stained protein 
bands, one could speculate that sample X=Y and LR had significantly more total protein than 
other samples. This phenomenon could be a result of variability in enrichment ability of 
each ABP or cell lysis susceptibility, and non-specific co-pull down could increase in the case 
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of X=Y and LR. To prevent this problem, more stringent wash and loading normalisation 
prior SDS-PAGE could be applied in future experiments. Because of the unequal loading, 
quantitative evaluation of the identified proteins could not follow. Importantly, the 
quantitative aspects of the data illustrated below are only indicative, and require future 
repetition and refinement. However, identification of proteins appears secure.  
The quantitative values generated by Scaffold are given in Table 6. 3. The relatively similar 
quantitative value of ADH in most samples (excepting the E-64 treated sample) 
demonstrated the effective injection of an equal amount of sample by the auto sampler in 
each run, variation was likely related with the unequal amount of protein in each lane. 
Assuming that this variation is small and negligible , in general Cwp84 seemed to be 
enriched in all samples treated with ABPs.   
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band 1 band 2 band 1 band 2 band 1 band 2 band 1 band 2 band 1 band 2
Cwp84 87 kDa 13 50 64 159 74 241 65 130 87 222
Cwp13 87 kDa 4 8 46 1 40 48 57 80 41 37
SlpA 76 kDa 26 32 46 36 75 35 26 17 41 25
Slp2 66 kDa 11 40 11 19 22 19 17 14 16 20
Cwp66 67 kDa 1 40 1 14 19 27 15 30 14 28
CD2784 73 kDa 1 1 1 8 6 3 4 1 3 1
ADH 37 kDa 34 51 32 24 27 24 33 24 27 39
Trypsin 24 kDa 66 100 50 67 75 65 70 59 64 63
EP-A-PEG3-Biotin EP-LR-PEG3-BiotinIdentified 
Proteins 
Molecular 
Weight
E-64 EP-R-PEG3-Biotin EP-Y-PEG3-Biotin
 
Table 6. 3: Quantitative value of identified proteins. ADH = yeast alcohol dehydrogenase standard. 
band 1 band 2 band 1 band 2 band 1 band 2 band 1 band 2 band 1 band 2
Cwp84 0.38 0.98 2.00 6.63 2.74 10.04 1.97 5.42 3.22 5.69
Cwp13 0.12 0.16 1.44 0.04 1.48 2.00 1.73 3.33 1.52 0.95
SlpA 0.76 0.63 1.44 1.50 2.78 1.46 0.79 0.71 1.52 0.64
Slp2 0.32 0.78 0.34 0.79 0.81 0.79 0.52 0.58 0.59 0.51
Cwp66 0.03 0.78 0.03 0.58 0.70 1.13 0.45 1.25 0.52 0.72
CD2784 0.03 0.02 0.03 0.33 0.22 0.13 0.12 0.04 0.11 0.03
ADH 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Trypsin 1.94 1.96 1.56 2.79 2.78 2.71 2.12 2.46 2.37 1.62
Identified 
Proteins 
E-64 EP-R-PEG3-Biotin EP-Y-PEG3-Biotin EP-A-PEG3-Biotin EP-LR-PEG3-Biotin
 
Table 6. 4: Relative abundance of identified proteins to the ADH control. ADH = yeast alcohol dehydrogenase standard. 
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6.5 Cwp13 may be an off-target of epoxysuccinyl ABPs 
Given that Cwp84 is the target protease mediating SlpA cleavage, it is clear why active ABPs 
possess a corresponding strong labelled band at apparently 76 kDa on the Bis-Tris gel. 
However, it was unclear why inactive ABPs seemed to label the same band even though 
they did not functionally inhibit Cwp84 (see labelling effect in Chapter 5). Proteomic analysis 
described in section 6.3 also revealed the presence of Cwp13 in the identification after 
enrichment, leading to the hypothesis that the cysteine protease Cwp13 could be an off-
target of epoxysuccinyl inhibitors/ABPs targeted by both inactive and active ABPs; because 
both proteases are very similar in size they appear at the same position on the gel.  
To verify this hypothesis, we employed antibody against recombinant Cwp84 which was 
raised in mice. Recombinant Cwp84 was obtained by transforming plasmid pET-28a orf 4H-
1, containing the cysteine protease domain of Cwp84, which was kindly donated by the 
Fairweather’s laboratory, into E. coli Rosetta cells. These cells were grown and induced for 
protein expression using a pre-optimised protocol. After purification using nickel affinity 
chromatography, the concentrated recombinant Cwp84 was sent to School of Biological 
Sciences (Royal Holloway University of London, Surrey, UK) for raising of  antibodies in mice.  
C. difficile was treated with dual fluorescent ABPs overnight, and a glycine extraction 
performed as previously described to obtain S-layer fractions. The labelled proteins were 
enriched via pull-down on streptavidin Dynabeads and labelling was demonstrated using in-
gel fluorescence, while the presence of Cwp84 was revealed using Western blot. As seen in 
Figure 6. 8, strong labelling was observed in all ABPs before and after enrichment. However, 
Cwp84 was only significantly enriched by the active ABPs and not by the inactive probes. 
Furthermore, multiple bands of Cwp84 observed in the enrichment suggested the 
intercepting of self-processing intermediates of this protease. Interestingly, the apparent 
labelled Cwp84 band by the EtEP-RK(Biotin)G-PEG3-TAMRA, is slightly shifted in higher 
molecular weight compared to other bands. This observation will be discussed in a later 
session of this chapter.  
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Figure 6. 8: Labelling effect and identification of Cwp84 from epoxysuccinyl ABPs. C. difficile 630 was treated 
with 50 µM of ABPs overnight, followed by isolation of the S-layer fraction as described in section 3.5. A pull-
down step was added to enrich the labelled proteins prior SDS-PAGE analysis. Visualisation was performed 
using in-gel fluorescence and Western blot against Cwp84. 
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6.6 Effect of Cwp84 on other cell wall proteins 
At the time this work was performed, Kirby et al. [411] had reported the genetic knock-out 
of cwp84 in C. difficile using the Clostron system. This work was repeated and further 
developed by Dr. de la Riva Perez, a postdoctoral researcher in Neil Fairweather’s 
laboratory, Imperial College London, UK, providing access to several mutants using in the 
work of this session. Colony morphology changes and effect in cell integrity in the 
630Δcwp84 mutant [411] indicated a significant change in the S-layer and cell wall 
composition. Aside from the major effect on SlpA, there are other cell wall proteins present 
as minor components in the S-layer which could be also affected. Building on the initial work 
of Dr. de la Riva Perez investigating the 630Δcwp84 strain, the effect of inhibitor on other 
cell wall proteins was investigated. Interestingly, treatment of wild type strain 630 with 
inhibitors possessing different levels of potency also resulted in shedding of Cwp66 and 
Cwp2 in the culture supernatant. Furthermore, shedding behaviour seemed to depend on 
the potency of the inhibitors (Figure 6. 9).  
 
Figure 6. 9: Effect of Cwp84 on Cwp66 and Cwp2. C. difficile 630 were treated with compound at 100 µM 
overnight, followed by isolation of the S-layer fraction as described in section 3.5 and culture supernatant 
concentration. Visualisation was using Western blot against Cwp66 and Cwp2 as indicated. Note: Black spot on 
Western blot against Cwp66 is a random signal. 
6.7 Proteomic studies with a C. difficile 630Δcwp84 mutant 
Revisiting the labelling effect of epoxysuccinyl ABPs in wild type 630, it was noticed that the 
labelled Cwp84 signal was very strong. Consequently, this signal might prevent the 
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detection of possible other less strongly labelled targets. In this section, a hunt for those 
potential hiding targets was attempted by treatment of 630Δcwp84 with a series of 
biotinylated ABPs. However, the NeutrAvidin-HRP blot of the overnight treated samples 
revealed no further labelling, except the strong bands of the positive control treated with 
the wild type 630.  
 
Figure 6. 10: Labelling of fluorescent ABPs in C. difficile 630 and 630Δcwp84 mutant visualised by in-gel 
fluorescence. 630 was treated with 50 µM ABPs overnight, while 630Δcwp84 mutant was treated with 25 µM 
ABPs. Whole cell bacteria were boiled in loading buffer for SDS-PAGE analysis. Single-label ABPs EtEP-X-PEG3-
TAMRA were shown in pink and dual-label ABPs EtEP-XK(Biotin)G-PEG3-TAMRA were shown in blue. 
It was difficult to locate the exact position of the labelled bands on the Coomassie stained 
gel, so gel slices were cut to include all proteins between the bands for SlpA and Cwp2, as 
shown in Figure 6. 12A. Each gel slice was divided into three further smaller bands and 
treated separately as independent samples to enhance coverage [412]. LC-MS/MS services 
were provided by Dr Andrew Bottrill as described in the previous section. A pre-digested 
standard, alcohol dehydrogenase from yeast ADH, was added post-digest to allow later 
quantitative evaluation. Each sample had three technical replicates and the spectral counts 
of each run were added together to give a final value minimising the impact of run-to-run 
variation on subsequent quantification. 
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Figure 6. 11: Enrichment of proteins labelled by biotinylated and fluorescent ABPs in 630Δcwp84 mutant, 
visualised by in-gel fluorescence and NeutrAvidin blot as indicated. Knock-out mutant was treated with ABP at 
25 µM overnight, followed S-layer fraction isolation and cell fraction preparation as described in section 3.5. 
Labelling is shown before and after the enrichment.  
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Identification of peptides against the database revealed the presence of SlpA, Cwp2, Cwp66, 
Cwp6 and Cwp13 as the most abundant cell wall proteins across the excised gel slices. 
Relative abundance of the identified cell wall proteins was calculated in correlation first to 
the control ADH, and then to the uninhibited control sample, as summarised in Figure 6. 
12B.  
As expected, SlpA and Cwp2 were by some margin the most abundant proteins identified, 
although there is some variation between runs. Cwp13 was enriched significantly (ca. 3-fold) 
more than other proteins in EtEP-AK(Biotin)G-PEG3-TAMRA and EtEP-RK(Biotin)G-PEG3-
TAMRA relative to control. Furthermore, other cell wall proteins were found to co-purified 
as well including Cwp6 and Cwp66, which tend to be significantly enriched by EtEP-R-
K(Biotin)G-PEG3-TAMRA compared to EtEP-AK(Biotin)G-PEG3-TAMRA.  
Because the NeutrAvidin-HRP blot might not be sufficiently sensitive due to the practical 
issues discussed in section 5.1.2, fluorescent ABPs were tested again in both wild type 630 
and 630Δcwp84, and run side by side for comparison. A relatively weakly labelled band was 
found in all 630Δcwp84 samples at the same position as Cwp84 in wild type 630. 
Furthermore, a small shift of this band to higher apparent molecular weight was observed 
when 630Δcwp84 treated with EtEP-RK(Biotin)G-PEG3-TAMRA in agreement with all 
labelling observations with ABPs bearing arginine at the AA1 position. It should be noted 
that the loading on the gel was not normalised between wild type and mutant samples, and 
therefore samples with wild type 630 contained more protein due to better growth. The 
effect of non-normalised loading is reflected in the different intensities of labelled bands in 
both strains. However, the presence of the labelled bands in 630Δcwp84 was confirmed in a 
pull down experiment repeat. The same phenomenon was seen with biotinylated ABPs 
suggesting that separating the cell in fractions resolved the practical problem mentioned at 
the beginning of this section.  
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Figure 6. 12: A) Coomassie stained gel and in-gel fluorescent of glycine extracts labelled by dual fluorescent 
ABPs. 630Δcwp84 mutant was treated with ABPs at 25 µM overnight, followed by glycine extraction as 
described in section 2.1.1. Red box indicated the part of the gel lane excised for proteomic analysis and 
labelled bands are: 1) SlpA, 2) Cwp2. B) Table of proteomic analysis results. Relative abundances were 
calculated based on the total spectra counts of each proteins. 
6.8 Conclusion 
This chapter has described the MS-based proteomics of labelled proteins by epoxysuccinyl 
ABPs. Starting from in vitro enrichment of labelled proteins after in vivo labelling, the pull 
down protocol was improved by replacing NeutrAvidin agarose resin with Streptavidin 
A) 
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inhibitor control  
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EtEP-XK(Biotin)G-PEG3-TAMRA  
 X = R X = A  X = R X = A 
SlpA  7,80 11,29 14,20 0,55 0,79 
Cwp2 (CD2791) 5,05 3,96 6,67 0,76 0,59 
Cwp6 (CD2784)  1,76 0,74 1,08 1,63 0,68 
Cwp13 0,87 0,96 0,29 3,01 3,33 
Cwp66  0,32 0,17 0,38 0,85 0,44 
Trypsin  4,26 5,02 5,40 0,79 0,93 
ADH 3,00 3,00 3,00 1,00 1,00 
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Dynabeads. In general, the enrichment showed that active ABPs enriched more proteins 
than inactive ABPs. This tendency was also found for certain co-purified proteins. 
Proteomic analysis after enrichment was first applied using MALDI-TOF-MS and PMF, where 
only one putative cysteine protease, Cwp84, was found, corresponding to the labelled band. 
Furthermore, a number of proteins were co-purified during the enrichment process, 
including Cwp66, SlpA, Cwp19 (CD2767), CD2797 and Cwp6 (CD2784). LC-MS/MS was found 
to be more sensitive and useful in terms of identifying multiple proteins in a mixture and 
providing data for relative quantification. Re-exploration of proteomic experiments using 
LC-MS/MS reveal the identity of another cysteine protease, the Cwp13, a homologue of 
Cwp84. Some of the co-purified protein species were also identified as traces in the Cwp84 
and Cwp13 bands by LC-MS/MS. This observation could be properly related to many reasons 
including distribution of proteins over lane of the gel, sensibility of LC-MS/MS system. 
In-depth proteomics analysis using the spectral counting method was applied and improved 
during the work of this chapter. However, due to some inherent problems such as 
inconsistencies in gel loading, these experiments require repetition and optimisation. For 
example, the enrichment process could optimised with more stringent washes to remove as 
much of the non-specific binding as possible, and by using on-bead digest for ‘gel-free’ 
proteomic experiments rather than in-gel digest to avoid inconsistency related to gel 
loading, protein migration on gel, altered behaviour of proteins due to modification, or the 
excised band not including all proteins of interest. Above all, the on-bead digest method 
would be very useful for quantification of S-layer proteins that tend to undergo auto-
processing and distribute over several molecular weight ranges on the gel.  
Despite the limitations of the applied method, the results of this chapter still enrich our 
understanding of the influence of proteases in S-layer processing of C. difficile. First, the 
identification of the two putative cysteine proteases confirmed the success of ABPP 
application to C. difficile system. Second, the results described this chapter contribute 
further evidence for potential functions of the identified proteases, which will be discussed 
in the chapter 8.2. 
One interesting point is the SAR across inhibitors/ABPs (described in chapter 4) and the 
genetic study (described in the work of Dr. de la Riva Perez): both studies demonstrated the 
164 
 
importance of the AA1 position of inhibitors/ABPs or the corresponding P2 position of the 
substrate. Combining the significant enrichment of Cwp84 by active ABPs and less effective 
enrichment by inactive ABPs (see section 6.1) with the proteomics data showing Cwp84 
enriched when wild type 630 is treated with active ABPs and significant enrichment of 
Cwp13 in 630Δcwp84 strain, these results suggest that active ABPs label both proteases.  
Another interesting finding is the mysterious property of ABPs bearing an arginine in the AA1 
position that causes “the double band effect”. In the proteomic study with wild type 630, 
the upper labelled band contained almost as much Cwp13 as Cwp84, but the amount of 
Cwp13 in the bottom band was insignificant for EP-R-PEG3-Biotin (see section 6.4). In 
addition, the similar relative abundance of Cwp13 when 630Δcwp84 was treated with ABPs 
having AA1 as arginine and alanine (section 6.7) indicated that arginyl ABPs labelled Cwp13 
as strongly as inactive alanyl ABPs. There appears to be a structure-activity effect for the 
arginyl ABPs that is not yet fully explicable.  
Although proteomic data strongly indicate specific labelling of Cwp13 by both active and 
inactive ABPs, the function of Cwp13 and any the potential impact of this protease in S-layer 
processing (e.g.: Cwp13 might process Cwp84 or it might be involved in the host-pathogen 
interactions) remain unclear. Future work could focus on investigation of Cwp13 to provide 
better understanding of S-layer biogenesis of C. difficile. 
As part of this work, the effect of Cwp84 on other cell wall proteins was also investigated. 
Affecting the activity of this protease either by chemical inhibition or gene knock-out tended 
to increase the shedding of Cwp2 and Cwp66 into the culture supernatant. This increased 
the shedding could be an indication of up-regulation of these proteins or somehow related 
with the stabilisation of these proteins causing their detection on Western blot. In addition, 
proteomic analysis of 630Δcwp84 strain also indicated a larger enrichment of Cwp66 and 
Cwp6. However, much of these data is preliminary and further work will be required to 
provide a clearer picture of the effects of deleting cwp84 and the effects of inhibitors on 
Cwp84 and Cwp13.  
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Chapter 7 Exploring the scope and potential antibacterial activity of 
irreversible cysteine protease inhibitors in C. dfficile 
 
The discovery of the first inhibitors of SlpA processing, and their development into 
epoxysuccinyl warhead-containing inhibitors/ABPs, led to the identification of two cysteine 
proteases: Cwp84 and Cwp13. It was subsequently verified that only Cwp84 was 
responsible for SlpA cleavage, while its homologue Cwp13 was unable to complement its 
functions. Furthermore, in addition to the genomic studies by various groups [276, 413], 
the SAR of epoxysuccinyl inhibitors with their targets developed in this study suggested 
strongly that Cwp84 and presumably also Cwp13 belong to the papain subclass of cysteine 
protease.  
Cysteine protease inhibitors/probes were widely studied and applied to identify novel 
cysteine proteases [50, 60-61, 150, 377]. Among those selective cysteine protease 
inhibitors/probes, various types of electrophilic warhead appended to a specific peptidyl 
moiety were found to target different sub-classes of cysteine proteases [414]. In this 
chapter, a number of inhibitor classes bearing different electrophilic warheads were 
designed and investigated with the objective of exploring their scope and potential 
antibacterial activity as well as identifying further potentially unknown cysteine proteases 
in C. difficile. These inhibitors were categorised according to both the chemical properties 
of the warhead as well as where it is positioned in the molecule (N-terminus or C-terminus 
of the peptidic chain).   
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7.1 Warheads against cysteine protease inhibitors 
Cysteine proteases can be differentiated into three major structurally distinct classes: 
papain-like (e.g. cathepsins), interleukin-1β converting enzyme (ICE)-like (e.g. caspases) and 
picorna-viral like (similar to serine proteases with cysteine substituting serine) proteases 
[415]. Having developed epoxysuccinyl inhibitors, the next major aim of this study was to 
design novel inhibitors/probes in order to explore the potential S-layer processing inhibition 
and antibacterial activity of these irreversible inhibitors. Furthermore, variation of the 
warhead might lead to labelling of additional potential cysteine proteases as well as serine 
proteases in C. difficile that can accommodate and react with such compounds. A strategy 
commonly used for designing specific protease inhibitors is the substrate mimetic approach, 
which is based on cleavage site of the protease substrate and appending a reactive warhead 
to that substrate moiety. Similar to epoxysuccinyl inhibitors/probes, the design was centred 
on the specificity element bearing a peptidyl mimic of a particular length so as to fit in the 
protease’s active site and a reactive electrophilic warhead to trap irreversibly the 
nucleophilic active centre of the proteases. Common warheads include aldehydes, 
halomethyl ketones, diazomethyl ketones, acyloxymethyl ketones, epoxides and Michael 
acceptors. These warheads, with the exception of epoxides (which have been explored in 
detail in previous chapters) and aldehydes (discussed in Chapter 2), will be discussed in the 
following section.  
Halomethyl ketone (HMK) 
Peptidyl chloromethyl ketones (CMK) were first developed for serine proteases [416-417], 
however, it was found subsequently that this type of inhibitor was also potent against 
cysteine proteases [417-418]. Various studies have established the different mechanisms of 
inhibition by HMK to serine and cysteine proteases (Figure 7. 1). In the case of serine 
proteases, HMKs form two covalent bonds with the protease: the first is formed with the 
active site histidine residue [419-420] while the second is generated between the 
nucleophile catalytic serine oxygen and the ketone carbonyl carbon, leading to the 
formation of a tetrahedral adduct [421]. In the case of cysteine proteases, HMKs alkylate the 
active site cysteine residue, forming a covalent thioether bond [422-423]. Altering the 
peptidyl moiety of the inhibitors can lead to enhanced specificity against individual serine or 
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cysteine proteases, while the variation of the strength of HMK has been shown to improve 
both inhibitor potency (F>I>Br>Cl) and selectivity [129]. Fluoromethyl ketones (FMKs) are 
usually more specific for cysteine proteases, whereas CMKs inhibit both protease classes 
[129]. 
 
Figure 7. 1: Inactivation of serine and cysteine proteases by HMK inhibitors. (X = F, Br, Cl) 
Diazomethyl ketone 
Peptidyl diazomethyl ketones irreversibly inactivate cysteine proteases by alkylating the 
active site cysteine residue. They have been developed for some sub-classes of cysteine 
proteases including papain [424-425], cathepsins [426-428], and calpain [427, 429]. The 
proposed inhibition mechanism of diazomethyl ketones involves a proton transfer from the 
active site histidine residue to the methylene carbon of the inhibitor, and the alkylation of 
the active cysteine residue eliminates N2. It is still unclear which of these processes occurs 
first.  
 
Figure 7. 2: Inactivation of cysteine proteases by diazomethyl ketone inhibitors. 
Acyloxymethyl ketone (AOMK) 
AOMKs are analogues of HMKs that bear an ester group instead of a halogen atom, and 
were first designed by Krantz et al. [153, 430]. The major drawback of using HMKs is that 
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they possess an inherently reactive halomethyl functional group, which can lead to issues 
with broad reactivity. The exploitation of AOMKs in inhibitor design overcomes this design 
flaw by having a less reactive functional group than HMKs, and thus these compounds suffer 
from non-specific reactivity to a lesser extent. Similar to other types of inhibitors, AOMKs 
alkylate the active site cysteine residue to form a thioether ketone. AOMKs were found to 
inhibit cathepsins (B, L, S) [431-432], calpain [154], caspases [433] and other cysteine 
proteases [434]. The potency of an AOMK depends on the nature of the leaving group as 
well as the affinity of the peptidyl region.  
 
Figure 7. 3: Inactivation of cysteine proteases by AOMK inhibitors.  
Michael acceptor (MA) 
Peptidyl derivatives bearing an MA are generally specific cysteine protease inhibitors, found 
to inhibit cathepsins [149, 435-436], papain [436-438], calpains [149], cruzain [149, 439] and 
rhinovirus 3C proteases [62, 440]. They remain unreactive towards other nucleophiles, and 
require the catalytic system of cysteine proteases for activation. A number of studies have 
shown that the alkylation process takes place on the β-carbon of the α,β-unsaturated 
carbonyl moiety by the active site cysteine residue, followed by protonation of the α-carbon 
to form the thioester adduct [149, 436-437] (Figure 7. 4). Furthermore, the strength of the 
electron-withdrawing groups on the MA correlates linearly with the potency of the 
inhibitors.  
 
Figure 7. 4: Inactivation of cysteine proteases by MA inhibitors. R is the amino acid side chain and EWG can be 
varied with different electron withdrawing groups e.g.: vinyl sulfone (-SO2R) to various carbonyl derivatives 
(COOR). 
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7.2 Inhibitor design  
As detailed in previous chapters, an ABP usually consists of three moieties: the warhead, the 
specificity element and the tag. These three elements were considered separately in the 
design as follows.  
The reporter unit 
It was necessary to use some kind of reporter unit in order to detect the labelling of the 
probes, and this could occur either via direct attachment of a label to the inhibitors or 
indirectly via small chemical tag accessible for subsequent bioorthogonal ligation in vitro. 
However, when the in vivo assay was taken into consideration, a biotin direct label was 
chosen as the reporter for all inhibitors. There are two major advantages gained from using 
biotin in this manner: it is smaller than the fluorescent label, and attaching biotin has the 
potential to enhance the uptake of inhibitor into the cell via the biotin-mediated vitamin up-
take pathways [441]. The biotin group was linked either via a PEG linker, as described in 
Chapter 5, or via incorporated on the side-chain of a lysine residue in the peptidic chain. 
The specificity element 
The aim of this study is to explore the S-layer inhibitory and antibacterial activity of 
irreversible inhibitors in C. difficile. Considering the substrate mimetic strategy, a panel of 
probes containing different peptide components were chosen based on their diverse 
physical properties and the knowledge of SlpA processing inhibition gained thus far: alanine, 
serine and threonine were chosen for the ‘inactive’ compounds whereas arginine, tyrosine 
and arginine-leucine dipeptide were chosen for the ‘active’ compounds.  
The warhead 
The warheads were attached either on the N-terminus or on the C-terminus of the peptidic 
specificity element (Figure 7. 5). Inhibitors with the warhead at the N-terminus were derived 
using a similar route to that exploited for the epoxysuccinyl inhibitors (see section 3.3). In 
contrast to introducing a ketone group upon warhead attachment (as for HMKs), the 
warhead was coupled onto the N-terminal amine hence forming haloacetamide unit. Since 
the electron withdrawing effect of amines is much weaker than that of ketones, these newly 
designed probes would be expected to have reduced potency in comparison to the ketones. 
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Nevertheless, these compounds would still retain moderate potency, and since inhibitor 
potency was not the main focus of this study haloacetamides and acyloxyacetamides were 
included as warheads.  
Introducing the warhead onto the C-terminus of the peptidyl inhibitor during SPPS is 
synthetically more challenging. One useful method of achieving this however involves 
having the warhead preloaded on the solid support before peptide elongation. For this 
reason, the building block containing the warhead should comprise of at least two 
functional groups: one handle for attachment to the resin and another for appending the 
specificity element. In the case of the MA warhead, Fmoc-Ser was modified on its C-
terminus to provide the corresponding MA. Once this building block was obtained, 
attachment onto the solid support could follow via the serine side chain while the peptide 
elongation could occur on the Fmoc protected amine as usual. In the case of the CMK and 
AOMK warheads, Z-alanine served as the starting point to generate Z-alanine-CMK or Z-
alanine-AOMK, with the aim of introducing these compounds onto a solid support. Details of 
the synthetic route taken will be described in the following sections.  
 
Figure 7. 5: Inhibitor design. The warhead was attached either on the N-terminus (A) or the C-terminus (B) of 
the peptidyl specificity element. The biotin label was introduced at the C-terminus via use of PEG-Biotin-
Novatag
TM
 resin in A or at the side chain of a lysine residue in the peptidyl sepecificity element in B.  
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7.3 Inhibitors with the warhead appended to the N-terminus  
7.3.1 Synthesis  
The generic route employed for the preparation of inhibitors with the warhead appended to 
the N-terminus of the specificity element is similar to that employed for the synthesis of the 
epoxysuccinyl inhibitors described in Chapters 3 and 5. The specificity element was 
prepared on the PEG-Biotin-NovatagTM resin utilising standard Fmoc/tBu SPPS. Once the 
desired peptide chain had been made and still attached to the resin, the warheads were 
incorporated in a straightforward manner onto the peptide N-terminus (Figure 7. 6).  
         
CAA-AA1-AA2-PEG3-Biotin         FAA-AA
1-AA2-PEG3-Biotin 
No. WH AA1 AA2 Abbr. Name 
TD 67 CAA Leu Arg CAA-LR-PEG3-Biotin 
TD 68 CAA Ala - CAA -A-PEG3-Biotin 
TD 69 CAA Ser - CAA-S-PEG3-Biotin 
TD 70 CAA Thr - CAA-T-PEG3-Biotin 
TD 71 CAA Arg - CAA-R-PEG3-Biotin 
TD 72 CAA Tyr - CAA-Y-PEG3-Biotin 
TD 73 FAA Leu Arg FAA -LR-PEG3-Biotin 
TD 74 FAA Ala - FAA -A-PEG3-Biotin 
TD 75 FAA Ser - FAA -S-PEG3-Biotin 
TD 76 FAA Tyr - FAA -Y-PEG3-Biotin 
TD 77 FAA Arg - FAA -R-PEG3-Biotin 
Table 7. 1: Inhibitors with the haloacetamide warhead appended to the N-terminus of the specificity element.  
To obtain chloroacetamide (CAA) warhead, the resin-bound peptide chain was treated with 
chloroacetyl chloride in the presence of N-methyl morpholine (NMM). Alternatively, the 
fluoroacetamide warhead (FAA) was obtained from the coupling of preactivated sodium 
fluoroacetate using HCTU and DiPEA, while the Michael acceptor (MA) warhead was derived 
from coupling with preactivated fumaric acid mono ethyl ester also using HCTU and DiPEA. 
Cl
O
H
N AA1-AA2-PEG3-Biotin F
O
H
N AA1-AA2-PEG3-Biotin
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Figure 7. 6: Synthesis of inhibitors with warhead appended to the N-terminus. The specificity element was 
synthesised on the PEG-Biotin-Novatag
TM
 resin using standard SPPS with subsequent coupling of the desired 
warhead. CAA warhead: ClCOCH2Cl (1.2eq.), NMM (2.5eq.), 1h, RT, yield 4-37%. FAA warhead: NaCOOCH2F 
(5eq.), HCTU (5eq.) and DiPEA (6eq.), 1h, RT, yield 6-15%. MA warhead: HOOCCHCHCOOEt (5eq.), HCTU (5eq.) 
and DiPEA (6eq.), 1h, RT, yield 10-39%. AOAA warhead: tBuAcBr (1eq.), 4-MeOBnCOOH (2eq.), KF (4eq.), RT, 
o/n; coupling was used 4-MeOBnCOOCH2COOH (5eq.), HCTU (5eq.) and DiPEA (6eq.), 1h, RT, yield 18-87%. 
The advantage of using this method is that all three starting materials (chloroacetyl chloride, 
sodium fluoroacetate and fumaric acid ethyl ester) are commercially available. In contrast, 
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the AOAA warhead building block was synthesised from tert-butyl bromoacetate and 
methoxybenzoic acid in the presence of potassium fluoride, followed by deprotection with 
TFA. The resulting methoxy benzoyloxy acetic acid was then activated with HCTU and DiPEA 
before coupling to the resin-bound peptide chain. Finally, all inhibitors were cleaved from 
the resin using standard conditions with 95% TFA. After purification via LC-MS, inhibitors 
stocks were prepared as described in section 3.3 ready for the inhibition assay. In summary, 
23 inhibitors were generated as shown in Table 7. 1 and Table 7. 2.  
  
MA-AA1-AA2-PEG3-Biotin                               AOAA-AA
1-AA2-PEG3-Biotin 
No. WH AA1 AA2 Abbr. Name 
TD 78 MA Leu Arg MA-LR-PEG3-Biotin 
TD 79 MA Ala - MA -A-PEG3-Biotin 
TD 80 MA Ser - MA-S-PEG3-Biotin 
TD 81 MA Thr - MA-T-PEG3-Biotin 
TD 82 MA Arg - MA-R-PEG3-Biotin 
TD 83 MA Tyr - MA-Y-PEG3-Biotin 
TD 84 AOAA Leu Arg AOAA-LR-PEG3-Biotin 
TD 85 AOAA Ala - AOAA-A-PEG3-Biotin 
TD 86 AOAA Ser - AOAA-S-PEG3-Biotin 
TD 87 AOAA Tyr - AOAA-Y-PEG3-Biotin 
TD 88 AOAA Arg - AOAA-R-PEG3-Biotin 
TD 89 AOAA Thr - AOAA-T-PEG3-Biotin 
Table 7. 2: Inhibitors with Michael acceptor or acyloxyacetamide warhead appended to the N-terminus of the 
specificity element.  
7.3.2 Activity and labelling effect 
In order to explore the scope and activity of the newly synthesised inhibitors as well as 
enable a comparison between different types of inhibitors, the inhibitors were tested at 
100 µM with Cd630 and whole cells boiled in loading buffer analysed using SDS-PAGE. For 
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O
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the sake of more practical sample handle (e.g.: sample processing, loading on one gel 
instead of several gels, etc.), the library was divided into two sets: the haloacetamides were 
classed as one set and the rest of the compounds made up the other set.  
 
Figure 7. 7: Activity and labelling effect of haloacetamide inhibitors. C. difficile 630 were treated with 100 µM 
inhibitors and whole cells were boiled in loading buffer prior to SDS-PAGE analysis. A) Western blot against 
LMW-SLP is shown to demonstrate the activity. B) NeutrAvidin blot is shown to demonstrate the activity the 
labelling effects. C) Western blot membrane of A was stripped and re-probed against Cwp84. E*=EtEP-R-PEG3-
Biotin. 
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As can be seen in Figure 7. 7, the inhibitory effect of the haloacetamides against S-layer 
processing at the tested concentration varied between samples. CAA-R-PEG3-Biotin and 
CAA-LR-PEG3-Biotin appeared to be slightly active, but at a much lower level than found 
with EtEP-R-PEG3-Biotin, while the remaining inhibitors did not show any activity. The 
labelling showed similarity to one of the epoxysuccinyl inhibitors, EtEP-R-PEG3-Biotin probe. 
Besides the “double band effect” as seen in active compounds CAA-R-PEG3-Biotin and CAA-
LR-PEG3-Biotin, strong bands were observed at approximately 80 kDa, where Cwp84 was 
identified with EtEP-R-PEG3-Biotin probe. There were a few additional signals on the 
NeutrAvidin blot compared to the epoxysuccinyl probe control, although it is hard to claim 
which signals are labelling related and which are biotinylated native proteins in the cell 
lysates. It should be noted that the differential lysis of the cells also affects the detected 
labelling signal of biotinylated native proteins (e.g.: fewer bands were found in the no 
inhibitor control sample). After probing against LMW-SLP, the membrane was stripped using 
low pH buffer and re-probed against Cwp84 (membrane C in Figure 7. 7). Unfortunately, the 
quality of the blot was poor and some signals were missing, which may due to the nature of 
the stripping process. Despite this, the few strong bands that were observed on the blot 
indicated that Cwp84 was among the proteins labelled by these HAAs.  
The set of MA and AOAA inhibitors were tested in the same manner as the HAA inhibitors 
(Figure 7. 8). No inhibition activity against SlpA processing could be detected under the 
tested conditions, which may also relate to the low quality of the Western blot. The labelled 
protein pattern was almost identical to that of the control probe (EtEP-R-PEG3-Biotin), 
except for MA-LR-PEG3-Biotin. Despite the noticeably stronger bands in the Western blot 
against Cwp84 for the MA and AOAA probes, there was still a visible reduction in signal 
detection due to the stripping and re-probing process as observed in the corresponding blot 
for the HAAs. As for the HAAs, it was observed that the strongly labelled bands in the higher 
molecular weight range did indeed contain Cwp84.  
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Figure 7. 8: Activity and labelling effect of MA and acyloxyacteamide inhibitors. C. difficile 630 were treated 
with 100 µM inhibitors and the whole cells were boiled in loading buffer prior to SDS-PAGE analysis. A) 
Western blot against LMW-SLP is shown to demonstrate the activity. B) NeutrAvidin blot is shown to 
demonstrate the labelling effects. C) Western blot membrane was probed against Cwp84. E*=EtEP-R-PEG3-
Biotin. 
Because NeutrAvidin blots of both inhibitor sets were unclear with many bands, analysis 
proved difficult and thus further experiments were needed to be conducted in order to 
make concrete conclusions. It was thought that dividing the bacterial cells into sub-factions 
should simplify the proteome and provide clearer and more interpretable results, as 
observed previously (see section 5.1.2). One representative compound from each of the 
four classes of inhibitors (CAA, MA, FAA, AOAA) was chosen for in vivo testing at 100 µM, 
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each possessing the same specificity element (LR), in addition to the positive control EtEP-R-
PEG3-Biotin. C. difficile was divided into two fractions: the S-layer fraction and the cell 
fraction as previously described in section 3.5. In addition, a pull down step was added to 
remove non-specific labelling. Figure 7. 9 depicts the Western blots obtained from this 
experiment, and it is seen that the results, as expected, are indeed much cleaner than those 
conducted without splitting the cell into two fractions (Figure 7. 7 and Figure 7. 8). On the 
NeutrAvidin blot, one major band at approximately 80 kDa was observed for all of 
biotinylated inhibitors in the S-layer fraction except AOAA-LR-PEG3-Biotin. The ”double 
labelled band” effect of EtEP-R-PEG3-Biotin was also observed for CAA-LR-PEG3-Biotin. Once 
again, the Western blot against Cwp84 strongly indicated that those labelled bands 
contained Cwp84, which is also present in the lane containing the S-layer fraction treated 
with the AOAA compound. On the Coomassie-stained gel, which showed the enriched 
proteins, it was difficult to determine a distinct band in comparison to the positive and 
negative controls (EtEP-R-PEG3-Biotin and no inhibitor lanes). Extrapolating from the results 
seen in Western blot against Cwp84 and the Coomassie-stained gel, the missed labelling 
effect of AOAA-LR-PEG3-Biotin on the NeutrAvidin blot is most likely due to incomplete 
transferring or unexpected blotting effect during the sample processing.  
In the cell fraction, no additional labelling was observed, as only biotinylated proteins of the 
bacteria were seen, which were also present in the no inhibitor control. Similar to S-layer 
fraction, no distinct bands were observed when compared to the enriched proteins on 
Coomassie stained gel. As a result, no further attempt was made to identify any enriched 
proteins in either fraction.   
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Figure 7. 9: Activity and labelling effect of inhibitors with the warhead appended to the N-terminus. C. difficile 
630 were treated with 100 µM Inhibitors and sub-fractionated into the S-layer fraction and the cell fraction. A 
pull-down was conducted prior to SDS-PAGE analysis to remove the majority of non-specific labelling. A) 
NeutrAvidin blot shows the labelling effects. B) Western blot against Cwp84. C) Coomassie stained gel 
visualised the enriched proteins for proteomic evaluation. All inhibitors have the LR specificity element, except 
the control EtEP=EtEP-R-PEG3-Biotin. 
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7.4 Inhibitors with the warhead appended to the C-terminus  
As mentioned in section 7.2, the strategy for synthesising inhibitors with the warhead 
appended to the C-terminus commences with the synthesis of the warhead building block 
using solution phase chemistry before attachment to the solid support for further peptide 
elongation. The details for each warhead type will be treated separately in the following 
sections.  
7.4.1 Synthesis of Michael acceptor inhibitors 
Revisiting the cleavage site of SlpA, it was noted that P1 of the substrate is either an alanine 
or a serine in most of the strains. The synthesis of inhibitors with warhead appended to the 
C-terminus using SPPS proved difficult to adapt for a number of reasons, including 
restriction on the number of amino acids with the properties required for transformation 
into the corresponding warhead functionality and/or loading onto resin. For example: a 
functionalised side chain is required to enable the attachment on the resin, and acid and/or 
base stability is typically essential to survive the harsh condition during solution phase 
warhead synthesis.  
 
Ac-AA1-AA2-AA3-AA4-MA 
No. AA1 AA2 AA3 AA4 Abbr. Name 
TD 90 Leu Glu Thr Lys Ac-LETK-MA 
TD 91 - - Lys(Biotin) Tyr Ac-K(Biotin)-Y-MA 
TD 92 - - Lys(Biotin) Leu Ac-K(Biotin)-L-MA 
TD 93 - - Lys(Biotin) Glu Ac-K(Biotin)-E-MA 
TD 94 - - Lys(Biotin) Met Ac-K(Biotin)-M-MA 
Table 7. 3: Inhibitors with Michael acceptor warhead appended to the C-terminus of the specificity element. 
COOEtN
H
HO
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Figure 7. 10: Synthesis of inhibitors with an MA warhead appended on the C-terminus. Reagents and 
conditions: IX) DCC (1.05eq.), DMAP (0.10eq.), BnSH (2eq.), RT, o/n; X) Et3SiH (5eq.), Pd/C (10%), in acetone 
RT,1h; XI) Ph3PCHCOOEt (1.5eq.) in THF, RT, 24h; XII) 20%TFA in DCM, RT, 2h; loading on resin in pyridine and 
THF, 60°C, 6h; peptide elongation using standard SPPS; cleavage with 95% TFA, 2.5%H2O, 2.5% TIS, 2h, RT.  
The synthesis of MA inhibitors commenced with Fmoc-Ser(tBu)-OH, which consists of three 
functional groups utilised for conversion into the MA warhead building block: the carboxyl 
group for modifying to the corresponding MA, the alcohol side chain to enable attachment 
onto the solid support and the Fmoc protected amine for subsequent peptide elongation. 
The reaction conditions were adapted from the literature procedure [62] (Figure 7. 10). 
Firstly, serine was converted into S-benzyl thioester (15) by coupling to benzyl mercaptan. 
Reduction of this thioester (15) using palladium over carbon and a source of hydrogen 
(Et3SiH in this case) provided the corresponding aldehyde intermediate (16). Crude 16 was 
then condensed with the carbethoxymethylene triphenylphosphorane Wittig reagent to 
afford the α,β-unsaturated ester (17). Removal of the tBu protective group using 20% TFA 
supplied the corresponding side chain deprotected ester (18) allowing the attachment of 
the modified serine onto the solid support, which is a trityl resin in this case. Subsequently, 
the peptidyl specificity element was built up on the loaded resin by exploiting standard 
Fmoc/tBu SPPS. The biotin label was introduced to the inhibitor by incorporating a side 
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chain biotinylated lysine in the peptidic specificity element, and the free amine at the 
N-terminus was acetylated to prevent additional charges in the molecule. Under standard 
TFA cleavage conditions as used previously, MA inhibitors was obtained and presented in 
Table 7. 3. The warhead of MA inhibitors is defined as the combination of the remaining 
serine side chain and the α,β-unsaturated ester (indicated in red). 
7.4.2 Synthesis of AOMK- and CMK- inhibitors 
A general method for synthesising AOMK and CMK probes was developed by Bogyo and co-
workers [53], and this involved the attachment of Fmoc-protected CMK derivatives on 
hydrazine preloaded resin. Based on this work, an adapted synthetic route was proposed for 
the production of CMK inhibitors (Figure 7. 11).  
Like the synthesis of the MA inhibitors, the initial amino acid building block was modified to 
contain the CMK functionality using solution chemistry. CMK derivative syntheses have been 
widely reported in the literature [53, 442-443]. The conventional route involves multiple 
transformations of the corresponding amino acid via diazomethyl ketones as intermediates 
[444]. These methods utilised diazomethane as the key reagent to generate the diazomethyl 
ketone moiety. However, diazomethane suffers from numerous safety issues due to its high 
toxicity, shock sensitivity and explosiveness [444-446]. Alternative routes avoiding the use of 
diazomethane and employing other reagents of a significantly reduced toxicity were 
explored, such as the use of chloromethyl lithium enolate, silyl enol ether, or a bromination 
step followed by decarboxylation, and a sulfur ylide. However, only the sulfur ylide route, 
which was based on the work of Wang et al. [444], proved to be simple and reliable with 
only three steps in total to obtain the CMK derivative. This procedure was adapted to 
synthesise the CMK building block used in the present study. Firstly, Z-protected alanine, 
where the ‘Z’ group is stable under acidic conditions, was converted into the corresponding 
methyl ester (20) Figure 7. 12. Treatment of this ester (20) with trimethylsulfoxonium iodide 
and potassium tert-butoxide afforded the trimethylsulfoxonium ylide (21), which, without 
further purification, was subsequently converted into Z-Ala-CMK (22) utilising HCl generated 
in situ via heating a mixture of lithium chloride and methanesulfonic acid in THF. One part of 
22 was transformed into the AOMK derivative (23) by treatment with methoxybenzoic acid 
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in the presence of potassium fluoride in DMF; a protocol adapted from the work of Wood et 
al. [443].  
 
Figure 7. 11: Proposed synthetic route for CMK and AOMK inhibitors [53]. The Fmoc-protected building blocks 
are loaded onto hydrazine-functionalised resin in THF at 50°C. Standard SPPS was used for peptide elongation 
and final cleavage was performed with 95% TFA, 2.5% TIS, 2.5% H2O, 2h at RT.  
Prior to loading these building blocks onto the solid support, via a hydrazone linkage as 
depicted in Figure 7. 11, removal of the Z protecting group was attempted in order to 
enable subsequent substitution by an Fmoc group. Unfortunately, classical Z-deprotection 
methods such as catalytic (Pd/C) hydrogenlysis led to decomposition for both the CMK and 
AOMK building blocks, and therefore replacement with an Fmoc group was not possible. 
Due to time constraints, persistent decomposition upon deprotection meant that these 
building blocks could not be coupled onto the solid support and hence the desired final 
inhibitors could not be synthesised. The Z-Ala-CMK and Z-Ala-AOMK compounds were 
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nevertheless taken through to in vivo testing as representatives for these classes of 
inhibitors.  
 
Figure 7. 12: Synthesis of CMK and AOMK building blocks. Reagents and conditions: XIV) K2CO3 (1eq.), MeI 
(2eq.) in DMF, 0°C, 30min; XV) KO
t
Bu (3eq.), Me3SOI (3eq.) in THF, 2h reflux, then cooled down to 0°C before 
adding XIV (1eq.), 4h; XVI) MeSO3H (1.1eq.), LiCl (1.14 (eq.) in THF, 0°C-> 70°C, 2h, and quenched with H2O; 
XVII) 4-MeOBnCOOH (2eq.), KF (4eq.) in DMF, RT, o/n.  
7.4.3 Activity and labelling effect of inhibitors with the warhead appended to C-
terminus 
Testing all inhibitors with the warhead appended at the C-terminus at 100 µM against 
C. difficile 630 revealed that all inhibitors possessed moderate inhibition activity towards 
SlpA processing with the exception of Z-Ala-CMK (Figure 7. 13). This suggests that the 
strength of the electrophilic trap may play an important role since the corresponding amides 
were not active at the concentration tested. In addition, the resultant significant change in 
structure may also contribute to activity variation between inhibitors with the warhead 
appended to different ends of the peptidic chain. Intriguingly, although Z-Ala-CMK did not 
possess activity against SlpA processing, it did prove effective at killing C. difficile. Further 
investigation of this compound is discussed in a later section. 
The labelling effect was observed on the NeutrAvidin blot; however, it was observed that 
there was a similar tendency to that found for other inhibitor types. Generally, the labelled 
protein pattern of Michael acceptor inhibitors (Ac-XXS-MA) was almost identical to the one 
of the control sample EtEP-R-PEG3-Biotin though less intense. Since no distinct bands were 
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observed in comparison with the epoxysuccinyl control sample, no post proteomics study 
was carried out on this type of inhibitor.  
 
Figure 7. 13: Activity and labelling effect of inhibitors with the warhead appended to the C-terminus. C. difficile 
630 cultures were treated with indicated inhibitors/probes at 100 μM, as described standard inhibition assays 
(see section 2.1.1). 
7.5 Growth inhibition of C. difficile  
7.5.1 Growth inhibition by Z-Ala-CMK and EtEP-R-Pra in solution culture 
As mentioned in previous section, Z-Ala-CMK tends to kill C. difficile at 100 µM, as judged by 
the failure of many growth attempts in the presence of this compound. Only moderate 
bacterial growth was achieved at 10 µM concentration (with OD of 0.5 after overnight 
culturing) while normal growth was attained at 1 µM (with OD of 0.85 after overnight 
culturing). Following this finding, the concentration required for 50% effect (EC50) was 
investigated by growing C. difficile in the presence of Z-Ala-CMK at different concentrations 
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ranging from 1 µM to 50 µM in BHI medium. Considering that the S-layer might play an 
important role in the growth inhibition, two mutants were chosen for this experiment: 
630Δerm (possessing a correctly-assembled S-layer as found in the wild type) and 
630Δcwp84 (possessing a less stable S-layer containing full length SlpA). Interestingly, the 
result revealed that the EC50 of Z-Ala-CMK was about 10 µM and small inhibition effect was 
observed already at 1 µM (Figure 7. 14). However, it should be noted that the small 
inhibition effect could be related with the growth variation of C. difficile. 
 
Figure 7. 14: Antibacterial effect of Z-Ala-CMK. C. difficile was grown overnight with different concentrations of 
Z-Ala-CMK. The percentages of bacterial growth were calculated based upon the OD values of the cultures.  
Discovering the growth inhibition effect of Z-Ala-CMK and revisiting the inhibition results of 
epoxysuccinyl inhibitors, it was noticed that growing 630Δcwp84 in the presence of 
inhibitors bearing arginine in the AA1 position appeared to be difficult at high concentration 
(see section 6.7). The growth inhibition experiment was repeated using EtEP-R-Pra. 
Generally, inhibition effect was only observed for the 630Δcwp84 mutant and not for the 
630Δerm mutant. Monitoring the growth over a concentration range from 0 µM to 50 µM it 
appeared that the EC50 is about 10 µM, similar to that of Z-Ala-CMK (Figure 7. 15).  
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Figure 7. 15: Growth inhibition effect of EtEP-R-Pra. C. difficile mutants was grown overnight with different 
concentrations of EtEP-R-Pra. The percentages of bacterial growth were calculated based upon the OD values 
of the cultures. 
7.5.2 Growth inhibition of 630 and 630Δcwp84 by antibiotics 
Both full deletion of Cwp84 by gene knockout mutation and partial Cwp84 inactivation using 
inhibitors lead to a marked effect on cell integrity as judged by lysis sensitivity of the cell 
(see section 6.6), and by growth rate in rich medium in the case of the knockout mutant (see 
section 7.5.1). It was speculated that this effect might have a domino effect on viability 
under stress conditions such as antibiotic treatment or attack by the host immune system, 
presenting S-layer biogenesis as a potential therapeutic target. To examine this hypothesis 
the effect of antibiotics on wild type C. difficile 630 and 630Δcwp84 are described in this 
section. Both strains were streaked evenly on agar plates and subsequently E-test strips 
(Biomerieux, Marcy l’Etoile, France) containing antibiotics of interest were placed on the 
agar surface for 24 hours growth. Afterward, the minimum inhibitory concentrations (MICs) 
to chloramphenicol (CL), clindamycin (CM), erythromycin (EM), metronidazole (MZ), 
moxifloxacin (MX) and tetracycline (TC) were determined, a summary of the results is 
illustrated in Figure 7. 16. Higher MIC of the mutants compared to the wild type means the 
mutant strains are less sensitive to the antibiotics, which was observed when 630Δcwp84 
mutant treated with chloramphenicol, moxifloxacin and tetracycline. Only metronidazole 
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caused an opposite effect. This result is interesting, however further experiments are 
required to ensure any conclusive antibitotic effect of the knockout mutants.  
 
Figure 7. 16: Antibiotic effects. E-test strips containing antibiotic was placed on even streaked agar plated with 
C. difficile strains. MICs were determined after 24 hour growth according to manufacturer’s instructions. 
Antibiotics were chloramphenicol (CL), clindamycin (CM), erythromycin (EM), metronidazole (MZ), 
moxifloxacin (MX) and tetracycline (TC). MIC is given in µg/mL while R means resistant.  
7.6 Conclusion 
This chapter has described the exploration of putative irreversible cysteine protease 
inhibitors bearing diverse types of warhead attached either side of the peptidyl specificity 
element. The synthesis of inhibitors with the warhead attached to the N-terminus was 
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adapted successfully from the previous synthesis used to generate epoxysuccinyl inhibitors. 
This success confirmed the adaptability of the synthetic route. On the other hand, the 
synthesis of inhibitors with the warhead attached on the C-terminus using SPPS proved 
difficult. Although five MA inhibitors/probes were successfully synthesised, modification of 
the warhead was still restricted to only a few amino acids possessing the side chain 
functionality required for preloading on solid support (e.g.: serine, threonine, tyrosine). 
Serine was used in this study because of its alcohol side chain and being the most common 
P1 amino acid at the cleavage site of SlpA in many C. difficile strains (Table 1. 2). Future 
studies could apply the synthesis route to other functionalised amino acid side chains such 
as the primary amine in lysine, carbonate in asparatic acid and glutamic acid, or the amide in 
asparagine and glutamine, which would require an alternate choice of resin than the trityl 
resin used for loading the alcohol side chain in this work.  
In contrast to the synthesis of MA inhibitors, amino acids bearing a side chain without polar 
functionality (alanine, leucine, isoleucine etc.) are more useful for the synthesis of 
CMK/AOMK inhibitors because these amino acids are base and acid stable, which is 
essential to survive the harsh conditions of solution phase synthesis. Unfortunately, removal 
of the Z-protecting group of the intermediate suffered from decomposition of the whole 
compound. Facile reduction of the CMK/AMOK warheads may be the cause of the 
decomposition when using palladium on carbon to reduce the Z-group. Future studies could 
vary the protecting group of the amino acid to one that is still acid stable but requires a non-
reductive deprotection method to remove (e.g.: acetamide) 
Activity of the newly generated inhibitors was variable, as only weak inhibitory effect was 
observed in two of the CAA inhibitors (CAA-R-PEG3-Biotin and CAA-LR-PEG3-Biotin), while 
the rest of the inhibitors having the N-terminus attached warhead were not active. 
Inhibitors bearing the warhead at the C-terminus appeared to have increased inhibitory 
effect, as all of these inhibitors were moderately active, except Z-Ala-CMK. Interestingly, the 
specificity element does not tend to affect the inhibitory effect as strongly as was found in 
epoxysuccinyl inhibitors. This observation is reflected in the similar activity level of these 
inhibitors. In the case of MA inhibitors, it could be that the alcohol side chain of the serine 
included in the warhead occupies the S1 pocket of the protease, which was found to be 
important in epoxysuccinyl inhibitors. Therefore, the adjacent amino acid like lysine, 
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tyrosine, leucine, glutamic acid and methionine might not affect the activity significantly by 
occupying the S3 pocket (which was found to be relatively unimportant in epoxysuccinyl 
inhibitors). However, if this hypothesis is true for MA inhibitors, it is then difficult to 
understand the activity of Z-Ala-AOMK, as the alanine being adjacent to the warhead was 
not active in epoxysuccinyl inhibitors. If future studies could provide a crystal structure of 
Cwp84 for docking experiments with all of these inhibitors in the active site further insight 
and better explanation for these observations might be obtained.  
Intriguingly, although Z-Ala-CMK did not show activity in the inhibition of SlpA processing, it 
did inhibit bacterial growth at concentrations above 10 µM. One hypothesis is that this CMK 
inhibitor might target protease(s) (e.g.: sortase, serine proteases) that may be involved in 
posttranslational processing of surface proteins. This hypothesis is supported by the known 
inactivation of cysteine and serine proteases by CMK inhibitors [417] and the predicted 
serine protease serving as the signal peptidase responsible for posttranslational signal 
peptide cleavage of secreted proteins (discussed in section 3.1). It is possible that Z-Ala-CMK 
targets this protease and blocks all proteins possessing a signal peptide inside the cell, which 
may lead to the growth inhibition observed in the work of this chapter. Further work is 
required in order to answer these questions, including the development of a new synthetic 
strategy for synthesising the corresponding probes to enable target identification.  
Although activity of the new inhibitors was observed in some cases, labelling was relatively 
similar to that of the positive control (EtEP-R-PEG3-Biotin). Only a few bands were found to 
be distinct to the control, however, these bands were not found on the Coomassie stained 
gel after fractionating the bacteria. Therefore, post-proteomic studies were not conducted.  
One general observation of labelling with the new compounds is the appearance of a band 
at ca. 80 kDa in NeutrAvidin blot. In addition, Western blot against Cwp84 also reveals a 
band at the same region. Previous proteomic studies described in Chapter 6 with both wild 
type and 630Δcwp84 excising gel slices at a similar region showed the dominant presence of 
Cwp84, Cwp13 and traces of SlpA, Cwp6, Cwp66 and Cwp2. Considering the combined 
observations, it suggested that the new inhibitors in the work of this chapter might also 
label and enrich these proteins. 
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In addition, growth inhibition of 630Δcwp84 by EtEp-R-Pra, representative of epoxysuccinyl 
inhibitors bearing an arginine at AA1 position, occurs readily at low concentration raising 
further questions about the effect of these compounds against C. difficile generally and 
against the S-layer specifically. As the Arg-containing compounds resulted in several 
unexpected observations across the whole study, further detailed discussion summarising 
all observed effects is continued in the next chapter.  
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Chapter 8 Conclusion and Perspectives 
 
The main aim of this thesis was to apply ABPP to the pathogen C. difficile to identify 
potential therapeutic targets, with the ultimate objective of aiding in the battle against this 
multi-drug resistant bacterium. In this chapter, results of this study are evaluated from two 
perspectives: a technology development aspect and a biological aspect. Placing this work in 
the wider picture of chemical biology and current understanding of C. difficile, future 
perspectives are discussed, and suggested directions for future study. 
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8.1 Technology development 
Chemical proteomics is a multidisciplinary research area that makes use of synthetic organic 
chemistry, biochemistry, cell biology and mass spectrometry. It is a powerful tool for the 
identification of small molecule-protein interactions within a complex proteome. As the aim 
of the project is to find a potential therapeutic target, the process of this study has 
similarities with drug development. Starting from initial discovery of a compound from a 
screen, in this case the natural product E-64, a cycle of design, synthesis and testing led to 
the identification of the target, and insights into its mode of action.  
8.1.1 Design 
Design of inhibitors/ABPs considered all three components of a typical ABP: the warhead, 
the specificity element and the reporter unit. Creation of a specificity element was based on 
the known cleavage locus of SlpA, whilst the choice of reporter units depended on the 
labelling method (e.g.: two-step labelling or direct labelling). Designing the warhead was 
difficult in terms of finding an optimal electrophilic warhead strong enough to be potent 
towards the target protease, but not too reactive to attack any nucleophile in the cell. 
Following a screen (see section 2.1), an epoxysuccinyl warhead was chosen as the 
electrophilic trap to react with the thio-nucleophile of cysteine residue of cysteine 
proteases; both the type and position (on C- or N-terminus of the specific element) of the 
warhead were based on E-64. This type of warhead has been investigated most intensively, 
but other cysteine protease-targeted warheads such as MA, CMK or AOMK were also 
developed.  
As the electrophilic strength of the warhead contributes directly to the potency of the 
compounds, future design of the warhead could put more effort in improving this property. 
While the HAA, AOAA and MA warheads at the N-terminus of the specificity element benefit 
from ease of synthesis compared to the HMK, AOMK and MA warheads at the C-terminus, 
these compounds suffer from lower electrophilicity due to the presence of a weakly 
electron-withdrawing amide. In addition, inhibitors with a warhead at the N-terminus 
possess a different chemical composition, which makes side-by-side comparison with C-
terminal warhead inhibitors more difficult, especially the putative orientation and fitting of 
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these compounds into the protease active site. Future work could make more effort in 
establishing more comparable compound sets Figure 8. 1.  
 
Figure 8. 1: Suggested comparable compound sets. The warheads have similar electrophilicity, but are 
attached at different end of the peptide. 
8.1.2 Synthesis of inhibitors/ABPs 
8.1.2.1 Inhibitors/ABPs bearing a warhead at the N-terminus of the specificity element 
Based on numerous literature approaches to epoxysuccinyl peptidic inhibitors, the synthesis 
of inhibitors/ABPs of this group was adapted and improved [50, 72, 375]. Low-yielding 
reactions and even failure to couple the warhead to the peptidyl resin-bound specificity 
element arose from defects in reported literature procedures (e.g.: using crude warhead 
building block directly from solution phase synthesis). These were prevented by including 
additional purification of the warhead prior to coupling, as it turned out that warhead purity 
is very important for successful coupling. This synthesis route was further integrated for 
other types of warhead (see chapter 7).  
One advantage of the optimised synthesis route is flexibility, as both warhead and specificity 
element can be easily varied. Therefore this method has the potential for a wide range of 
applications, and provides access to different inhibitors; a few proposed examples are 
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displayed in Figure 8. 2. Furthermore, the synthesis is relatively straightforward. Because 
the coupling of both components is a peptide coupling, the choice of the warhead building 
block is restricted to those possessing a free carboxylate group available for coupling. Some 
building blocks are hydrophilic and dissolve poorly in the organic solvent used in SPPS. 
Consequently, the yield for those couplings was also limited.  
 
Figure 8. 2: Examples of potential application of the synthesis of inhibitors bearing a warhead at the N-
terminus for access to other inhibitor types.  
8.1.2.2 Inhibitors/ABPs bearing warhead at the C-terminus of the specificity element 
Most common syntheses of inhibitors/ABPs bearing the warhead at the C-terminus involve 
either preloading of the warhead building block on the solid support with subsequent on-
resin peptidyl elongation, or coupling of the warhead on the C-terminus when the 
elongation was already performed (e.g.: coupling to the secondary amine of an aza 
peptide).[61, 150]  
The first approach was chosen for this study, where MA inhibitors/ABPs were successfully 
generated, while CMK and AOMK inhibitors could not be transformed into the 
corresponding ABPs. Although the MA inhibitor/ABP synthesis was well-adapted, the 
loading of the warhead on the resin was not easy to control under the conditions tested. As 
a result, the yield of these compounds might be adversely affected (see section 7.4.1). 
Similar observations were found in attempted loading of CMK or AOMK on resin. 
Furthermore, in order to be accessible for subsequent peptidic elongation, the protecting 
group of the amine is preferably an Fmoc-group, which is non-trivial to achieve in some 
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cases. Another drawback of this approach is the requirement of dual functionality in 
addition to the warhead itself: one for the loading on resin and one for peptide extension. 
Consequently, the choice of the warhead building block is also limited. Despite the synthesis 
hurdle, this group of inhibitors/ABPs is worth consideration, as they present the same 
orientation of the peptide backbone as the substrate (i.e. do not have the backbone 
reversed). Future work could build up from an aza peptide to prevent the inefficient 
preloading step (Figure 8. 3).  
 
Figure 8. 3: Proposed synthesis of aza-peptidyl inhibitors to access CMK and AOMK inhibitors. 
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8.1.3 Activity assay 
The assay for SlpA cleavage was very successfully implemented in vivo with live bacteria, 
however, working with C. difficile is very challenging. Variation in bacterial growth might 
affect the result, despite normalisation using OD600. Normalisation confirms equal total 
loading between samples for comparison on a gel, but does not reflect any effects of 
inhibitors on bacteria at different stages of growth, such as inducing stress response or up-
regulation of SlpA synthesis. Although the inhibitors were carefully designed to target SlpA 
processing by mimicking the substrate, the potency of generated inhibitors in general was 
not very high, except EP-Y-Pra-NH2 and EP-R-NH2. This could result from a number of 
factors, including: 
 Inhibitor concentration. There are inherent problems in determining the absolute 
concentration of inhibitor stock (see section 3.3). Therefore, the actual effective 
concentration of inhibitor given in each assay likely differs to some degree from the 
calculated concentration. This is more obvious in attempted concentration 
determination using a fluorescent standard (see section 5.2.2), which revealed that 
this stock concentration may be up to four to five fold lower than that determined 
by the weighing method.  
 Substrate competition. Imagining that each second ca. 400 units of SlpA are 
synthesised and transported to the surface per cell, the amount of SlpA substrate 
against which the inhibitor has to compete is huge. This may decrease the effect of 
the inhibitors towards the target protease.  
 Inhibitor composition. Both orientations of the peptidic moiety were investigated by 
integrating the warhead at different ends of the specificity element. The potency 
differences of inhibitors of both groups were big enough to clarify a structure-
activity trend. However, it is impossible to prove that these differences derive mainly 
from better fitting of the specificity element into the active pocket of the protease or 
from warhead reactivity, as each inhibitor possesses a slightly different warhead and 
might also have a different binding mode.  
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To improve the potency on the target (Cwp84), an in vitro assay could be designed, which 
could introduce high through put screening of a library for covalent and non-covalent 
inhibitors. Based on the hits of this screening, future compounds could be designed and 
optimised. 
Although an SAR was developed (for epoxisuccinyl inhibitors/ABPs), several aspects 
remained unclear, particularly questions regarding the binding mode of inhibitors into the 
active pocket of the target protease. A crystal structure of the target protease or co-crystal 
structure with inhibitors would provide further insight and aid our understanding of the 
binding mode, as well as offer a way to improve the potency.  
Homology models of a protease based on crystal structures of proteases in the same family 
do not give as much information as a co-crystal structure with inhibitor, but they can give 
hints for possible binding modes. Accordingly, a Cwp84 homology model to a cathepsin C 
(1JQP) [288] was built using the Open Source Swiss-Model [447]. Aligning this with the co-
crystal of Ervatamin-C – E-64 (2PRE) [372], it can be seen that E-64 fits nicely in the active 
pocket of the Cwp84 homology model (Figure 8. 4). According to this model, the S2 pocket 
can tolerate long charged side chains at AA1 that interact with Arg215/Asp165, or 
hydrophobic side chains that could bind to Leu260. Furthermore, the S2 pocket seems 
relatively large and offers sufficient space for optimisation of the AA1 to achieve optimal fit. 
The S’ side is free and offers the possibility for development of “double headed 
inhibitors”[72]. For example, a large aromatic group could be introduced to form π-π 
interactions with Trp296. Although this model might not reflect the real binding mode of 
epoxysuccinyl inhibitors, it clearly suggests that there is scope available for optimisation to 
reach higher potency.  
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Figure 8. 4: Fitting of E-64 in Cwp84 homology model, based on the crystal structure of a cathepsin C (1JQP) 
[288]. A) Surface view of the active centre. Catalytic triad is shown in purple, some specific side chain of amino 
acid presented for possible envolving in the binding are shown in blue.B) Overlay of Cwp84 model (green) and 
1JQP (purple) (RSMD = 3.459 (171 to 171 atoms). C) Overlay of Cwp84 model (green) and 2PRE (blue) (RSMD = 
2.647 (131 to 131 atoms). E-64 is presented as sticks, the warhead is labelled in red and the peptidyl moiety in 
gray. 
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8.1.4 Labelling effect 
Different types of probes were developed during this thesis. Two-step labelling using alkyne-
tagged probes was optimised and achieved a certain amount of success, considering that 
click ligation conditions tend to vary strongly between biological systems. However, the 
results were still bias, and in some cases not explainable at this stage (see section 4.4.3). The 
difficulties lay in the decision of whether a labelled band is real and related to the probe, 
and when it is just an effect of background labelling resulting from unspecific binding or 
endogenous biotinylated proteins. Further optimisation might lead to clearer and unbiased 
results, but this might require an extensive investment of time. 
To circumvent the above mentioned problem, direct label probes were generated. Single 
label probes such as biotinylated or fluorescent ABPs tended to provide more consistent 
results than dual-label probes. This observation could be a result of detrimental effects of 
significantly increasing the size and hydrophobicity of the probes. Although direct labelling 
was very clean and aided the identification of the target proteases in the S-layer fraction, 
the labelling of the cell/soluble fractions still contained too much background signal. It was 
very difficult to differentiate between background labelling and probe related labelling. 
Similar results were also found with alkyne-tagged probes, and there could be several 
reasons for this phenomenon.  
 Permeability of probes. Probes generated in this study possessing different size (e.g.: 
alkyne-tagged probes are small, whilst the dual label probes are very big) and groups 
that could potentially aid up-take (e.g.: biotin [112, 115]), the possibility that at least 
one of the probes can get inside the cell seems high. However, none of the probes 
provided concrete evidence of cell permeability. If the probe cannot penetrate inside 
the cell, intracellular probe-related labelling can be excluded.  
 Target specificity of the probes. Despite the high number of predicted proteases in C. 
difficile (see section 1.6.3), only two cysteine proteases were identified in the S-layer 
fraction. Either the probes designed in this study targeted very specifically the 
cysteine protease(s) involved in SlpA processing and not other cysteine proteases, or 
there are no other proteases assessable to the tested probes. In both cases, probe 
related labelling in the cell fraction can also be excluded. It should be noted that the 
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manner in which the proteomic experiments were conducted probably also led to 
bias, potentially missing other targets that were not included in the excised bands.  
 High degree of background. It has been observed that the reporter units give a high 
level of background signal, potentially from biotinylated proteins of the cell co-
visualised in the streptavidin blot or hydrophobic sticking of the TAMRA group to 
hydrophobic proteins causing fluorescent signals. Optimisation of washing 
conditions could minimise the problem, however, due to the small working volume 
of samples, intensive and harsh wash conditions might cause loss of sample material 
during each wash step. Finding optimal conditions is often non-trivial. 
To summarise, direct label probes were more useful in this particular study, however they 
also have some drawbacks and there is still scope to improve e.g.: reducing the size of the 
probes, optimising washing steps to reduce background signal, trying other reporters (e.g. 
other fluorescent groups) or introducing cleavable linkers for further investigation. It might 
be worth optimising click ligation in C. difficile, as this could be very useful in other 
applications to hunt for new targets. 
8.1.5 Proteomics 
Different proteomic techniques were used in this study, starting from classic MALDI-TOF to 
more modern LTQ-Orbitrap LC–MS/MS. As the primary interest of the study was the 
identification of the target protease, MALDI-TOF was the most simple and quickest method 
to access protein identification by PMF. In addition, this approach offers cost efficiency and 
flexibility by using in-house facilities. However, the data generated using MALDI-TOF were 
not very sensitive, less informative and not suitable for quantification analysis, whilst 
Orbitrap LC-MS/MS can overcome these limitations. With Orbitrap LC-MS/MS, the second 
protease (Cwp13) was revealed, whereas the MALDI-TOF only identified the presence of the 
cysteine protease Cwp84. Interest in quantitative analysis was evoked only later in the study 
by the desire to compare specific labelling of Cwp84 and Cwp13 between probes. Therefore, 
experimental design was not considered to cover quantification issues at the outset, such as 
adding standard peptide controls, producing biological and technical replicates, minimising 
variation through in-gel digestion, etc. Consequently, the data generated were very 
informative but insufficient for absolute quantification analysis (see section 6.8). Future 
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work could optimise the proteomic experiments by using on-bead digest rather than 
running SDS-PAGE and in-gel digestion to avoid missing target proteins either through 
absence in the excised bands or misbehaviour of proteins during SDS-PAGE, and introducing 
normalisation methods in each step to avoid variation in relative protein concentration. 
Despite imperfections in implementation, the primary objective of the study was fulfilled, 
revealing the identity of cysteine protease Cwp84, and a putative cysteine protease Cwp13.  
8.2 Impacts of this study on current understanding of C. difficile biology. 
Although ABPP has proven to be valuable for identifying new proteins and facilitating 
studies on a wide range of basic biological processes, it has primarily been used in 
eukaryotic systems. There are only a handful of examples demonstrating the application of 
ABPP in bacteria generally, and in pathogens specifically [448-449]. This is somewhat 
surprising, because many pathogens lack genetic tools or the necessary machinery for 
genetic manipulating, and have a complex biology (e.g. host pathogen interactions), which 
would make ABPP even more useful. On the other hand, application of ABPP on bacteria 
possessing advanced genetic tools such as E. coli is less unique due to the more convenient 
access to information via genetic experiments; however, in combination with genetics, ABPP 
can provide more striking insights into dynamic posttranslational phenomena than genetics 
alone.  
At the outset of this study, proteases involved in SlpA processing were unknown. The 
identification of the target protease, Cwp84, has resulted in the first reported successful 
application of ABPP in live C. difficile. This achievement offers an additional chemical tool to 
study this challenging pathogen and related bacteria with similar limitations. Recently, Puri 
et al. reported the use of ABPs to identifying inhibitors of C. difficile cysteine protease 
domain in the toxins, and intend to use these probes as tools for studying inactivation 
mechanism of these protease domains [450]. However, it should be noted that this work 
was applied to recombinant toxin, and not live bacteria.  
8.2.1 Cwp84 is the target protease responsible for SlpA internal cleavage 
In vitro protease activity of Cwp84 had been previously reported against extracellular matrix 
proteins but not S-layer processing [280]. After the identification of Cwp84 using different 
proteomic techniques, a series of subsequent experiments confirmed our revised functional 
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assignment of this protease. Firstly, the identification of Cwp84 coincides with the ABP 
labelling signal, and this result was consistent, no matter which types of probes or which 
type of proteomic techniques were used. Furthermore, similar labelling was found in 
multiple strains of C. difficile. Secondly, cwp84 locates in the same gene cluster as slpA and 
shows normal expression in the genetic analysis (see section 1.6.3.1). Thirdly, the knockout-
strain 630Δcwp84 suggested strongly that Cwp84 is responsible for SlpA cleavage due to the 
morphology change, the presence of only full-length SlpA and absence of its cleavage 
products in the S-layer [411], and this mutant was later generated for further experiments 
by Lucia de la Riva Perez (Fairweather and Tate, unpublished work). In addition, the 
presence of SlpA cleavage products was found only in mutant strains complemented with 
active Cwp84 (unpublished work of Dr. de la Riva Perez, ICL). Fourth, a reconstituted 
cleavage assay in E. coli provided further conclusive proof that Cwp84 is the only cysteine 
protease responsible for internal cleavage of SlpA into mature HMW- and LMW SLPs, at 
least under the conditions of laboratory culture used here [451]. Furthermore, this cleavage 
assay additionally confirmed aspects of the substrate specificity, which was in line with the 
SAR found in this study (see section 4.5).  
While the function of Cwp84 was confirmed, further properties of the protease were also 
revealed. Although a crystal structure of Cwp84 is not yet available, our SAR suggests that 
Cwp84 acts as a papain-like cysteine protease. Cys116 is essential for activity, as the 
mutation of this Cys residue to Ala led to inactivation of the protease [451].  
Several results suggested strongly that Cwp84 undergoes further (possibly autocatalytic) 
processing to form the active form (Figure 8. 5). The first observation was the ability of 
certain inhibitors such as EP-R-PEG3-Biotin to intercept the processing, apparently labelling 
both forms of the protease. In one of the ABP experiments (Figure 6. 8), only the upper 
band of Cwp84 was observed by EtEP-RK(Biotin)G-PEG3-TAMRA before pull-down, while the 
derivative containing tyrosine in the AA1 position labelled both apparent ‘forms’ of Cwp84, 
as confirmed by Western blot against Cwp84, but favouring the lower band. Furthermore, 
several Cwp84 bands appeared in the pull down, also supporting the hypothesis of (auto-) 
processing. 
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In parallel work in the Fairweather laboratory, two different bands of Cwp84 have been 
confirmed genetically with mutants over-expressing active Cwp84, whilst only one band was 
shown in mutants expressing inactive Cwp84 (unpublished work of Dr de la Riva Perez, ICL). 
In addition, degradation of this protease was observed in the culture supernatant. 
Interestingly, degradation tended to be stronger if the activity of Cwp84 was neutralised, as 
judged by the amount of degraded product in culture supernatant. However, the 
mechanism of (auto-) processing remains unclear as well as other components that may be 
involved in this maturation process. This offers a new direction for future study, especially if 
Cwp84 is considered to be a potentially useful therapeutic target. 
 
Figure 8. 5: A proposal for Cwp84 processing.  
8.2.2 Cwp13 and other cell wall proteins  
The discovery of the second putative cysteine protease, Cwp13, was perhaps surprising, and 
confirmed the sensitivity of the Orbitrap LC-MS/MS. Lying outside the SlpA locus at ca. 
1.2 Mb distance, Cwp13 was labelled by epoxysuccinyl ABPs, but does not seem to target 
SlpA as Cwp84 does. The results of section Cwp13 may be an off-target of epoxysuccinyl 
ABPs suggest that Cwp13 is a target for many epoxysuccinyl inhibitors/ABPs. Despite the 
tendency of greater enrichment of Cwp13 by ABPs in the knockout strain 630Δcwp84, 
Cwp13 was unable to complement Cwp84 function, as only SlpA was found in the S-layer 
fraction of 630Δcwp84(pCwp13) mutant, i.e. a mutant lacking cwp84 but over-expressing 
cwp13. Constitutive over-expression of the protein was achieved by placing the gene under 
the control of Pcwp2, a promoter responsible for constitutive expression of a cell wall protein 
in C. difficile [279] (unpublished work of Dr. Riva de la Perez, ICL). Apart from being 
identified as a cell wall protein containing a putative cysteine protease domain [452], no 
studies on Cwp13 are reported as yet. The function of Cwp13 remains to be elucidated, but 
its co-purification together with Cwp84 and the effect with ABPs possessing arginine at the 
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AA1 position (see next section) lead to speculation that Cwp13 may play a role in Cwp84 
maturing process.  
A number of other cell wall proteins were co-purified along with the two cysteine proteases 
(see section 6.2). Cwp6 is an interesting case, as it was identified at lower molecular weight 
range in the wild type strain, but at high molecular weight in the 630Δcwp84 strain. This 
might be related to a protein processing effect involving Cwp84, in which case unprocessed 
Cwp6 could be found at higher molecular weight regions in 630Δcwp84. Cwp6 shows distant 
homology to Cwp13, but its function remains unknown. This tendency was also found for 
Cwp66, suggesting that the co-purification of these proteins might be related to a complex 
formed with the labelled target proteases rather than non-specific binding to the beads. 
8.2.3 Epoxysuccinyl inhibitors/ABPs with Arg as AA1 is a special case 
A general SAR was developed for epoxysuccinyl inhibitors/ABPs providing better 
understanding of the mode of action of Cwp84 (see section 4.5). However, inhibitors/ABPs 
bearing arginine at the AA1 position (arginyl ABPs) did not fit in the observed SAR. For 
example, although the inhibitory activity of EP-R-PEG3-Biotin was better than that of EP-LR-
PEG3-Biotin, this compound seemed to label Cwp84 less efficiently (see section 6.4). Arginyl 
ABPs are also unique in provoking the Cwp84 “double band effect” clearly and reasonably 
consistently across many experiments. Both of these bands contain Cwp84 giving rise to the 
hypothesis of Cwp84 auto-processing. Naming the top band as a putative ‘stage one’ of 
Cwp84 processing and the bottom band ‘stage two’, a larger amount of Cwp84 was 
intercepted at stage two than at stage one by these ABPs. Furthermore, arginyl ABPs 
appeared to label significantly more Cwp13 than others ABPs judging by the proteomic 
experiments. However, it should be noted that the data are in most cases preliminary and 
require further reproduction. Unfortunately, an antibody against Cwp13 is not yet available, 
and quantitative proteomic analysis requires further optimisation. Making firm conclusions 
about the relationship between arginyl ABPs, Cwp84 and Cwp13 would therefore be 
premature at this point. 
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Figure 8. 6: Hypotheses on the role of Cwp13 and the interception of active enzymes by arginyl inhibitors/ABPs 
in the Cwp84 maturation process.  
8.2.4 Could Cwp84 be a potential therapeutic target for CDI treatment? 
Although the knockout strain 630Δcwp84 is very sick and difficult to culture, as well as very 
prone to lysis, it was reportedly able to cause CDI in a hamster model with similar pathology 
to the wild type strain [411]. Generally, animal models are used to mimic the pathological 
features and immunological responses observed in humans. However, different animal 
models have different specific features, particularly in the response to pathogens and 
toxins, leading to slightly varied results or sometimes to completely different results to 
those observed in humans. This is especially the case when comparing the survival time 
after infection for hamsters, which are extremely susceptible to C. difficile toxins and die 
after a few days to that of humans, who typically survive for many weeks, or can remain 
asymptomatic. Therefore, one cannot conclude that 630Δcwp84 will also induce CID in 
humans; testing of this strain in other animals less prone to the toxic effects of CDI is 
ongoing and may provide interesting results.  
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Targeting Cwp84 means targeting SlpA specifically or the S-layer in general. The question is 
what role does the S-layer play for C. difficile, particularly during infection? From an 
evolutionary perspective, the huge effort the bacteria make in synthesising an enormous 
number of SlpA molecules in each cell each second to build up the S-layer has to provide a 
payoff. Notably, the expression of SlpA and Cwp84 is up-regulated when the bacteria are 
under stress conditions such as antibiotic treatment [394], or Cwp84 inhibitor treatment 
(see section 4.3 and 6.4). Still, the question raised above remains open for future study, and 
therapeutic aspects of Cwp84 inhibition could be investigated through establishing a 
method of infection human enteric tissue cells with C. difficile to mimic the infection in real 
human body as closely as possible. The colonisation ability of 630Δcwp84 on human enteric 
tissue cell could then be compared with the wild type strain, as well as the wild type strain 
treated with inhibitors against Cwp84. 
8.2.5 Other potential targets in C. difficile 
Other targets in C. difficile might also be interesting in the battle against this bacterium, with 
the objective of finding new methods to cure CDI. It is fascinating that Z-Ala-CMK can 
prevent C. difficile from growing at early stage or at 10 μM, similar to the effective 
concentration of antibiotics such as chloramphenicol. This concentration is also much lower 
than that of the epoxysuccinyl inhibitors, and Z-Ala-CMK does not inhibit SlpA processing. 
Unfortunately, the conversion of this compound into an ABP failed in this study, but future 
studies could invent a more effective synthesis for CMK probes (see suggestions in section 
7.6) and open up new applications for ABPP in hunting down the next potential targets in C. 
difficile.  
  
207 
 
 
 
 
 
  
Chapter 9 Materials and methods 
 
This chapter provides details about materials and methods including the characterisation of 
the inhibitors synthesised in this study. It is divided in three parts : 
 Microbiology 
 Proteomics 
 Chemistry 
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9.1 Microbiology 
9.1.1 Buffers  
Name of buffer Components in buffer 
Running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS 
Sample loading buffer 45 mM Tris-Cl pH 6.8, 0.7% SDS, 0.7 mg/mL sucrose, 3.5% β-
mercaptoethanol, 0.01 mM bromophenol blue 
NuPAGE® MES SDS 
running buffer 
Tris, SDS, 4-morpholinoethane sulfonic acid 
NuPAGE® LDS 4x sample 
loading buffer 
141 mM Tris base, 2% LDS, 10% glycerol, 0.51 mM EDTA, 
0.22 mM SERVA Blue G250, 0.175 mM Phenol Red, pH 8.5 
Staining buffer 45% methanol, 10% glacial acetic acid, 1 mg/mL Coomassie blue 
Destaining buffer 45% methanol, 10% glacial acetic acid 
Transfer buffer 25 mM Tris, 192 mM glycine, 20% methanol 
10 × PBS 2 g KCl, 80 g NaCl, 17.8 g Na2HPO4(2H2O) and 2.4 g KH2PO4 in 
800 mL dH2O 
1 × PBS or PBS 100 mL of 10 × PBS in 900 mL dH2O 
FPLC wash buffer 50 mM NaH2PO4, 300 mM NaCl pH 7.8, 20 mM imidazole 
FPLC elution buffer 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole 
Ambic buffer  50 mM NH4HCO3 pH 8.4 
CHCA solution 20 mM α-cyano-4-hydroxycinnamic acid in 70% ACN, 0.1% TFA 
(v/v) 
BCA reagent A sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1 M sodium hydroxide 
BCA reagent B 4% cupric sulphate 
Table 9. 1: Buffers used in this study. 
9.1.2 Bacteria strains and culture conditions 
C. difficile strains  
C. difficile 630 [453] and the erythromycin sensitive derivative of 630 (630Δerm) [454] were 
provided by Dr Peter Mullany, Eastman Dental Institute, London, and has been fully 
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sequenced by the Wellcome Trust Sanger Institute [277]. CD1, CD17[455], and Y [456] were 
obtained from St. Bartholomew’s Hospital, London. CD167 and CD959 are clinical isolates 
that were provided by Professor C. P. Kelly, Harvard Medical School, Boston, USA. CD167 
was isolated from a patient with a single episode of diarrhoea that responded well to 
metronidazole treatment; CD959 was obtained from an asymptomatic carrier. SE528 is a 
toxin negative strain and was provided by Professor Michel Demee, Université Catholique 
de Louvain, Brussels, Belgium. R13549, R13540, R13699 were obtained from Dr Deirdre Ni 
Eidhin, Univeristy of Limerick, Limerick, IRELAND. 630Δcwp84, 630Δcwp84(pCwp84+) and 
630Δcwp84(pCwp84C116A) were generated by Dr. Lucia de la Riva Perez, ICL, UK (Table 9. 2). 
C. difficile culture conditions  
C. difficile was routinely cultured either on blood agar base II (Oxoid Ltd, Basingstoke, UK) 
supplemented with 7% horse blood (TCS Biosciences, Botolph Claydon, UK); or in brain-
heart infusion (BHI) broth (Oxoid). Culture was undertaken in an anaerobic cabinet (Don 
Whitley Scientific, Shipley, UK) at 37 °C in a reducing anaerobic atmosphere (10% CO2, 10% 
H2, 80% N2).  
To obtain cells during exponential phase, an overnight (ca. 16-18 h) liquid culture was 
inoculated 1:20 v/v into BHI that had been pre-equilibrated (at least 2 h) to the temperature 
and atmosphere of the anaerobic cabinet, and the culture was shaken vigorously for 15 sec 
to mix thoroughly. During growth, the culture liquid was agitated gently using the shaker at 
200 rpm to allow evenly growth. In order to monitor the growth of C. difficile, the OD600 of a 
sample was determined using either a Spectronic™ Heλios™ ε spectrometer (Thermo 
Scientific, Waltham, MA) or a WPA biowave CD8000 cell density meter (Isogen Life Science, 
UK).  
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Strain name 
Alternative 
names 
Toxin status Ribotypea Serotypeb Source 
630*  A+ B+ CDT - 012 C P. Mullany, UCL, UK 
CDKK167 CD167 A+ B+ CDT - 016 nk C. Kelly, Boston, USA 
CDKK959 CD959 A+ B+ CDT - 053 K C. Kelly, Boston, USA 
Y Y A- B- CDT - 010 nk P. Mullany, UCL, UK 
R8366 CD1 A+ B+ CDT - 001 G S. Ward, London, UK 
R7404 CD17 A- B+ CDT - 017 F S. Ward, London, UK 
SE528  A- B-  nk C 
M. Delmee, Brussels, 
Belgium 
R13549  A+ B+  002 A2 D. Eidhin, Dublin, Ireland 
R13540  A+ B+  078 nk D. Eidhin, Dublin, Ireland 
R13699  A- B-  066 A9 D. Eidhin, Dublin, Ireland 
630Δerm  A+ B+ CDT - 012 C P. Mullany, UCL, UK 
630Δcwp84  A+ B+ CDT - 012 C L. de la Riva Perez, ICL,UK 
630Δcwp84 
(pCwp84+) 
 A+ B+ CDT - 012 C L. de la Riva Perez, ICL,UK 
630Δcwp84 
(pCwp84C116A) 
 A+ B+ CDT - 012 C L. de la Riva Perez, ICL,UK 
Table 9. 2: Table of C. difficile strains used in this study.  
The table presents known characteristics of C. difficile strains used in this study. The data in italics is predicted 
from the known characteristics of the ribotype. 
a
 as determined by the method of Stubbs [455] 
b
 according to 
Delmee [457-458]; nk, not known. * genome sequence is available.  
9.1.3 SDS-PAGE  
Glycine-Tris gels: 
Standard glycine-Tris gels at 10% or 12% acrylamide were prepared using mini-protean kits 
(Bio-Rad Laboratories). The separating gel (10 or 12% 39:1 acrylamide: bisacrylamide, 
375 mM Tris pH 8.8, 0.1% SDS, 0.5% APS, 0.07% TEMED) was poured and ethanol carefully 
layered on top. Once the gel was set, the ethanol was discarded and the stacking gel (5% 
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39:1 acrylamide:bisacrylamide, 62.5 mM Tris pH 6.8, 0.1% SDS, 0.1% APS, 0.24% TEMED) 
was poured and the comb put in place to form the wells.  
Once set, the comb was removed and the gel was immersed in the running buffer. Protein 
samples were diluted in sample loading buffer. These, along with a 10 μL aliquot of Broad 
Range Protein Marker (NEB), and a 3.5 µL aliquot of biotinylated protein ladder (Cell 
Signalling Technology) were heated to 100 °C for 5 minutes. Samples were loaded into the 
wells of the gel and a constant voltage of 200 V applied for 40 minutes.  
Bis-Tris gels:  
Bis-Tris gels at 12% acrylamide were prepared using mini-protean kits (Bio-Rad 
Laboratories). The separating gel (4 mL 30% acrylamide, 2.9 mL Bis-tris (1.25 M, pH 6.7), 
3 mL dH2O, 0.1 mL 10% w/v ammonium persulfate and 4 μL TEMED) was poured and 
ethanol carefully layered on top. Once the gel was set, the ethanol was discarded and the 
stacking gel (0.333 mL 30% acrylamide, 0.741 mL Bis-tris (1.25 M, pH 6.7), 1.453 mL dH2O, 
0.0125 mL 10% w/v ammonium persulfate and 2 μL TEMED) was poured and the comb put 
in place to form the wells.  
Once set, the comb was removed and the gel was immersed in NuPAGE® MES SDS running 
buffer from Invitrogen. Protein samples were diluted in NuPAGE® LDS 4x sample loading 
buffer containing 16% 2-mercaptoethanol and were heated to 100 °C for 5 minutes. These, 
along with a 10 μL aliquot of Broad Range Protein Marker (NEB), a 3.5 µL aliquot of 
biotinylated protein ladder (Cell Signalling Technology), and a 2.5 µL aliquot of Amersham 
ECL Plex™ Fluorescent Rainbow Markers were used where appropriate to allow molecular 
weight comparison. Samples were loaded into the wells of the gel and a constant voltage of 
200 V applied for 40 minutes.  
Visualisation 
For general visualisation of proteins, gels were stained in Coomassie blue staining buffer for 
4–16 hours, followed by destaining using destaining buffer. Gels were image scanned and 
then rehydrated in 10% glycerol and dried between two cellulose membranes. Alternatively, 
gels were transferred to PVDF membrane for immunoblotting.  
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In-gel fluorescence visualisation was applied with Bis-Tris gels. Generally gels were soaked in 
water for 5 min and visualisation was carried out using an Ettan™ D GE  mager (Amersham 
Biosciences, Cy3 channel used to detect TAMRA-labelled proteins) and results analysed with 
 mageQuant™ TL software. 
9.1.4 Western immunoblotting  
SDS-polyacrylamide gels were transferred to Trans-blot™ transfer medium (Bio-Rad 
Laboratories) PVDF membrane using a semi-dry protocol. The membrane was prepared for 
transfer by incubation sequentially in methanol (1-2 sec), H20 (1-2 min) and finally in 
transfer buffer (2 min). It is important to keep the membrane wet at all times; if it dries out, 
the transfer can be adversely affected. Gel and filter paper were pre-soaked in transfer 
buffer. Filter paper, membrane and gel were stacked in the Trans-blot™ SD semi-dry 
transfer cell (Bio-Rad) as a sandwich in the following order: filter paper-membrane-gel-filter 
paper. The transfer was performed at 15 V for 15 minutes.  
After transfer, the membrane was soaked in methanol (5 mL) and dried for 20 minutes, 
which avoids the additional blocking step typically required for minimising non-specific 
binding or back ground signal. The membrane was incubated with primary antibody diluted 
to the specified ratio v/v (Table 9. 3) in 10 mL PBS-T +3% (w/v) non-fat powdered milk for at 
least 1 hour with gentle rocking. After three washes in 10 mL PBS-T, secondary antibody 
diluted to the specified ratio v/v (Table 9. 3) in 10 mL PBS-T + 3% (w/v) non-fat powdered 
milk was added and the membrane rocked gently for at least 30 minutes. The membrane 
was washed three times in PBS-T. Signal was detected using ECL reagents (Amersham 
Biosciences) or SuperSignal®
 
West Pico Chemiluminescent Substrate (Pierce) followed by 
image capture using a LAS-3000 Image Reader (Fujifilm), with appropriate sizing carried out 
using Microsoft Office PowerPoint 2007. 
9.1.5 NeutrAvidinTM–HRP immunoblotting 
SDS-polyacrylamide gels were transferred using the method describe above, and the 
membranes were blocked for 1 hour in 10 mL PBS-T containing 5% BSA (w/v) before 
washing for 3 × 10 min in 10 mL PBS-T. The blots were probed using NeutrAvidinTM-HRP at 
1:5000 dilution in 10 mL PBS-T for 1 hour at room temperature. The membranes were then 
washed with 10 mL PBS-T for 3 × 5 min before detection as described above. 
213 
 
 
Antibody Species 
Conjugate  
or Label 
Specificity 
Antigen 
Purification 
Source 
Dilutions 
used: 
α-Cwp84 mouse none Cd79685 Cwp84 
Ni-Affinity 
Purification 
This study 1/4000 
α-HMW-SLP Rabbit none 630 HMW SLP 
Ni-Affinity 
Purification 
E. Calabi, Fairweather 
laboratory 
1/200,000 
α-LMW-SLP Rabbit none 630 LMW SLP 
Ni-Affinity 
Purification 
R. Fagan, Fairweather 
laboratory 
1/200,000 
α-Cwp66 mouse none 630 Cwp66 
Ni-Affinity 
Purification 
J. Emerson, 
Fairweather laboratory 
1/20,000 
α-Cwp2 mouse none 630 Cwp2 
Ni-Affinity 
Purification 
J. Emerson, 
Fairweather laboratory 
1/50,000 
α-rabbit-HRP goat horse radish peroxidase 
rabbit 
immunoglobulins 
Commercial Dako Cytomation 1/2000 
α-mouse-HRP goat horse radish peroxidase 
mouse 
immunoglobulins 
Commercial Sigma Adrich 1/2000 
NeutrAvidinTM-HRP (synthetic) horse radish peroxidase biotin Commercial Sigma Aldrich 1/5000 
Table 9. 3: Primary and secondary antibodies and immune sera used in this study, including the species in which they were raised, and the antigen against which they were 
raised. The antibody dilution used in Western blotting is also given. 
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9.1.6 Cell fractionation 
Glycine extraction of SLPs 
Standard SLP extraction was performed essentially as previously described in Dubreuil et al. 
[459]. C. difficile bacteria from a 16–18 hour culture in BHI were harvested by centrifugation 
(15 min at 3,500 × g) and resuspended in 0.04 volumes (relative to culture volume) of 0.2 M 
glycine-HCl pH 2.2. After rotating incubation for 30 min at room temperature, the mixture 
was centrifuged to remove bacteria (5 min at 10,000 × g) and the supernatant neutralised 
by adding 2 M Tris portion-wise (5 μL at a time) until the desired pH was obtained 
(monitoring the pH with pH strips (Whatman). 
Preparations of soluble and insoluble fractions 
After removing the SLPs, the pellet was washed two times with PBS and resuspended in 
1 mL PBS supplemented with 30 µL of a 50 mg/mL solution of lysozyme in water. The 
suspension was incubated for 20 minutes at room temperature, and the cells were then 
sonicated (Sonoplus sonicator, Bandelin) on ice for 4 minutes in pulses of 10 s on, 10 s off. 
After centrifugation at 17,900 × g at 4 °C for 20 minutes the supernatant was separated as 
the soluble fraction. The pellet was resuspended in 100 µL of 10% SDS solution; this was 
defined as the insoluble fraction.  
Preparations of only soluble fraction using glass bead lysis 
After removing the SLPs, the pellet was washed two times with PBS and resuspended in 
1 mL PBS and 30 µL of a 50 mg/mL solution of lysozyme in water. The suspension was 
incubated for 20 minutes at room temperature and then added to a vial containing ca. 
0.5 mL of 150-212 μm diameter glass beads (Sigma). The sample and the glass beads were 
vigorously agitated in a closed vial in a BIO101 Fast Prep FP120 bead beater (BIO101 Savant) 
at setting 6 for 45 s to lyse the cells. The supernatant was separated as the soluble fraction. 
The glass beads were subsequently washed with 200 μL PBS. Wash supernatant was 
removed using centrifugation at 14000 rpm for 2 min and combined with the soluble 
fraction.  
9.1.7 CuAAC ligation  
CuAAC reagents were prepared and stored as stocks in DMSO or water (Table 9. 4). The 
reagents were premixed in the given order as shown in Table 3 from top to bottom. CuAAC 
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ligation was carried out on protein fractions (e.g.: glycine extraction, soluble fraction) by 
vortexing the sample for 1 hour (unless otherwise specified) at RT and then quenched by the 
addition of at least 10 volumes of ice-cold MeOH. Samples were left at -80°C overnight for 
precipitation and then protein pelleted by centrifugation at 13300 rpm for 20 min and at 
4°C. Pellets were washed with another ~0.5 mL ice-cold MeOH and pelleted once more, 
then air-dried for ~15 min. Protein was resuspended in buffer (usually 4 % SDS in PBS). 
Reagents  Concentration of stock  Typical final concentration 
Capture reagents  10 mM in DMSO  50 μM 
CuSO4  40 mM in dH2O  1 mM 
TCEP  50 mM in dH2O  1 mM 
TBTA  10 mM in DMSO  100 μM 
Table 9. 4: Reagents and their stock concentration using for click ligation. 
9.1.8 Enrichment of captured proteins 
Using NeutrAvidin™ agarose beads 
Typically, 30 μL NeutrAvidin™ agarose beads (supplied as a 50% slurry from Thermo 
Scientific) were added to the bacterial sample fraction (starting from a 5 mL culture) 
containing the captured proteins and incubated with rotation for 2 hours at 4 °C. The beads 
were then pelleted and the supernatant removed, followed by washing of the beads 3 times 
with PBS. Then the beads were boiled in ca. 20 μL sample loading buffer for 10 min for 
subsequent SDS-PAGE analysis.   
Using Dynabeads® MyOne™ Streptavidin C1 
Typically, 20 μL Dynabeads® MyOne™ Streptavidin C1 (10 mg/mL suspension from 
Invitrogen) were added to the bacterial sample fraction (starting from a 5 mL culture) 
containing the captured proteins and incubated with rotation for 2 hours at 4 °C. The 
supernatant was removed, followed by washing of the beads 3 times with PBS (unless 
otherwise specified). Then the beads were boiled in ~20 μL sample loading buffer for 10 min 
for subsequent SDS-PAGE analysis.   
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9.1.9 Expression and purification of recombinant protein  
E. coli strains used in this study 
Protein expression was carried out in Rosetta™ (Novagen) cells. Rosetta™ are BL21(DE3) 
cells carrying a plasmid encoding tRNAs specific to codons that are rare in E. coli but 
common in other organisms. Genotype: F- ompT hsdSB (rB
-, mB
-) gal dcm (DE3) pRARE (CmR). 
Plasmid purification 
Plasmids were purified using QIAprep miniprep kit (Qiagen), following the procedure 
recommended by the manufacturer. The Qiaprep column was transferred to a fresh 1.5 mL 
microfuge tube and 50 µL of dH2O or buffer EB (elution buffer; 10 mM Tris-Cl, pH 8.5) was 
added to the centre of the QIAprep membrane and incubated at room temperature for 
1 minute. The column was centrifuged for 1 minute at 17,900 × g to elute the DNA into the 
microfuge tube. Purified plasmid DNA was then stored at –20 °C. 
Plasmid DNA sequencing  
30 µL of a plasmid after purification was subjected to sequencing at GATC, Germany, where 
the samples were subjected to dideoxy chain terminator DNA sequencing using BigDye™ 
technology.  
E. coli heat-shock transformation 
A 100 µL aliquot of CaCl2 competent E. coli Rosetta cells in a 1.5 mL microfuge tube was 
thawed on ice. 2 µL of p-DNA purified as described above was added, and the cells chilled 
on ice for 15 minutes. The mixture was heat-shocked at 42 °C for 30 seconds and then 
chilled on ice for 1 minute. To the cells, 250 µL of S.O.C medium (Invitrogen, Paisley, UK) 
was added and the mixture incubated at 37 °C for 1 hour. The culture was then plated on LB 
agar plates containing kanamycin and chloramphenicol antibiotic to facilitate the selection 
of transformants. 
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Figure 9. 1: The pET-28a (+) plasmid vector. A) The circular vector map of the pET-28a (+) plasmid is shown; the 
HC DNA sequence is cloned between Bam HI and Nde I. The plasmid is 5369 bp in size (6695 bp with HC 
sequence) and contains a kanamycin (Km) resistance gene for selection. The plasmid also contains the gene for 
the lac repressor (lac I) preventing expression of the HC DNA until induced. Panel B) shows in more detail the 
multiple cloning site and the red arrows indicate the location of the HC DNA sequence. Images from the 
Novagen catalogue (Novagen, TB074 12/98, Cat. No. 69337-3). 
A) 
 
 
 
 
 
 
 
 
 
B) 
HC cloned here 
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Growth and induction 
Overnight cultures of E. coli Rosetta/pEt orf 4H-1, kindly donated by Neil Fairweather’s 
laboratory, ICL, UK, harbouring plasmids based on the pET vector system (Figure 9. 1) were 
used to inoculate LB (CM and KM 50 µgmL-1). Cultures were incubated at 37 °C on a shaking 
incubator until the OD600 was 0.3–0.6. A 1 mL sample was taken, pelleted and stored at 
-20 °C. Expression of the cloned genes was chemically induced to alleviate repression by the 
lac repressor using 0.1–0.2 mM isopropyl--D-thiogalactoside (IPTG). Protein over-
expression was induced by the addition of IPTG at the appropriate concentration 
(37 °C/30 °C). The culture was incubated for a further 3–4 hours, and the bacterial cells 
pelleted by centrifugation at 16,700 × g for 15 min. Bacterial cell pellets were stored at 
-20 °C. Samples of culture were taken prior to and after IPTG induction and SDS-PAGE was 
used to compare the protein content of these samples prior to protein purification. 
Affinity purification of Cwp84 
The Cwp84 mutant protein has a 6 × His affinity tag at the N-terminus and was therefore 
purified by nickel affinity chromatography. 
E. coli Rosetta/pEt orf 4H1 carrying the Cwp84 mutant plasmid was grown in 5 mL Overnight 
ExpressTM Instant TB medium containing 50 g mL-1 of kanamycin and 50 g mL-1 
chloramphenicol overnight at 37 °C. The 5 mL culture was pelleted by centrifugation at 
5000 × g for 15 minutes and the supernatant discarded. The bacterial pellet was then stored 
at -20 °C.   
The bacterial pellet from the 5 mL cultures was defrosted and was resuspended in 500 µL of 
PBS, with 10% of 10 × BugBuster Protein Extraction Reagent (Novagen) as well as 5 µL 
lysozyme (50 mg/mL stock) and 5 µL DNase  (50 mg/mL stock) added to a final 
concentration of 1 mg mL-1. The lysed cell pellet was centrifuged for 20 minutes at 
17,000 × g, 4 °C and the supernatant containing the soluble protein was removed. The pellet 
was resuspended in 100 µL of PBS, with 10% of 10 × BugBuster solution. After vortexing to 
obtain an even suspension, 600 µL 0.1 × BugBuster solution was added and the suspension 
was centrifuged at 5000 × g, 4 °C. The supernatant containing the soluble protein was 
removed, and the pellet was washed three times by resuspending in 50 µL of 
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0.1 × BugBuster solution, centrifuging at 5000 × g, 4 °C, for 15 minutes. Finally, the pellet 
was resuspended in 1 mL of FPLC wash buffer, incubated for 1 hour at room temperature 
and diluted to 3 mL in a syringe ready for purification by FPLC with an affinity 
chromatography Ni-NTA agarose column (Qiagen). The column was then washed with 5 
column volumes of FPLC wash buffer. Wash fractions were monitored at A280 to determine 
the contamination level of other proteins. Finally His-tagged recombinant protein was 
eluted and collected as fractions with 5 column volumes of FPLC elution buffer. A280nm was 
used to monitor elution and if necessary more elution buffer was added to elute all protein 
from the column. Estimation of protein purity was based on the stained SDS-PAGE gel 
containing fractions of interest. The pure protein fractions were combined and dialysed at 
4 °C. Slide-A Lyzer Dialysis Cassette (Thermo Scientific) with a 10 kDa molecular weight cut-
off limit and 3 mL sample volume were used and three changes of the dialysis buffer (2 L of 
1 × PBS) were made. The protein was then aliquoted (150 μL/aliquot) and stored at –70 °C. 
Concentration of Cwp84 proteins 
Proteins were concentrated using ultrafree 0.5 mL centrifugal filter devices (Millipore) with 
a 10 kDa molecular weight cut-off limit. The membrane in the centrifugal device allows the 
passage of the solvent but retains molecules larger than 10 kDa. The separation membrane 
was first pre-rinsed; 0.5 mL of dH2O was added to the filter device and centrifuged for 
5 minutes at 3,264 × g. The flow through was discarded and the protein solution added. The 
filter device was centrifuged at 3,264 × g until most of the solution had flowed through. 
Additional protein solution was added and repeated rounds of centrifugation and protein 
addition were carried out until an appropriate protein concentration (judged by volume 
change) was achieved. At this point the concentrated protein was removed for 
concentration determination.  
Determination of protein concentrations 
The absorbance maximum of the samples were determined at 280 nm (A279 – A350) using a 
Perkin-Elmer Lambda 800 UV-Vis spectrophotometer. The protein concentrations were 
calculated using theoretically determined extinction coefficients (determined from amino 
acid content). Solutions of 0.5 mL were scanned in 1 cm path length quartz cuvettes from 
500 nm to 240 nm. Because the protein concentrations determined by BCA assay (see 
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below) and by absorbance using the theoretical and calculated extinction coefficients (from 
amino acid content) agreed reasonably well, the theoretical extinction coefficients were 
used for the purposes of the optical spectroscopy. Samples of approximately 2 mg ml-1 were 
diluted to an A280nm of approximately 1.0, and the concentrations were determined for these 
solutions. 
BCA protein concentration assay 
The Pierce BCA assay was used according to the manufacturer’s guidelines. This system 
relies on the fact that Cu2+ ions are reduced to Cu+ by protein in an alkaline environment, 
and reduction is proportional to protein concentration. Bicinchoninic acid (BCA) detects Cu+ 
ions by chelating them to form a soluble complex (purple) with a strong absorbance at 
562 nm (A562). Because this assay is reliant on a colour reaction proportional to the number 
of exposed peptide bonds (which will be different for different proteins), the standard 
protein used should ideally be a known concentration of the same protein. However, a 
known concentration of the protein may be unavailable and bovine serum albumin (BSA) is 
commonly used instead. A series of seven concentrations of BSA were made starting at 
1 mg mL-1 (made from a 2 mg mL-1 stock solution), doubling the dilution at each step. 20 L 
of each standard solution was added to a 96 well micro-titre plate in triplicate. Test proteins 
were diluted (1:5, 1:10, 1:15 or 1:20) and 20 L of each sample was added to the plate in 
duplicate. Pierce working reagent (WR) was made up in a 50:1 ratio of BCA reagent A: BCA 
reagent B and 180 µL of this mixture were added to each sample well and the plate 
incubated for 30 min covered in Clingfilm at 37 °C. Absorbance was measured on a plate 
reader at 595 nm and the averaged, reference corrected standards used to plot a protein 
concentration standard curve, allowing unknown concentrations of protein to be calculated. 
9.1.10 Antibiotic inhibition using Etest 
The minimum inhibitory concentrations (MICs) of chloramphenicol, clindamycin, 
erythromycin, metronidazole, moxifloxacin and tetracycline were determined using Etest 
strips (Biomérieux, Marcy l'Etoile, France). 150 µL of an overnight C. difficile culture in BHI at 
OD 0.7 (equivalent to no. 3 McFarland standard) was spread evenly onto the surface of a 
BHI agar plate and was then dried openly in the anaerobic cabinet for 5 minutes. Etest strips 
221 
 
were placed onto the agar surface. Agar plates were incubated for 24 hours and MICs were 
determined following the manufacturer’s instructions.  
9.2 Proteomics 
9.2.1 Proteomics using Imperial College facilities 
Gel Preparation 
Protein sample was separated using SDS-PAGE. The gel was stained with coomassie stain 
and the bands of interest were excised. 200 µL of ambic buffer and 200 µL acetonitrile (ACN) 
were added to the excised gel pieces and incubated at RT (ca. 25 °C) for 5 min. The mixture 
including gel pieces was mixed well in order to disperse the stain at the bottom of the 
Eppendorf tube and the supernatant carefully removed followed by drying the gel pieces on 
SpeedVac.  
Reduction/carboxymethylation 
Gel pieces were swelled in 200 μL solution of 10 mM dithiothreitol (DTT) in ambic buffer and 
incubated at 56 °C for 30 min. After removing the DTT solution, gel pieces were washed 
briefly with 200 μL ACN and dried on SpeedVac. Gel pieces were then re-swelled in 200 µL 
55 mM iodoacetic acid dissolved in ambic buffer and incubated at RT for 30 min in the dark. 
The iodoacetic acid solution was removed and gel pieces were washed with 500 µL ambic 
buffer for 15 min. The supernatant was removed by pipette and discarded followed by 
addition of 200 µL ACN. After 5 min ACN was removed and gel pieces were dried by 
SpeedVac. 
Tryptic digestion 
Gel pieces were re-swelled in 20 µL sequencing grade modified trypsin solution (Promega 
cat V5111; 0.5 µg trypsin in 195 µL ambic buffer) and incubated at RT for 15 min. Further 
ambic buffer was added to cover gel pieces and the digestion was allowed to proceeded 
overnight in a water bath at 37 °C . 
Elution of peptides from the gel pieces 
The supernatant containing hydrophilic peptides was removed from the gel pieces, and 
placed in a clean, labelled 1.5 mL Eppendorf tube. 50 µL 0.1% TFA was added to each gel 
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piece (to halt digestion) and incubated at 37 °C for 10 min. Afterwards 100 µL ACN was 
added and incubated further at 37 °C for 15 min. The supernatant was removed and pooled 
with the hydrophilic peptide solution. These procedures (adding ACN) were repeated once 
before reducing the volume to 10-30 µL by SpeedVac. 
MALDI-TOF Tandem Mass Spectrometric Analysis 
The eluent was mixed 1:1 with CHCA solution (Agilent) and spotted on the MALDI target. 
Peptides were identified by matrix-assisted laser desorption ionisation time-of-flight 
(MALDI-TOF) mass spectrometry on a 4800 MALDI tandem time-of-flight mass spectrometer 
(Applied Biosystems). Briefly, peptide mass fingerprints were acquired with 1000 shots in 
reflector positive mode from m/z 800–4000. Numerous peptide m/z signals were identified 
and MS peak masses were compared with the peptide fingerprint database by Mascot 2.1 
(Matrix Science) using Global Proteomics Sever 3.1 (Applied Biosystems).  
9.2.2 Proteomics using the facilities of the Proteomics Centre of the University of 
Leicester  
Sample processing 
Protein sample was separated using SDS-PAGE. The gel was stained with Coomassie stain 
and the band contained the interested protein will be cut out in pieces. Gel pieces were 
covered in 100 µL of ambic buffer and were frozen with liquid nitrogen. Samples were sent 
to University of Leicester and were processed by Dr Andrew Bottrill as follows: after 
digestion with trypsin the samples were spun-down and the supernatant (containing 
peptides) was removed. The gel pieces were extracted with acetonitrile for 30 min and this 
was then added to the supernatant. The combined sample was evaporated in a SpeedVac 
until dry. Each sample was resuspended in 20 µL of 0.1% trifluoroacetic acid containing 
10 fmol/µL of a standard protein digest (ADH—Alcohol dehydrogenase from yeast—Uniprot 
P00330). 6 µL of this sample was put into a vial for each replicate and 5 µL was injected for 
LC-MS/MS analysis. Thus each replicate consisted of 25% of the sample and contained 
50 fmol of the ADH standard. Mass spectra were analysed using Scaffold. 
Database searching 
Tandem mass spectra were extracted. Charge state deconvolution and deisotoping were not 
performed. All MS/MS samples were analysed using Mascot (Matrix Science, London, UK; 
223 
 
version Mascot). Mascot was set up to search the Trembl_39.6 database (selected for 
Clostridium difficile, 3896 entries) assuming the digestion enzyme trypsin. Mascot was 
searched with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 
5.0 PPM. Oxidation of methionine, iodoacetamide derivative of cysteine and inhibitors (e.g.: 
EtEP-R-PEG3-Biotin) of cysteine were specified in Mascot as variable modifications.  
Criteria for protein identification 
Scaffold (version Scaffold_2_06_02, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability as specified by the 
Peptide Prophet algorithm [408]. Protein identifications were accepted if they could be 
established at greater than 95.0% probability and contained at least two identified peptides. 
Protein probabilities were assigned by the Protein Prophet algorithm [460]. Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis alone 
were grouped to satisfy the principles of parsimony. 
9.3 Chemistry 
9.3.1 Reagents and Equipment 
All general laboratory chemicals obtained from chemical suppliers (Novabiochem UK or 
Aldrich Chemical Co.) were used without further purification.  
Flash chromatography was performed on Screening Devices silica gel 60 (0.04–0.063 mm). 
TLC-analysis was conducted on DC-alufolien (Merck, Kieselgel60, F254) with detection by 
UV-absorption (254 nm).  
1H and 13C NMR spectra were recorded on a Brüker AV-400 (400/100 MHz) spectrometer. 
Chemical shifts (δ) are given in ppm relative to tetramethylsilane and chloroform, H2O or 
DMSO residual solvent peak was used as internal standard. Coupling constants are given in 
Hz.  
Optical rotations were measured at 25 °C on a Perkin-Elmer 241 polarimeter with sodium 
lamp, and are given in 10−1 deg cm2 g−1; concentration (c) is in g per 100 mL. 
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Infrared spectra were obtained on PerkinElmer Spectrum 100 FT-IR spectrophotometer, 
from a thin film deposited onto a sodium chloride plate from dichloromethane. The IR 
spectra were then analyzed with Spectrum Express, Version 1.01.00 (PerkinElmer).  
Mass spectra and accurate mass data were obtained on an AUTOSPEC P673 spectrometer 
by J. Barton at the Chemistry Department Mass Spectrometry Service (Imperial College 
London) by electrospray ionisation or chemical ionisation techniques.  
Solid Phase Resins: Rink-amide resin and Biotin-PEG-Novatag resin were purchased from 
Novabiochem UK. The resin substitution ratios were as follows: Rink-amide resin: 
0.71 mmol/g; Biotin-PEG-Novatag resin: 0.48 mmol/g; Universal-PEG-Novatag resin: 
0.33 mmol/g. 
Amino Acids: N-α-9-Fluorenylmethoxycarbonyl (N-α-Fmoc) protected amino acids were 
obtained from Novabiochem UK with the following side chain protecting groups: Arg(Pbf), 
Lys(Boc), Tyr(tBu) , Thr(tBu), Glu(tBu), Ser(tBu). 
Reagents: Peptide synthesis grade dimethylformamide (DMF) was purchased from National 
Diagnostics, UK. Benzotriazole-1-yloxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
(PyBop), N-hydroxybenzotriazole (HOBt), diisopropylethylamine (DIPEA) and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) were 
purchased from Novabiochem UK and Sigma Aldrich. Dry tetrahydrofuran (THF) and DMF, 
chloroform, dimethylsulfoxide (DMSO), dichloromethane (DCM), methanol, piperidine, 
thioanisole, tbutylmethylether (TBME), trifluoroacetic acid (TFA), ethanedithiol (EDT), 
iodoacetonitrile, 3-mercaptoethyl propionate, sodium thiophenolate, monobasic and 
dibasic sodium phosphate, trimethylsilylisopropane (TIPS) were regent grade from Sigma 
Aldrich. A ‘deprotection mixture’ of TFA–H2O–TIPS (97:2.5:1) was used for cleavage and 
deprotection reactions. 
9.3.2 General procedures 
Solid Phase Peptide Synthesis (SPPS) 
Automated solid phase synthesis was performed using an Advanced ChemTech Apex 396 
multiple peptide synthesizer (Advanced ChemTech Europe, Cambridge, UK). Peptide 
synthesis was carried out in peptide synthesis grade DMF. Resin (25 μmol per well) was 
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swelled in DMF for 60 min before coupling each cycle, N-α-amino Fmoc group was treated 
with 20% (v/v) piperidine in DMF for 15 min, with two further repetitions. A fivefold excess 
of amino acid over resin reactive groups (125 μmol, 250 μL of 0.5 M solution) was used for 
each coupling. In situ activation and coupling was carried out for 45 min with a mixture of 
HBTU/HOBt (125 μmol, 250 μL of 0.5 M solution) and DIPEA (125 μmol, 250 μL of 0.5 M 
solution). The peptide was washed with DMF (3 × 1 mL) between each deprotection and 
coupling step. A typical cycle consisted of deprotection, DMF wash, coupling and a further 
DMF wash. The N-α-Fmoc protection at the final residue was removed at the end of the 
synthesis under the usual conditions. After synthesis was complete a preactivated solution 
of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid (12.01 mg, 3 eq), HCTU (51.7 mg, 
3 eq) and DiPEA (19.3 mg, 6 eq) in DMF (1 mL) was added to each well and agitated for one 
hour. The peptidyl resin was removed from the synthesiser, washed several times (3 × 2 mL 
DMF, 3 × 2 mL DCM, 3 × 2 mL methanol, 3 × 2 mL diethylether) and dried in vacuo. 
Deprotection and cleavage from resin 
Cleavage and deprotection of peptides was achieved by adding 1.5 mL of deprotection 
mixture to dry peptidyl resin (25 μmol). The mixture was agitated on an orbital shaker for up 
to 3 hr and then filtered. The resin was washed twice with a small volume of TFA and the 
combined washings and filtrate were precipitated with 10 mL ice cold tert-butylmethylether 
(tBME). The mixture was centrifuged at 5000 rpm for 15 min at 0 °C, the supernatant 
discarded and the remaining peptide washed with a fresh aliquot of tBME. The process was 
repeated three times to ensure complete removal of all organic impurities. The crude 
peptide was dried in a desiccator over silica gel to yield an off-white solid. 
Peptide purification 
Peptide analysis and purification was performed either on Gilson RP-HPLC system or Waters 
LC-MS system. 
Purification of crude peptides was performed on a Gilson semi-preparative RP-HPLC system 
(Anachem Ltd., Luton, UK) equipped with 306 pumps and a Gilson 155 UV/Vis detector. 
Analytical RP-HPLC was performed on a Gilson analytical HPLC system (Anachem Ltd., Luton, 
UK) equipped with a Gilson 151 UV/Vis detector and Gilson 234 auto injector. For both HPLC 
systems, the peptide bond absorption was detected at 223 nm. The following elution 
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methods were used: Method A: 2% to 98% MeCN in H2O over 40 min; Method B: 2% MeCN 
in H2O for 10 min then 2% to 98% MeCN in H2O over 40 min; all solvents used were 
supplemented with 0.1% TFA and were degassed with helium.  
LC-MS analysis was performed on Waters HPLC system (Waters 2767 autosampler for 
samples injection and collection; Waters 515 HPLC pump to deliver the mobile phase to the 
source; XBridge C18 column (Waters, 4.6 mm D × 100 mm L for analytical and 
19 mm D × 100 mmL for preparative); Waters 3100 mass spectrometer with ESI and Waters 
2998 Photodiode Array (detection at 200–600 nm)). The following elution methods were 
used: Method C: 5% to 95% MeOH in H2O over 15 min; Method D: 5% to 45% MeOH in H2O 
over 10 min, then 45% to 55% MeOH in H2O over further 10 min and finishing with 55% to 
95% MeOH in H2O over the remain 5 min. All solvents used were supplemented with 0.1% 
formic acid and were degassed with helium. 
9.3.3 Synthesis and characterisation 
Key data are summarised in Table 9. 5, experimental procedures and further 
characterisation data for selected compounds is provided below. 
Nr. Abbr. Name ESI-MS [M+H+] Rt PM Yield 
(%) Calculated (Chem. 
formular) 
found 
TD 1 EP-LR-NH2 401.2149 (C16H29N6O6) 401.2153 9.15 A 22 
TD 3 Ac-LR-NH2 329.2301 (C14H29N6O3) 329.2286 5.95 A 43 
TD 4 (R,R)EP-LR-NH2 401.2143 (C16H29N6O6) 401.2153 10.72 A 9 
TD 5 EtEP-LR-NH2 429.2462 (C18H32N6O6) 429.2463 10.88 A 22 
TD 6 EtEP-K-NH2 288.1559 (C12H22N3O5) 288.1588 4.12 A n.d 
TD 7 EP-KT-NH2 389.2050 (C16H29N4O7) 389.2046 4.15 A n.d 
TD 8 EP-KTE-NH2 490.2513 (C19H32N5O10) 490.2506 4.15 A n.d 
TD 9 EP-KTEL-NH2 603.2990 (C25H43N6O11) 603.2997 8.62 A 25 
TD 9b EtEP-KTEL-NH2 631.3320 (C27H47N6O11) 631.3297 10.11 A 25 
TD 10 EP-KA-NH2 331.1612 (C13H23N4O6) 331.1606 3.83 A 8 
TD 11 EP-KTT-NH2 462.2200 (C18H32N5O9) 462.2212 4.08 A 2 
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TD 12 EP-YT-NH2 396.1401 (C17H22N3O8) 396.1414 6.72 A 17 
TD 13 EP-LT-NH2 346.1609 (C14H24N3O7) 346.1618 9.39 A 39 
TD 14 EP-LTT-NH2 447.2091 (C18H31N4O9) 447.2084 10.36 A 16 
TD 15 EP-LTTL-NH2 560.2932 (C24H41N5O10) 560.2953 10.78 B 1 
TD 16 EP-LGR-NH2 458.2363 (C18H32N7O7) 458.2375 9.08 A 33 
TD 17 EP-T-NH2 233.0729 (C8H13N2O6) 233.0768 8.91 A 62 
TD 18 EtEP-AT-NH2 332.1438 (C13H22N3O7) 332.1461 5.81 A 87 
TD 19 EtEP-ATT-NH2 433.1935 (C17H29N4O9) 433.1930 3.39 A n.d 
TD 20 EtEP-R-NH2 316.1621 (C12H22N5O5) 316.1609 9.44 A 62 
TD 21 EP-LR-Pra-NH2 496.2520 (C21H33N7O7) 496.2539 8.02 C 60 
TD 22 EtEP-LR-Pra-NH2 524.2833 (C23H37N7O7) 524.2811 9.08 C 44 
TD 23 EtEP-A-Pra-NH2 326.1352 (C14H19N3O6) 326.1339 7.68 C 7 
TD 24 EtEP-F-Pra-NH2 402.1665 (C20H23N3O6) 402.1679 10.56 C 1 
TD 25 EtEP-I-Pra-NH2 368.1822 (C17H25N3O6) 368.1830 9.85 C 4 
TD 26 EtEP-L-Pra-NH2 368.1822 (C17H25N3O6) 368.1808 10.00 C 8 
TD 27 EtEP-V-Pra-NH2 354.1660 (C16H23N3O6) 354.9669 9.01 C 3 
TD 28 EtEP-Y-Pra-NH2 418.1599 (C20H23N3O7) 418.1614 8.98 C 8 
TD 29 EtEP-S-Pra-NH2 342.1301 (C14H19N3O7) 342.1293 7.55 C 7 
TD 30 EtEP-H-Pra-NH2 392.1568 (C17H22N5O6) 392.1570 6.44 C 2 
TD 31 EtEP-K-Pra-NH2 383.1931 (C17H27N4O6) 383.1920 6.48 C 4 
TD 32 EtEP-R-Pra-NH2 411.1992 (C17H27N6O6) 411.2005 6.92 C 1 
TD 33 EtEP-E-Pra-NH2 384.1407 (C16H22N3O8) 384.1394 5.44 C 4 
TD 34 EtEP-G-Pra-NH2 312.1196 (C13H18N3O6) 312.1206 7.09 C 7 
TD 35 EtEP-P-Pra-NH2 352.1509 (C16H22N3O6) 352.1494 7.90 C 4.6 
TD 36 EtEP-T-Pra-NH2 356.1458 (C15H22N3O7) 356.1464 7.82 C n.d 
TD 37 (R,R)EtEP-LR-Pra-NH2 524.2833 (C23H37N7O7) 524.2833 9.85 C n.d 
TD 38 EtEP-Pra-NH2 255.0981 (C11H15N2O5) 255.0978 7.67 C 5 
TD 39 EtEP-(D)-A-Pra-NH2 326.1352 (C14H19N3O6) 326.1354 7.70 C 29 
TD 40 EtEP-(D)-K-Pra-NH2 383.1931 (C17H27N4O6) 383.1931 6.18 C 53 
TD 41 EtEP-(D)-R-Pra-NH2 411.1992 (C17H27N6O6) 411.1992 7.08 C 62 
TD 42 EtEP-(D)-Y-Pra-NH2 418.1614 (C20H23N3O7) 418.1619 10.55 C 64 
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TD 43 EP-LR-PEG3-Biotin 830.4468 (C36H64N9O11S) 830.4470 10.68 A 46 
TD 44 EtEP-LR-PEG3-Biotin 858.4781 (C38H68N9O11S) 858.4778 11.09 A 46 
TD 45 
(R,R)EtEP-LR-PEG3-
Biotin 
858.4759 (C38H68N9O11S) 858.4757 11.12 A 20 
TD 46 EtEP-A-PEG3-Biotin 660.3278 (C29H50N5O10S) 660.3270 10.01 A 54 
TD 47 EtEP-F-PEG3-Biotin 736.3645 (C35H54N5O10S) 736.3611 12.53 B 14 
TD 48 EtEP-I-PEG3-Biotin 702.3751 (C32H56N5O10S) 702.3751 11.66 B 8 
TD 49 EtEP-L-PEG3-Biotin 702.3748 (C32H56N5O10S) 702.3747 11.94 B 46 
TD 50 EtEP-V-PEG3-Biotin 688.3573 (C31H54N5O10S) 688.3601 11.52 B 54 
TD 51 EtEP-Y-PEG3-Biotin 752.3452 (C35H54N5O11S) 752.3539 10.40 B 8 
TD 52 EtEP-S-PEG3-Biotin 676.3228 (C29H50N5O11S) 676.3232 9.55 A 20 
TD 53 EtEP-H-PEG3-Biotin 726.3577 (C32H52N7O10S) 726.3529 9.81 A 30 
TD 54 EP-K-PEG3-Biotin 689.3557 (C30H53N6O10S) 689.3557 11.45 A 29 
TD 55 EtEP-R-PEG3-Biotin 745.3918 (C32H57N8O10S) 745.3939 9.78 A 16 
TD 56 EtEP-E-PEG3-Biotin 718.3255 (C31H52N5O12S) 718.3333 9.73 A 13 
TD 57 EtEP-G-PEG3-Biotin 646.3103 (C28H48N5O10S) 646.3131 10.70 B 62 
TD 58 EtEP-P-PEG3-Biotin 686.3475 (C31H52N5O10S) 686.3447 11.73 A 43 
TD 59 EtEP-T-PEG3-Biotin 690.3424 (C30H52N5O11S) 690.3389 9.94 A 33 
TD 60 EtEP-PEG3-Biotin 589.2907 (C26H45N4O9S) 589.2911 11.81 A 25 
TD 61 
EtEP-AG-PEG3-
TAMRA 
903.4122 (C46H59N6O13) 903.4135 11.22 D n.d 
TD 62 
EtEP-YG-PEG3-
TAMRA 
995.4442 (C52H63N6O14) 995.4438 11.22 D n.d 
TD 63 EtEP-R-PEG3-TAMRA 988.4861 (C49H66N9O13) 988.4819 10.84 D n.d 
TD 64 
EtEP-AK(Biotin)G-
PEG3-TAMRA 
1256.5787 (C62H85N10O16S) 1256.5787 9.39 D n.d 
TD 65 
EtEP-RK(Biotin)G-
PEG3-TAMRA 
1341.6427 (C65H92N13O16S) 1341.64 9.37 D n.d 
TD 66 
EtEP-YK(Biotin)G-
PEG3-TAMRA 
1348.6050 (C68H89N10O17S) 1348.6050 10.76 D n.d 
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TD 67 CAA-LR-PEG3-Biotin 792.4209 (C34H62ClN9O8S) 792.4240 9.87 C 28 
TD 68 CAA-A-PEG3-Biotin 594.2728 (C25H45ClN5O7S) 594.2730 9.45 C 5 
TD 69 CAA-Y-PEG3-Biotin 686.2990 (C31H49ClN5O8S) 686.2992 10.69 C 3 
TD 70 CAA-R-PEG3-Biotin 679.3337 (C28H52ClN8O7S) 679.3362 8.71 C 37 
TD 71 CAA-T-PEG3-Biotin 624.2834 (C26H47ClN5O8S) 624.2831 9.47 C 4 
TD 72 CAA-S-PEG3-Biotin 610.2677 (C25H45ClN5O8S) 610.2681 9.16 C 7 
TD 73 FAA-LR-PEG3-Biotin 776.4504 (C34H63FN9O8S) 776.4523 9.59 C 7 
TD 74 FAA-A-PEG3-Biotin 578.3024 (C25H45FN5O7S) 578.3052 9.18 C 15 
TD 75 FAA-Y-PEG3-Biotin 670.3286 (C31H49FN5O8S) 670.3282 9.67 C 6 
TD 76 FAA-R-PEG3-Biotin 663.3664 (C28H52FN8O7S) 663.3661 8.46 C 9 
TD 77 FAA-S-PEG3-Biotin 594.2973 (C25H45FN5O8S) 594.2974 8.91 C 1 
TD 78 MA-LR-PEG3-Biotin 842.4810 (C38H68N9O10S) 842.4819 10.39 C 10 
TD 79 MA-A-PEG3-Biotin 644.3329 (C29H50N5O9S) 644.3331 10.18 C 17 
TD 80 MA-Y-PEG3-Biotin 736.3591 (C35H54N5O10S) 736.3600 10.52 C 21 
TD 81 MA-R-PEG3-Biotin 729.3969 (C32H57N8O9S) 729.3961 9.33 C 39 
TD 82 MA-T-PEG3-Biotin 674.3435 (C30H52N5O10S) 674.3438 9.74 C 26 
TD 83 MA-S-PEG3-Biotin 660.3278 (C29H50N5O10S) 660.3292 9.92 C 25 
TD 84 AOAA-LR-PEG3-
Biotin 
908.4897 (C42H70N9O11S) 908.4933 11.61 C 99 
TD 85 AOAA-A-PEG3-Biotin 710.3435 (C33H52N5O10S) 710.3442 11.60 C 17 
TD 86 AOAA-Y-PEG3-Biotin 802.3737 (C39H56N5O11S) 802.3736 11.99 C 51 
TD 87 AOAA-R-PEG3-Biotin 795.4075 (C36H59N8O10S) 795.4080 10.65 C 38 
230 
 
TD 88 AOAA-T-PEG3-Biotin 740.3541 (C34H54N5O11S) 740.3546 11.02 C 88 
TD 89 AOAA-S-PEG3-Biotin 726.3384 (C33H52N5O11S) 726.3384 11.20 C 31 
TD 90 Ac-LTEKS-MA 673.3772 (C30H53N6O11) 673.3775 5.26 A 1.5 
TD 91 Ac-K(Biotin)Y-MA 832.4279 (C40H62N7O10S) 832.4247 10.35 B 11 
TD 92 Ac-K(Biotin)L-MA 782.4486 (C37H64N7O9S) 782.4479 10.55 B 4 
TD 93 Ac-K(Biotin)E-MA 798.4072 (C36H60N7O11S) 798.4069  10.52 B 4 
TD 94 Ac-K(Biotin)M-MA 800.4050 (C36H62N7O9S2) 800.4009 10.48 B 7 
Table 9. 5: Table of inhibitors synthesised and used in this study. The retention time (Rt) for LC-MS used a 
gradient of Methanol in H2O with 0.1% of FA from 2 to 98% over 15 min. PM = Purification method.  
(2R, 3R)-Diethyl-2-acetoxy-3-bromosuccinate [461-462] 
 
To neat (-)-diethyl-D-tartrate (10 mL, 58.44 mmol) cooled in ice was added hydrobromic acid 
33% in solution in acetic acid (5.7 M) (40 mL) drop wise over 30 minutes. The reaction 
mixture was allowed to warm to room temperature and stirred for 16 h. The reaction 
mixture was poured into 50 g crushed ice and extracted four times with diethyl ether. The 
combined organic layers were washed three times with water and once with brine. After 
drying over magnesium sulphate all volatiles were removed under reduced pressure to 
afford the product (2R,3R)-diethyl-2-acetoxy-3-bromosuccinate (18.61 g, 59.88 mmol, 88% 
yield) as a colourless oil. The product contained acetic acid (ca. 50%) and was used in the 
next synthesis step without further purification. 
δH/ppm (400 MHz; CDCl3): 5.56 (1H, d, J = 5.4, CHOAc), 4.76 (1H, d, J = 5.4, CHBr), 4.28–4.16 
(4H, m, 2 × CH2), 2.07 (3H, s, COCH3), 1.33–1.24 (6H, m, 2 × CH3). δC/ppm (100 MHz; CDCl3): 
169.44, 166.25, 165.63 (CO), 72.66 (COAc), 62.81, 62.53 (CH2), 43.86 (CBr), 20.70 (COCH3), 
13.94, 13.86 (CH3). 
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(2R,3R)-Diethyl 2-bromo-3-hydroxysuccinate (3)  
 
A solution of acetyl chloride (2.08 mL, 29.22 mmol) was added to a solution of (2R, 3R)-
diethyl-2-acetoxy-3-bromosuccinate (18.61 g, 59.88 mmol) in ethanol (60 mL). The reaction 
mixture was heated to a gentle reflux for 6 hours, 1 hour longer than literature procedure, 
due to difficulty visualising on TLC. After 6 hours all volatiles were removed by rotary 
evaporation. The product (2R,3R)-diethyl-2-bromo-3-hydroxysuccinate was recovered as 
pale yellow oil (15.30 g, 56.86 mmol, 97% yield).  
δH/ppm (400 MHz; CDCl3): 7.48 (1H, s, OH), 4.68 (1H, d, J = 4.5, HOCH), 4.65 (1H, d, J = 4.5, 
BrCH), 4.36–4.16 (4H, m, 2 × CH2), 1.29 (6H, t, J = 7.2, 2 × CH3). δC/ppm (100 MHz; CDCl3): 
170.32 (COCOH), 166.72 (COCBr), 72.52 (COH), 62.84, 62.53 (CH2), 47.55 (CBr), 14.00, 13.88 
(CH3). 
(2S,3S)-Diethyl-2,3-epoxysuccinate(4)  
 
To an ice cooled solution of (2R,3R)-diethyl-2-bromo-3-hydroxysuccinate (15.03 g, 
56.86 mmol) in diethyl ether (80 mL) stirring, a solution of 1,8-diazabicyclo-undec-7-ene 
(DBU) (11 mL, 73.9 mmol) in diethyl ether (40 mL) dropwise over 2 hours. Once the addition 
was completed the reaction mixture was stirred for a further 30 minutes. Water (10 mL) was 
added to the mixture. The separated organic layer was washed three times with 1 M 
potassium hydrogen sulphate and twice with water. After drying over magnesium sulphate 
all volatiles were removed under reduced pressure to afford a product (8.31 g, 44.15 mmol, 
77% yield) as yellow oil. 
δH/ppm (400 MHz; CDCl3): 4.35–4.13 (4H, m, CH2), 3.65 (2H, s, CHOCH), 1.31 (6H, t, J = 7.2, 
CH3). νmax (neat)/cm
–1 2983, 2940, 2875 (CH), 1748 (CO), 1447, 1371, 1329, 1197, 1029, 901. 
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(2S,3S)-3-(Ethoxycarbonyl)oxirane-2-carboxylic acid (EtEP-OH) (5 or TD 2)  
 
To an ice cooled solution of (2S,3S)-diethyloxirane-2,3-dicarboxylate (1.00 g, 5.31 mmol) in 
ethanol (13 mL) was added drop wise a solution of potassium hydroxide (0.35 g, 6.26 mmol) 
in ethanol (7 mL) over 15 minutes. After this addition the reaction mixture was allowed to 
stir in ice for 3 hours. The cooling bath was then removed and the reaction mixture was 
stirred for further 2 hours at room temperature. Afterwards the ethanol was removed 
under reduced pressure leaving an off-white solid. This salt was then taken up with 15 mL of 
water and washed three times with dichloromethane. The aqueous phase was acidified by 
addition of concentrated hydrochloric acid to pH 3 and extracted four times with ethyl 
acetate. The combined organic phases were dried over magnesium sulphate and 
concentrated under reduced pressure. After freeze drying the pure product was obtained as 
a pale yellow oil (0.67 g, 4.19 mmol, 79% yield). 
δH/ppm (400 MHz; CDCl3): 4.27 (2H, q, J = 7.3, CH2), 3.64 (1H, d, J = 1.6, CH), 3.61 (1H, d, 
J = 1.7, CH), 1.32 (3H, t, J = 7.1, CH3). δC/ppm (100 MHz; CDCl3): 168.87, 167.05 (CO), 62.12 
(CH2), 51.98, 51.90 (CH), 13.95 (CH3). [α]    +269 (c 1. in DCM). νmax (neat)/cm
–1: 2988 (CH), 
1744 (CO), 1448, 1374, 1206, 1095, 1025, 899. 
(2S,3S)-Oxirane-2,3-dicarboxylic acid[461-462] 
 
A solution of potassium hydroxide (2.76 g, 42.4 mmol) in ethanol (50 mL) was added to a 
solution of (2S,3S)-diethyl-2-bromo-3-hydroxysuccinate (4.00 g, 21.2 mmol) in ethanol 
(150 mL) and stirred for 3 hours at room temperature. After evaporation to dryness, the 
residue was dissolved in 10 mL of water and the pH was adjusted to 3 with concentrated 
hydrochloric acid. When the mixture was cooled, the precipitated product was filtrated and 
freeze dried to afford a white solid. The product contained potassium chloride, and thus it 
O
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was not possible to calculate an accurate yield.δH/ppm (400 MHz; CDCl3): 3.46 (2H, s, 
CHOCH). δC/ppm (100 MHz; CDCl3): 172.71 (CO), 52.78 (CH). 
(2S,3S)-Ethyl-2,3-epoxysuccinyl leucylargininamide (EtEP-LR-NH2) (TD 5)  
 
δ H/ppm (400 MHz; D2O): 4.334.30 (1H, m, NHCHArgCO), 4.274.22 (1H, m, NHCHLeuCO), 
4.21 (2H, q, J = 7.15, CH3CH2), 3.71 (1H, d, J = 1.86, CHOCHCOOEt), 3.64 (1H, d, J = 1.86, 
CHOCHCOOEt), 3.13 (2H, t, J = 6.92, CH2NHCNHNH2), 1.84–1.51 (7H, m, CH2CH(CH3)2, CH2), 
1.21 (3H, t, J = 7.17, CH3CH2), 0.86 (3H, d, J = 5.80, CH(CH3)2), 0.81 (3H, d, J = 5.75, 
CH(CH3)2).. Rt: 10.88. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl lysylthreonylglutamylleucinamide (EtEP-KTEL-NH2) (TD 9b) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.34–4.32 (2H, m, NHCHCO), 4.24–4.17 (4H, m, NHCHCO, CH3CH2), 
4.08 (1H, p, J = 6.29, CHOH), 3.71 (1H, d, J = 1.71, CHOCHCOOEt), 3.67 (1H, d, J = 1.73, 
CHOCHCOOEt), 2.90 (2H, t, J = 7.58, CH2NH2), 2.38 (2H, t, J = 7.31, CH2COOH), 2.09–2.00 (1H, 
m, CH2CH2COOH), 1.94–1.84, (1H, m, CH2CH2COOH), 1.82–1.65 (2H, m, CH2(CH2)3NH2), 
1.62–1.48 (5H, m, CH(CH3)2, CH2CH2NH2, CH2CH(CH3)2), 1.40–1.30 (2H, m, CH2CH2), 1.20 (3H, 
t, J = 7.14, CH3CH2), 1.10 (3H, d, CH3CHOH), 0.83 (3H, d, J = 5.88, CH(CH3)2), 0.78 (3H, d, 
J = 5.90, CH(CH3)2). Rt: 10.11. 
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(2S,3S)-2,3-Epoxysuccinyl leucylthreonylthreonylleucinamide (EP-LTTL-NH2) (TD 14) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.40–4.35 (2H, m, NHCHCO), 4.27–4.23 (2H, m, NHCHCO), 4.15–
4.09 (1H, m, CHOH), 3.65 (1H, d, J = 1.86, CHOCHCOOH), 3.55 (1H, d, J = 1.86, CHOCHCOOH), 
2.94 (2H, t, J = 7.42, CH2NH2), 2.42 (2H, t, J = 7.15, CH2COOH), 2.12–2.03, 1.97-1.90 (2H, m, 
CH2CH2COOH), 1.85–1.71 (2H, m, CH2(CH2)3NH2), 1.67–1.51 (5H, m, CH(CH3)2, CH2CH2NH2, 
CH2CH(CH3)2), 1.43–1.33 (2H, m, CH2CH2), 1.14 (3H, t, J = 6.19 CH3CHOH), 0.87 (3H, d, 
J = 5.19, CH(CH3)2), 0.81 (3H, d, J = 5.17, CH(CH3)2). ESI-MS: m/z = 603.2997 ([M + H]
+), 
652.9226 ([M + Na]+). Rt: 10.78. 
(2S,3S)-2,3-Epoxysuccinyl leucylglycylargininamide (EP-LGR-NH2) (TD 16) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.30 (1H, t, J = 7.02, NHCHArgCO), 4.24 (1H, dd, J = 5.04 and 9.04, 
NHCHLeuCO), 3.85 (2H, s, NH2CH2CO), 3.61 (1H, d, J = 1.35, CHOCHCOOH), 3.50 (1H, d, 
J = 1.77, CHOCHCOOH), 3.12 (2H, t, J = 6.90, CH2NHCNHNH2), 1.86–1.78 (1H, m, 
CH2CH(CH3)2), 1.71–1.50 (6H, m, 3 × CH2), 0.85 (3H, d, J = 5.56, CH(CH3)2), 0.81 (3H, d, 
J = 5.52, CH(CH3)2). Rt: 9.08. 
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(2S,3S)-ethyl-2,3-epoxysuccinyl leucylglycylargininamide (EtEP-LRG-NH2) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.33–4.29 (1H, m, J = 7.02, NHCHArgCO), 4.26–4.22 (1H, m, 
NHCHLeuCO), 4.20 (2H, q, J = 7.30, CH3CH2), 3.85 (2H, s, NH2CH2CO), 3.70 (1H, s, 
CHOCHCOOEt), 3.65 (1H, d, J = 0.89, CHOCHCOOEt), 3.12 (2H, t, J = 6.89, CH2NHCNHNH2), 
1.84–1.77 (1H, m, CH2CH(CH3)2), 1.71–1.49 (6H, m, CH2), 1.20 (3H, t, J = 7.04, CH3CH2), 0.85 
(3H, d, J = 5.52, CH(CH3)2), 0.80 (3H, d, J = 5.42, CH(CH3)2). Rt: 10.74. 
(2S,3S)-2,3-Epoxysuccinyl leucylarginyl propargylglycinaminde (EP-LR-Pra-NH2) (TD 21) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.41 (1H, t, J = 6.53, NHCHCO), 4.31 (2H, dt, J = 7.23, 10.19, 
NHCHCO), 3.49 (1H, d,J = 2.00, CHOCHCOOEt), 3.35 (1H, d, J = 1.98, CHOCHCOOEt), 3.13 (2H, 
t, J = 6.92, CH2NHCNHNH2), 2.66–2.64 (2H, m, CH2CCH), 2.37 (1H, t, J = 2.57, CCH), 1.83–1.51 
(7H, m, CH2CH(CH3)2, CH2), 0.85 (3H, d, J = 5.81, CH(CH3)2), 0.81 (3H, d, J = 5.79, CH(CH3)2). 
Rt: 8.02. 
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 (2S,3S)-Ethyl-2,3-epoxysuccinyl leucylarginyl propargylglycinaminde (EtEP-LR-Pra-NH2) 
(TD 22) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.41 (1H, t, J = 6.54, NHCHCO), 4.31 (2H, m, NHCHCO), 4.21 (2H, q, 
J = 7.15, 7.18, CH2OCO), 3.71 (1H, d, J = 1.78, CHOCHCOOEt), 3.65 (1H, d, J = 1.81, 
CHOCHCOOEt), 3.13 (2H, t, J = 6.91, CH2NHCNHNH2), 2.66–2.64 (2H, m, CH2CCH), 2.37 (1H, t, 
J = 2.55, CCH), 1.83–1.50 (7H, m, CH2CH(CH3)2, CH2), 1.21 (3H, t, J = 7.17, CH3CH2), 0.85 (3H, 
d, J = 5.75, CH(CH3)2), 0.81 (3H, d, J = 5.72, CH(CH3)2). Rt: 9.08. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl alanyl propargylglycinaminde (EtEP-A-Pra-NH2) (TD 23) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 8.70 (1H, d, J = 7.71, NHCHCONH), 8.21 (1H, d, J = 8.07, 
NHCHCONH2), 7.35 (1H, s, NH2), 7.21 (1H, s, NH2), 4.40–4.32 (1H, m, NHCHCO), 4.29 (1H, td, 
J = 5.89, 7.97, NHCHCO), 4.24–4.14 (2H, m, CH2CH3), 3.74 (1H, d, J = 1.68, CHOCHCOOEt), 
3.62 (1H, d, J = 1.84, CHOCHCOOEt), 2.85 (1H, t, J = 2.56, CCH), 2.60 (1H, dd, J = 2.66, 5.72 
CH2CCH), 2.46 (1H, dd, J = 2.57, 7.88, CH2CCH), 1.24 (6H, t, J = 7.20, CH2CH3 and CHCH3). Rt: 
7.68. 
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(2S,3S)-Ethyl-2,3-epoxysuccinyl-D-alanyl propargylglycinaminde (EtEP-(D)A-Pra-NH2) (TD 
39) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 8.72 (1H, d, J = 7.13, NHCHCONH), 8.34 (1H, d, J = 8.43, 
NHCHCONH2), 7.36 (1H, s, NH2), 7.26 (1H, s, NH2), 4.46–4.26 (2H, m, 2 × NHCHCO), 4.26–
4.08 (2H, m, OCH2CH3), 3.73 (1H, d, J = 1.82, CHOCHCOOEt), 3.62 (1H, d, J = 1.85, 
CHOCHCOOEt), 2.84 (1H, t, J = 2.56, CCH), 2.64 (1H, dd, J = 2.62, 5.02, CH2CCH), 2.45 (1H, dd, 
J = 2.56, 8.81, CH2CCH), 1.25 (3H, d, J = 7.00, CHCH3), 1.24 (3H, t, J = 7.12, CH2CH3). Rt: 7.70. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl phenylalanyl propargylglycinaminde (EtEP-F-Pra-NH2) (TD 
24) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 8.64 (1H, d, J = 8.47, NHCHCONH), 8.42 (1H, d, J = 7.97, 
NHCHCONH2), 7.39 (1H, s, NH2), 7.28–7.27 (5H, m, Bn), 7.23 (1H, s, NH2), 4.65 (1H, td, 
J = 4.22, 9.78, NHCHCONH), 4.33 (1H, td, J = 6.21, 7.70, NHCHCONH2), 4.21–4.13 (2H, m, 
OCH2CH3), 3.64 (1H, d, J = 1.66, CHOCHCOOEt), 3.40 (1H, d, J = 1.81, CHOCHCOOEt), 3.07 
(1H, dd, J = 4.25, 13.67, CHCH2Bn), 2.88 (1H, t, J = 2.55, CCH), 2.79 (1H, dd, J = 10.12, 13.68, 
CHCH2Bn), 2.55 (2H, s, CH2CCH), 1.22 (3H, t, J = 7.10, CH3). ESI-MS: m/z = 402.1679 
([M + H]+). Rt: 10.56. 
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(2S,3S)-Ethyl-2,3-epoxysuccinyl leucyl propargylglycinaminde (EtEP-L-Pra-NH2) (TD 26) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 8.65 (1H, d, J = 7.90, NHCHCONH), 8.24 (1H, d, J = 7.93, 
NHCHCONH2), 7.33 (1H, s, NH2), 7.17 (1H, s, NH2), 4.45–4.32 (1H, m, NHCHCO), 4.28 (1H, td, 
J = 6.91, 13.79, NHCHCO), 4.24–4.10 (2H, m, CH2CH3), 3.73 (1H, d, J = 1.59, CHOCHCOOEt), 
3.59 (1H, d, J = 1.81, CHOCHCOOEt), 2.83 (1H, t, J = 2.52, CCH), 2.59 (1H, dd, J = 2.68, 5.77 
CH2CCH), 2.45 (1H, dd, J = 2.49, 7.80, CH2CCH), 1.68–1.54 (1H, m, CH(CH3)2), 1.54–1.40 (2H, 
m, CHCH2CH), 1.23 (3H, t, J = 7.09, CH2CH3), 0.87 (6H, dd, J = 6.42, 13.73, CH(CH3)2). Rt: 
10.00. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl valyl propargylglycinaminde (EtEP-V-Pra-NH2) (TD 27) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 8.58 (1H, d, J = 8.40, NHCHCONH), 8.28 (1H, d, J = 8.00, 
NHCHCONH2), 7.34 (1H, s, NH2), 7.18 (1H, s, NH2), 4.36–4.14 (4H, m, 2 × NHCHCO, OCH2CH3), 
3.88 (1H, d, J = 1.65, CHOCHCOOEt), 3.60 (1H, d, J = 1.74, CHOCHCOOEt), 2.86 (1H, t, 
J = 2.53, CCH), 2.51–2.44 (2H, s, CH2CCH), 2.03 (1H, dq, J = 6.72, 13.41, CH(CH3)2) 1.24 (3H, t, 
J = 7.12, CH2CH3), 0.87 (6H, dd, J = 6.82, 10.49, CH(CH3)2). Rt: 9.01. 
 (2S,3S)-Ethyl-2,3-epoxysuccinyl tyrosyl propargylglycinaminde (EtEP-Y-Pra-NH2) (TD 28) 
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Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 9.21 (1H, s, OH), 8.56 (1H, d, J = 8.47, NHCHCONH), 8.37 (1H, d, 
J = 8.02, NHCHCONH2), 7.39 (1H, s, NH2), 7.23 (1H, s, NH2), 7.05 (2H, d, J = 8.45, Bn), 6.65 
(2H, d, J = 8.48, Bn), 4.56 (1H, td, J = 4.27, 9.56, NHCHCONH), 4.32 (1H, td, J = 6.17, 7.67, 
NHCHCONH2), 4.24–4.10 (2H, m, OCH2CH3), 3.65 (1H, d, J = 1.69, CHOCHCOOEt), 3.43 (1H, d, 
J = 1.64, CHOCHCOOEt), 2.94 (1H, dd, J = 4.12, 13.84, CHCH2Bn), 2.88 (1H, t, J = 2.56, CCH), 
2.67 (1H, dd, J = 9.95, 13.79, CHCH2Bn), 2.55 (2H, s, CH2CCH), 1.23 (3H, t, J = 7.10, CH3). Rt: 
8.98. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl -D-tyrosyl propargylglycinaminde (EtEP-(D)Y-Pra-NH2) (TD 
42)  
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; DMSO): 9.21 (1H, s, OH), 8.63 (1H, d, J = 8.14, NHCHCONH), 8.46 (1H, d, 
J = 8.33, NHCHCONH2), 7.41 (1H, s, NH2), 7.26 (1H, s, NH2), 7.04 (2H, d, J = 8.44, Bn), 6.65 
(2H, d, J = 8.45, Bn), 4.54 (1H, td, J = 4.69, 9.40, NHCHCONH), 4.37 (1H, td, J = 5.54, 8.22, 
NHCHCONH2), 4.18 (2H, q, J = 7.12, OCH2CH3), 3.67 (1H, d, J = 1.65, CHOCHCOOEt), 3.47 (1H, 
d, J = 1.69, CHOCHCOOEt), 2.94 (1H, dd, J = 4.55, 13.86, CHCH2Bn), 2.85 (1H, t, J = 2.56, 
CCH), 2.69 (1H, dd, J = 10.06, 11.79, CHCH2Bn), 2.40 (2H, ddd, J = 2.48, 8.18, 16.79, CH2CCH), 
1.23 (3H, t, J = 7.10, CH3). Rt: 10.55. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl lysyl propargylglycinaminde (EtEP-K-Pra-NH2) (TD 31) 
 
Standard SPPS. Product was obtained as white solid. 
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δH/ppm (400 MHz; D2O): 4.38 (1H, t, J = 6.67, NHCHCONH2), 4.29 (1H, dd, J = 6.02, 8.22, 
NHCHCO), 4.17 (2H, q, J = 7.15, CH2CH3), 3.69 (1H, d, J = 1.60, CHOCHCOOEt), 3.65 (1H, d, 
J = 1.58, CHOCHCOOEt), 2.88 (2H, t, J = 7.47, CH2NH2), 2.67–2.57 (2H, m, CH2CCH), 2.34 (1H, 
m, CCH), 1.84–1.64 (2H, m, CH2CHCO), 1.65–1.52 (2H, m, CH2CH2NH2), 1.41–1.27, (2H, m, 
CH2CH2CH2NH2), 1.18 (3H, t, J = 7.16, CH3). Rt: 6.48.  
(2S,3S)-Ethyl-2,3-epoxysuccinyl -D-lysyl propargylglycinaminde (EtEP-(D)K-Pra-NH2) (TD 40) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.42 (1H, dd, J = 5.32, 7.83, NHCHCONH2), 4.25 (1H, dd, J = 6.72, 
7.79, NHCHCO), 4.22–4.13 (2H, m, CH2CH3), 3.70 (2H, s, CHOCHCOOEt), 2.87 (2H, t, J = 7.66, 
CH2NH2), 2.69–2.57 (2H, m, CH2CCH), 2.34 (1H, t, J = 2.59, CCH), 1.82–1.64 (2H, m, 
CH2CHCO), 1.63–1.51 (2H, m, CH2CH2NH2), 1.44–1.26, (2H, m, CH2CH2CH2NH2), 1.18 (3H, t, 
J = 7.20, CH3). ESI-MS: m/z = 383.1915 ([M + H]
+). Rt: 6.18. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl arginyl propargylglycinaminde (EtEP-R-Pra-NH2) (TD 32)  
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.39 (1H, dd, J = 6.33, 7.22, NHCHCONH2), 4.30 (1H, dd, J = 5.96, 
8.23, NHCHCO), 4.17 (2H, q, J = 7.15, CH2CH3), 3.69 (1H, d, J = 1.89, CHOCHCOOEt), 3.64 (1H, 
d, J = 1.89, CHOCHCOOEt), 3.10 (2H, t, J = 6.81, CH2NHCNH), 2.65-2.56 (2H, m, CH2CCH), 2.33 
(1H, t, J = 2.63, CCH), 1.86 – 1.64 (2H, m, CH2CHCO), 1.57-1.50 (2H, m, CH2CH2CH2), 1.17 (3H, 
t, J = 7.16, CH3). Rt: 6.92. 
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(2S,3S)-Ethyl-2,3-epoxysuccinyl -D-arginyl propargylglycinaminde (EtEP-(D)R-Pra-NH2) (TD 
41) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.42 (1H, dd, J = 5.20, 7.97, NHCHCONH2), 4.26 (1H, t, J = 7.23, 
NHCHCO), 4.21–4.13 (2H, m, CH2CH3), 3.69 (2H, dd, J = 1.89, 4.80, CHOCHCOOEt), 3.10 (2H, 
t, J = 6.88, CH2NHCNH), 2.69 (1H, dd, J = 2.66, 5.20, CH2CCH), 2.61 (1H, dd, J = 2.69, 7.68, 
CH2CCH), 2.32 (1H, t, J = 2.59, CCH), 1.81–1.66 (2H, m, CH2CHCO), 1.61–1.51 (2H, m, 
CH2CH2CH2), 1.18 (3H, t, J = 7.18, CH3). Rt: 7.08. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl glutamyl propargylglycinaminde (EtEP-E-Pra-NH2) (TD33) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.45–4.30 (2H, m, 2xNHCHCO), 4.20–4.15 (2H, m, CH2CH3), 3.67 
(2H, d, J = 10.15, CHOCHCOOEt), 2.72–2.51 (2H, m, CH2CCH), 2.39 (2H, t, J = 6.89, CH2COOH), 
2.33 (1H, s, CCH), 2.06 (1H, dt, J = 6.46, 20.18, CH2CH2COOH), 1.93 (1H, dt, J = 7.07, 20.85, 
CH2CH2COOH), 1.17 (3H, t, J = 7.00, CH3). ESI-MS: m/z = 384.1394 ([M + H]
+). Rt: 5.44.  
(2S,3S)-Ethyl-2,3-epoxysuccinyl glycyl propargylglycinaminde (EtEP-G-Pra-NH2) (TD 34) 
 
Standard SPPS. Product was obtained as white solid. 
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δH/ppm (400 MHz; DMSO): 8.64 (1H, t, J = 5.71, NHCH2CO), 8.25 (1H, d, J = 8.16, NHCHCO), 
7.44, 7.24 (2H, s, NH2), 4.34 (1H, td, J = 5.59, 7.96, NHCHCH2), 4.25–4.12 (2H, m, OCH2CH3), 
3.83 (2H, qd, J = 5.77, 16.66, NHCH2CO), 3.72 (1H, d, J = 1.83, CHOCHCOOEt), 3.64 (1H, d, 
J = 1.80, CHOCHCOOEt), 2.86 (1H, t, J = 2.56, CCH), 2.61–2.40 (2H, m, CH2CCH), 1.24 (3H, t, 
J = 7.10, CH3). ESI-MS: m/z = 312.12.1206 ([M + H]
+). Rt: 7.09. 
 (2S,3S)-Ethyl-2,3-epoxysuccinyl threonyl propargylglycinaminde (EtEP-T-Pra-NH2) (TD 36) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.44 (1H, td, J = 2.77, 6.61, NHCHCONH2), 4.35 (1H, dd, J = 1.46, 
4.82, NHCHCO), 4.26–4.12 (3H, m, CH2CH3 and CHCHOH), 3.80 (1H, d, J = 1.88, 
CHOCHCOOEt), 3.72 (1H, d, J = 1.90, CHOCHCOOEt), 2.67–2.64 (2H, m, CH2CCH), 2.38–2.35 
(1H, m, CCH), 1.20 (3H, t, J = 7.14, CH2CH3), 1.14 (3H, dd, J = 4.05, 6.37, CHCH3). Rt: 7.82.  
(2S,3S)-2,3-Epoxysuccinyl leucylarginyl triethylene glycol biotin (EP-LR-PEG3-Biotin) (TD 43) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.51 (1H, dd, J = 4.89, 7.88, SCH2CH), 4.32 (1H, dd, J = 4.49, 7.92, 
SCHCH), 4.28 (1H, t, J = 7.17, NHCHArgCO), 4.20–4.16 (1H, m, NHCHLeuCO), 3.59–3.55 (9H, 
m, CHOCHCOOH, O(CH2)2O(CH2)2O), 3.49–3.43 (5H, m, CHOCHCOOH, NH(CH2)2CH2O), 3.26–
3.09 (7H, m, 3 × CH2NH, SCHCH), 2.89 (1H, dd, J = 4.96, 13.07, SCH2CH equatorial, same site 
with CHCH), 2.68 (1H, d, J = 13.04, SCH2CH axial), 2.15 (2H, t, J = 7.21 NHCOCH2), 1.76–1.43 
(15H, m, (CH2)3CHS, CH2CH(CH3)2, PEG-CH2CH2NHCO, CH(CH3)2, (CH2)2CH2NHCHNH2), 1.34–
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1.26 (2H, m, CONHCH2CH2CH2O), 0.84 (3H, d, J = 5.58, CH(CH3)2 ), 0.80 (3H, d, J = 5.57, 
CH(CH3)2 ). Rt: 10.68. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl leucylarginyl triethylene glycol biotin (EtEP-LR-PEG3-Biotin) 
(TD 44) 
 
Standard SPPS. Product was obtained as white solid.  
δH/ppm (400 MHz; D2O): 4.51 (1H, dd, J = 5.00, 7.88, SCH2CH), 4.32 (1H, dd, J = 4.35, 7.74, 
SCHCH), 4.29 (1H, t, J = 8.76, NHCHArgCO), 4.22–4.15 (3H, m, NHCHLeuCO, OCH2CH3), 3.69 
(1H, s, CHOCHCOOEt), 3.63 (1H, s, CHOCHCOOEt), 3.59–3.55 (8H, m, O(CH2)2O(CH2)2O), 3.48 
(2H, d, J = 6.36, NH(CH2)2CH2O), 3.45 (2H, d, J = 6.36, NH(CH2)2CH2O), 3.26-3.09 (7H, m, 3 × 
CH2NH, SCHCH), 2.89 (1H, dd, J = 4.88, 13.13, SCH2CH equatorial, same site as CHCH), 2.68 
(1H, d, J = 13.04, SCH2CH axial), 2.15 (2H, t, J = 7.19 NHCOCH2), 1.76–1.43 (15H, m, 
(CH2)3CHS, CH2CH(CH3)2, PEG-CH2CH2NHCO, CH(CH3)2, (CH2)2CH2NHCHNH2), 1.35–1.26 (2H, 
m, CONHCH2CH2CH2O), 1.20 (3H, t, J = 7.08, OCH2CH3), 0.84 (3H, d, J = 5.38, CH(CH3)2), 0.80 
(3H, d, J = 5.34, CH(CH3)2). Rt: 11.09. 
(2S,3S)-2,3-Epoxysuccinyl leucyl triethylene glycol biotin (EP-L-PEG3-Biotin) (TD 49) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.50 (1H, dd, J = 4.94, 7.88, SCH2CH), 4.32 (1H, dd, J = 4.50, 7.92, 
SCHCH), 4.22 (1H, t, J = 7.05, NHCHCO), 3.59–3.54 (9H, m, CHOCHCOOH, O(CH2)2O(CH2)2O), 
3.49–3.43 (5H, m, CHOCHCOOH, NH(CH2)2CH2O), 3.25–3.10 (5H, m, 2 × CH2NH, SCHCH), 2.89 
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(1H, dd, J = 4.96, 13.06, SCH2CH axial ,same site with CHCH), 2.67 (1H, d, J = 13.03, SCH2CH 
equatorial), 2.15 (2H, t, J = 7.21 NHCOCH2), 1.70–1.43 (11H, m, (CH2)3CHS, CH2CH(CH3)2, 
PEG-CH2CH2NHCO, CH(CH3)2), 1.35–1.25 (2H, m, CONHCH2CH2CH2), 0.83 (3H, d, J = 5.63, 
CH(CH3)2 ), 0.78 (3H, d, J = 5.61, CH(CH3)2 ). Rt: 11.60. 
(2S,3S)-Ethyl-2,3-epoxysuccinyl arginyl triethylene glycol biotin (EtEP-R-PEG3-Biotin) (TD 
55) 
 
Standard SPPS. Product was obtained as white solid. 
δH/ppm (400 MHz; D2O): 4.51 (1H, dd, J = 4.84, 7.91, SCH2CH), 4.32 (1H, dd, J = 4.49, 7.93, 
SCHCH), 4.20 (1H, q, J = 7.10, 0CH2CH3), 3.71 (1H, d, J = 1.80, CHOCHCOOEt), 3.66 (1H, d, 
J = 1.86, CHOCHCOOEt), 3.62–3.53 (8H, m, 2 × O(CH2)2O), 3.47 (4H, dt, J = 6.37, 10.46 
CH2O(CH2)2OCH2), 3.26–3.10 (7H, m, 3 × CH2NH, SCHCH), 2.90 (1H, dd, J = 4.95, 13.09, 
SCH2CH axial ,same site with CHCH), 2.68 (1H, d, J = 13.03, SCH2CH equatorial), 2.16 (2H, t, 
J = 7.21 NHCOCH2), 1.82––1.27 (14H, m, (CH2)3CHS, CH2CH2-PEG-CH2CH2, CONHCH2CH2CH2), 
1.20 (3H, t, J = 7.16). Rt: 9.78. 
2-(4-methoxybenzoyloxy)acetic acid  
 
Tert-butyl bromoacetate (0.886 mL, 6 mmol), methoxybenzoic acid (1.825 g, 12 mmol) and 
potassium fluoride (1.394 g, 24 mmol) were dissolved in DMF. After overnight stirring, Et2O 
was added after which the solution was extracted with NaHCO3 (sat. aq.).The organic layer 
was dried, concentrated in vacuo and subsequently dissolved in TFA/H2O (95/5). The 
solution was concentrated after 1h, coevaporated with toluene to remove residual traces of 
TFA and applied to silica gel chromatography (Hexane–EtOAc) giving the white solid product 
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(53%, 0.664 g). Rf = 0.59 (Hexane–EtOAc, 2:1 + 0.1%FA). δH/ppm (400 MHz; CDCl3): 8.07 (2H, 
d, J = 5.7, Bn), 6.97 (2H, dd, J = 6.6, 4.9, Bn), 4.91 (2H, s, CH2), 3.90 (3H, s, OCH3). δC/ppm 
(100 MHz; CDCl3): 132.10 (Bn), 121.24 (Bn), 113.80 (Bn), 60.34 (CH2), 55.50 (OCH3). 
Fmoc-L-(OtBu)Ser-SBn (15) 
 
DMAP (0.159 g, 1.30 mmol, 0.1 eq.) and DCC (2.820 g, 13.69 mmol, 1.05 eq.) were added 
sequentially to a solution of Fmoc-L-Ser(tBu)-OH (5.000 g, 13.04 mmol, 1eq.) and benzyl 
mercaptan (3.06 mL, 26.08 mmol, 2 eq.) in THF (65 mL) at RT. The cloudy reaction mixture 
was stirred at RT for 18 h and then filtered. After concentrating the filtrate it was 
partitioned between EtOAc (70 mL) and 1.0 M HCl (40 mL). The organic layer was dried over 
Na2SO4 and concentrated. Subsequent addition of Et2O (15 mL) resulted in a white 
precipitate that was collected by vacuum filtration and washed with petroleum ether. The 
product was obtained as a yellow solid and used without further purification (5.826 g, 
8.18 mmol, 91% yield). Rf = 0.66 (Hexane–EtOAc, 2:1); mp 163–165 °C; δH/ppm (400 MHz; 
CDCl3): 7.79 (2H, d, J = 7.50, Fmoc-4 and 5), 7.66–7.63 (2H, m, Fmoc-1 and 8), 7.41 (2H, app 
td, J = 2.72, 7.38, 7.35, Fmoc-3 and 6), 7.36–7.30 (7H, m, Bn, Fmoc-2 and 7), 5.78 (1H, d, 
J = 8.94, NH), 4.55 (2H, dd, J = 6.94, 10.40, Fmoc-CH2), 4.42–4.35 (1H, m, Sα), 4.29 (1H, t, 
J = 6.99, Fmoc-9), 4.16 (2H, dd, J = 13.76, 35.67, Sβ), 3.96 (1H, dd, J = 2.50, 9.02, Bn-CH2), 
3.57 (1H, dd, J = 3.44, 9.03, Bn-CH2), 1.15 (9H, s, tBu). νmax (neat)/cm
–1: 3322 , 2954, 2936, 
2908, 2853, 1724 (CO), 1684, 1625, 1554, 1509,  1392, 1331, 1234, 1174, 1071, 965, 698. 
HRMS (ESI): m/z =  found 490.2039 ([M + H]+), 512.1859 ([M + Na]+), (required 490.2052; 
C29H31NO4S [M + H]
+). 
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Fmoc-L-(OtBu)Ser-H (16) 
 
Triethylsilane (6.50 mL, 40.90 mmol, 5eq.) was slowly added to a suspension of Fmoc-L-
(OtBu)Ser-SBn (4 g, 8.18 mmol, 1 eq.) and Pd/C (10%, 2.20 g) in acetone (200 mL) at RT 
previously degassed with N2. The reaction mixture was stirred for 15 min and then filtered 
through Celite. The filtrate was concentrated to afford 6.21 g of brown oily crude, which was 
used without further purification. Rf = 0.57 (Hexane–EtOAc, 3:2); δH/ppm (400 MHz; CDCl3): 
9.66 (1H, s, CHO), 7.81 (2H, d, J = 7.34, Fmoc-4 and 5), 7.65 (2H, dt, J = 5.74, 11.49, Fmoc-1 
and 8), 7.44 (2H, t, J = 7.29, Fmoc-3 and 6), 7.36 (7H, dd, J = 4.98, 9.52, Fmoc-2 and 7), 5.70 
(1H, d, J = 7.30, NH), 4.46 (2H, dd, J = 1.41, 6.38, Fmoc-CH2), 4.41 (2H, dd, J = 5.84, 10.17, 
Sα), 4.29 (1H, t, J = 6.86, 13.98, Fmoc-9), 4.00 (1H, dd, J = 3.10, 9.30, Sβ), 3.67 (1H, dd, 
J = 4.20, 9.38, Sβ), 1.20 (9H, s, tBu). ESI-MS: m/z = found 390.1681 [M + Na]+, (required 
390.1681; C22H25NO4Na).    
Ethyl-3-[Fmoc-L-Ser(tBu)]-(E)-propenoate (17) 
 
(Carbethoxymethylene)-triphenyl phosphane (2.137 g, 6.135 mmol, 1.5 eq.) was added to a 
solution of crude Fmoc-L-(OtBu)Ser-H (6.210 g) in THF (60 mL) at RT. The resulting mixture 
was stirred for 24 h and then concentrated under reduced pressure. The residue was 
purified by silica gel flash column chromatography (Hexane–EtOAc, 9:1) to afford a white 
solid (0.662 g, 37% yield from Fmoc-L-(OtBu)Ser-SBn). Rf = 0.51 (Hexane–EtOAc, 2:1); mp 
50–53 °C; δH/ppm (400 MHz; CDCl3): 7.80 (2H, d, J = 7.49, Fmoc-4 and 5), 7.63(2H, d, 
J = 7.12, Fmoc-1 and 8), 7.43 (2H, t, J = 7.40, Fmoc-3 and 6), 7.35 (2H, t, J = 7.11, Fmoc-2 and 
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7), 6.96 (1H, dd, J = 4.64, 15.63, Sα-CH), 6.00 (1H, d, J = 15.66, CHCOOEt), 5.31 (1H, d, 
J = 7.85, NH), 4.49 (1H, s, Sα), 4.45 (2H, d, J = 6.88, Fmoc-CH2), 4.28 (1H, t, J = 6.92, Fmoc-9), 
4.23 (2H, q, J = 7.08, COOCH2CH3), 3.54–3.47 (2H, m, Sβ), 1.33 (3H, t, J = 7.15, COOCH2CH3), 
1.21 (9H, s, tBu). νmax (neat)/cm
–1: 3342 , 1725 (CO), 1697, 1541, 1182, 1032, 881, 738. ESI-
MS: m/z =  found 438.2276 ([M + H]+), 460.2100 ([M + Na]+), (required 460.2100, 
C26H31NO5Na). 
Ethyl-3-Fmoc-L-Ser-(E)-propenoate (18) 
 
TFA (2 mL) was added to a solution of ethyl-3-[Fmoc-L-Ser(tBu)]-(E)-propenoate (0.318 g, 
0.833 mmol) in DCM (8 mL) at RT. The reaction mixture was stirred for 2 h, and then the 
volatiles were removed under reduced pressure. The residue was triturated with a 1:1 
mixture of Et2O and hexanes (3 mL), and the resulting white solid was collected by filtration 
and washed thoroughly with cold Et2O–Hexane (1:1) to afford the product (0.197 g, 
0.518 mmol, 62% yield). Rf = 0.51 (Hexane–EtOAc, 2:1); mp 110–113 °C; δH/ppm (400 MHz; 
CDCl3): 7.78 (2H, d, J = 7.50, Fmoc-4 and 5), 7.60 (2H, d, J = 7.05, Fmoc-1 and 8), 7.41 (2H, t, 
J = 7.40, Fmoc-3 and 6), 7.32 (2H, t, J = 7.26, Fmoc-2 and 7), 6.92 (1H, dd, J = 4.19, 15.67, Sα-
CH), 6.00 (1H, d, J = 15.70, CHCOOEt), 5.50 (1H, d, J = 7.80, NH), 4.50–4.36 (3H, m, Fmoc-
CH2, Sα), 4.29–4.09 (3H, m, CH2CH3, Fmoc-9), 3.75 (2H, s, Sβ), 1.31 (3H, t, J = 7.14, 
COOCH2CH3). δC/ppm (100 MHz; CDCl3): 166.26 , 156.23 (CO), 145.10 (CH-Fmoc), 143.72, 
141.33 (C-Fmoc), 127.78, 127.12, 125.00, 122.67, 120.03 (CH-Fmoc, CHCH), 66.91, 64.03, 
60.76 (CH2), 53.80 (CH-Fmoc), 47.19 (Cα), 14.21 (CH3). νmax (neat)/cm
–1: 3320 , 2974, 2878, 
2839, 1716 (CO), 1692, 1535, 1461, 1377, 1287, 1212, 1016, 736. ESI-MS: m/z = 382.1650 
([M + H]+), 405.1526 ([M + Na]+), (required 382.1576, C22H24NO5). 
Ethyl-3-[Fmoc-L-Ser(ClTrt resin)]-(E)-propenoate 
2-Chlorotrityl chloride resin (0.199 g, 1 eq.) was added to a solution of ethyl-3-Fmoc-L-Ser-
(E)-propenoate (0.197 g, 0.518 mmol, 2 eq.) and pyridine (83.73 µL, 1.035 mmol, 4 eq.) in 
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dry THF (2 mL). The reaction mixture was heated at 60 °C with stirring for 6 h. The resin was 
filtered and washed with DCM–MeOH–DiPEA (17:2:1) and 3 × DCM, 2 × DMF, 2 × DCM. 
Finally, the resin was dried in vacuo over KOH. The yield of the loading was 72% as 
determined by the Fmoc-test.  
Ethyl-3-[-L-Ser-Lys-Thr-Glu-Leu-Ac]-(E)-propenoate (Ac-LETKS-MA) (TD 90) 
 
δH/ppm (400 MHz; D2O): 6.84 (1H, ddd, J = 3.41, 4.81, 15.79, CHCHCOOEt), 5.90 (1H, ddd, 
J = 1.72, 11.57, 15.86, CHCHCOOEt), 4.88 (2H, d, J = 3.76, OH), 4.55 (1H, dt, J = 3.12, 6.34, 
NHCHCO), 4.49 (1H, dd, J = 5.03, 9.04, NHCHCO), 4.36 (2H, dd, J = 5.39, 8.99, NHCHCO), 4.30 
(1H, dd, J = 5.55, 8.79, NHCHCO), 4.25–3.98 (6H, m, CH2(OEt), 4 × NHCHCO), 3.70–3.56 (2H, 
m, CH(Thr), NHCHCH), 2.91 (2H, t, J = 7.33, CH2), 2.78 (1H, t, J = 6.26, CH2(Ser)), 2.60–2.55 
(1H, m, CH2(Ser)), 2.44–2.25 (2H, m, CH2), 2.13–2.00 (1H, m, CH(Leu)), 1.94 (3H, s, CH3(Ac)), 
1.81–1.29 (10H, m, 5 × CH2), 1.19 (3H, t, J = 7.18, CH3(Thr)), 1.16–1.09 (3H, m, CH3(OEt)), 
0.84 (3H, d, J = 6.24, CH3(Leu)), 0.80 (3H, d, J = 6.24, CH3(Leu)). Rt: 5.26. 
Z-L-Ala-OMe (20) 
 
Z- L -Ala-OH (2.000 g, 8.961 mmol, 1.0 eq.) was dissolved in DMF (10 mL) and cooled to 0 °C. 
K2CO3 (1.240 g, 8.961 mmol, 1.0 eq.) was added and the resulting suspension was stirred for 
10 min at 0 °C before methyl iodide (1.120 mL, 17.921 mmol, 2.0 eq.) was added. The 
reaction was monitored by TLC (Et2O–hexane, 4:1), and no starting material was detected 
after 30 min at 0 °C and a further 1 h at room temperature with continued stirring. The 
reaction mixture was filtered and the filtrate diluted with EtOAc (40 mL), washed with H2O 
(15 mL) and brine (3 × 10 mL), and finally dried over Na2SO4, filtered and concentrated in 
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vacuo to afford a yellow oily crude product (1.92 g, 90.4%); Rf = 0.35 (Hexane–EtOAc, 4:1); 
δH/ppm (400 MHz; CDCl3): 7.39–7.30 (5H, m, Bn), 5.42 (1H, s, NH), 5.15–5.09 (2H, m, CH2), 
4.43–4.36 (1H, m, Aα), 3.75 (3H, s, OMe), 1.42 (3H, d, J = 7.20, Aβ). ESI-MS: m/z = found 
260.0890 ([M + Na]+), (required 260.0899, C12H15NO4Na).  
Z-L-Ala-dimethylsulfoxonium (21) 
 
A solution of 1 M potassium tert-butoxide in THF (12.650 mL, 12.653 mmol, 3.0 eq.) was 
added at RT to a suspension of trimethylsulfoxonium iodide (2.780 g, 12.653 mmol, 3.0 eq.) 
in THF (20 mL). The mixture was heated at reflux for 2h and then was cooled to 0 °C. A 
solution of Z-L-Ala-OMe (1.000 g, 4.218 mmol, 1.0 eq.) in THF (10 mL) was added dropwise 
at 0 °C and the resultant solution was stirred for 4 h at 0 °C. The reaction was quenched with 
water (20 mL). The organic layer was separated and washed with brine (2 × 20 mL). The 
solvent was removed at reduced pressure to afford the crude sulphur ylide (0.447 g) as a 
white off solid. Rf = 0.24 (5% MeOH in DCM); mp 129–132 °C; δH/ppm (400 MHz; CDCl3): 
7.37–7.31 (5H, m, Bn), 5.88 (1H, d, J = 7.60, NH), 5.12–5.03 (2H, m, CH2), 4.58 (1H, s, CHS), 
4.23–4.11 (1H, m, Aα), 3.35 (3H, s, SMe), 3.33 (3H, s, SMe), 1.32 (3H, d, J = 6.90, Aβ). νmax 
(neat)/cm–1: 3314 , 2930, 2906, 2853, 1687 (CO), 1552, 1391, 1320, 1257, 1174, 1002, 1037, 
855, 744. ESI-MS: m/z = found 298.1122 ([M + H]+), (required 298.1113, C14H20NO4S).  
Z-L-Ala-CMK (22) 
 
The crude Z- L -Ala-dimethylsulfoxonium (0.410 g, 1.381 mmol, 1.0 eq.) was dissolved in THF 
(5 mL) and the solution was cooled to 0 °C. Lithium chloride (0.066 g, 1.574 mmol, 1.1 eq.) 
and methanesulfonic acid (0.099 mL, 1.519 mmol, 1.1 eq.) were added. The temperature 
was slowly raised to 70 °C and stirring was continued at that temperature for 2 h. After 
cooling, the reaction was quenched by addition of water (4 mL). The reaction mixture was 
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extracted using 2:1 hexane–EtOAc (20 mL). To remove DMSO, the organic layer was washed 
with saturated NaHCO3 (20 mL), water (2 × 20 mL), and brine (20 mL) and dried over Na2SO4. 
Removal of solvent afforded the crude chloromethyl ketone. The crude product was purified 
by silica gel flash column chromatography (Hexane–EtOAc, 9:1) to afford white solid Z-Ala-
methyl chloromethyl ketone (0.221 g, 62.7%). Rf = 0.46 (Hexane–EtOAc, 2:1); m.p 50–52 °C; 
δH/ppm (400 MHz; CDCl3): 7.38–7.33 (5H, m, Bn), 5.71 (1H, d, J = 6.40, NH), 5.17–5.04 (2H, 
m, BnCH2), 4.62 (1H, p, J = 7.20, Aα), 4.33–4.21 (2H, m, CH2Cl), 1.38 (3H, d, J = 7.20, Aβ). 
δC/ppm (100 MHz; CDCl3):  201.71 (OCO), 155.87 (OCCH2), 136.28 (C-Bn), 128.61, 128.33, 
128.14 (CH-Bn), 67.16 (CH2), 53.62 (CH), 49.61 (CH2), 17.33 (CH3). νmax (neat)/cm
–1: 3324 , 
1741 (CO), 1680, 1531, 1396, 1273, 1048, 1007, 739. C.I.-MS: m/z = found 273.1008 
([M + NH4
+]), (required 273.1006, C12H18N2O3Cl).  
Z-L-Ala-AOMK (23) 
 
The Z-L-Ala-CMK (0.150 mg, 0.588 mmol, 1.0 eq.) and 4-methoxybenzoic acid (0.179 g, 
1.176 mmol, 2.0 eq.) were dissolved in DMF (2.35 mL). Potassium fluoride (0.136 g, 
2.352 mmol) was added to the reaction mixture and the reaction stirred overnight at RT. 
The reaction mixture was diluted with DCM (10 mL), washed with water, brine, dried over 
Na2SO4, filtered and concentrated under vacuum. Purification by SiO2 column 
chromatography using Hexane–EtOAc, 9:1 yielded the desired white solid product (0.988 g, 
45 %). Rf = 0.52 (Hexane–EtOAc, 2:1); m.p 92–95°C; δH/ppm (400 MHz; CDCl3): 8.06 (2H, d, 
J = 8.80, CH-BnOMe), 7.41–7.34 (5H, m, Bn), 6.99–6.93 (2H, m, CH-BnOMe), 5.48 (1H, d, 
J = 6.20, NH), 5.18–5.10 (2H, m, CH2), 5.04 (2H, q, J = 17.00, CH2), 4.62 (1H, p, J = 7.20, Aα), 
3.90 (3H, s, OMe), 1.48 (3H, d, J = 7.10, Aβ). δC/ppm (100 MHz; CDCl3): 203.16 (OCO), 165.50 
(CO), 163.88, 155.70 (C), 132.33, 132.06, 128.60, 128.28, 128.15, 113.83, 113.75 (CH-Bn), 
67.11, 66.19 (CH2), 55.50 (OCH3), 53.62 (CH), 17.70 (CH3). νmax (neat)/cm
–1: 2924, 2854, 
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1748 (CO), 1723, 1688, 1608, 1552, 1530, 1395, 1252, 1171, 1099, 1026, 846, 766. ESI.-MS: 
m/z =  found 372.1434 ([M + H]+), 394.1254 ([M + Na]+), (required 394.1267, C20H21NO6Na). 
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Chapter 11 Appendix 
Appendix 1: Strain dependency of inhibitors/ABPs.  
 
Figure 11. 1: Activity of inhibitors/ABPs, as measuared by Western blot. Indicated strains were treated with 
inhibitors/ABPs at 250 μM overnight. Whole cell lysis were analysed by SDS-PAGE.  
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Figure 11. 2: Activity of inhibitors/ABPs, as measuared by Western blot. Indicated strains were treated with 
inhibitors/ABPs at 250 μM overnight. Whole cell lysis were analysed by SDS-PAGE.  
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Figure 11. 3: Activity of inhibitors/ABPs, as measuared by Western blot. Indicated strains were treated with 
inhibitors/ABPs at 250 μM overnight. Whole cell lysis were analysed by SDS-PAGE.  
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Appendix 2: Proteomics data using Orbitrap LC-ESI MS/MS  
 
Figure 11. 4: List of identified protein of wild typ Cd 630 under the view of Scaffold software. Quantitative values are displayed.  
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Figure 11. 5: Data for Cwp84, generated using Scaffold software. A) Cwp84 sequence, matched peptides are indicated in yellow. B) Short cut view of identified peptide list. 
C) Sample of mass spectra, illustrated for peptide TSISLAQK. 
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Figure 11. 6: Data for Cwp13, generated using Scaffold software. A) Cwp84 sequence, matched peptides are indicated in yellow. B) Short cut view of identified peptide list. 
C) Sample of mass spectra, illustrated for peptide DNFNANIRPSK. 
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Figure 11. 7: List of identified protein of 630Δcwp84 strain under the view of Scaffold software. Quantitative values are displayed. Each samples (probes) was divided in 
three small samples and treated separately to enhance coverage. For evaluation the results, the values of the three small samples should be combined additively.  
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